



## **STI & HIV 2019 WORLD CONGRESS**


Joint Meeting of the  
**23rd ISSTD & 20th IUSTI**



**JULY 14 - 17, 2019 VANCOUVER, CANADA**

*The Evolving Landscape of STI and HIV Elimination*

[www.stihiv2019vancouver.com](http://www.stihiv2019vancouver.com)






Visit BD at Booth 105

## BD MAX™ Vaginal Panel

One clinician- or patient-collected vaginal swab provides results for the **three** most common causes of vaginitis – bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and *Trichomonas vaginalis* (TV)<sup>1</sup>.

BD MAX Vaginal Panel detects DNA from the following BV markers:



In addition, BD MAX Vaginal Panel utilizes the CDC-recommended diagnostic technology for **T. vaginalis** detection<sup>2</sup> and provides three results for microorganisms responsible for yeast infections:

- **Candida group**, including *C. albicans*, *C. parapsilosis*, *C. tropicalis*, and *C. dubliniensis*
- Differentiates fungal species – *C. glabrata* and *C. krusei* – associated with antimicrobial resistance<sup>3</sup>.

The BD MAX™ Women's Health and STI portfolio is focused on providing accurate, reliable results that enable clinicians and labs to elevate patient care.

- BD MAX™ Vaginal Panel
- BD MAX™ CT/GC/TV
- BD MAX™ GBS

### Reference

1. BD MAX Vaginal Panel Package Insert
2. CDC (2015, June). MMWR Sexually Transmitted Diseases Treatment Guidelines, 2015. Mills, BB (2017) Vaginitis: Beyond the Basics. *Obstet Gynecol Clin North Am.* 44(2):159-177.
3. Gaydos CA (2017) Clinical Validation of a Test for the Diagnosis of Vaginitis. *Obstet Gynecol.* 130(1):181-189.



BD, the BD Logo and the BD MAX are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. April 2019.

## STI & HIV 2019 SUPPORTERS

STI & HIV 2019 would like to thank the following companies for their generous support:

### SPONSORS

#### PLATINUM LEVEL



#### GOLD LEVEL




#### SILVER LEVEL



#### BRONZE LEVEL



#### OTHER SUPPORTERS



Page 5	<b>WELCOME ADDRESS</b>
Page 6	<b>COMMITTEES</b>
Page 11	<b>ABOUT</b>
Page 12	<b>ISSTD R BOARD LISTING</b>
Page 13	<b>IUSTI EXECUTIVE COMMITTEE LISTING</b>
Page 15	<b>KEYNOTE, PLENARY &amp; DEBATE SPEAKERS</b>
Page 23	<b>SCHOLARSHIPS</b>
Page 24	<b>ABSTRACT REVIEWERS</b>
Page 26	<b>PROGRAM AT A GLANCE</b>
Page 29	<b>SCIENTIFIC PROGRAM</b>
	<ul style="list-style-type: none"> <li>• Sunday, July 14</li> <li>• Monday, July 15</li> <li>• Tuesday, July 16</li> <li>• Wednesday, July 17</li> <li>• Posters</li> </ul>
Page 80	<b>INDUSTRY-SUPPORTED SYMPOSIA</b>
Page 82	<b>BOARD &amp; SIDE MEETINGS</b>
Page 84	<b>NETWORKING EVENTS</b>
Page 85	<b>GENERAL INFORMATION</b>
Page 89	<b>VENUE FLOOR PLAN</b>
Page 90	<b>EXHIBIT FLOOR PLAN</b>
Page 92	<b>EXHIBITOR BIOGRAPHIES</b>

Dear Friends and Colleagues,

On behalf of the Organizing Committee, we are delighted you have decided to attend the STI & HIV 2019 World Congress to be held July 14 – 17, 2019, at the Vancouver Convention Centre East Building, in Vancouver, British Columbia, Canada.

This Congress is a joint meeting of the International Society for Sexually Transmitted Diseases Research (ISSTD R) and the International Union Against Sexually Transmitted Infections (IUSTI). This biennial meeting is the world's largest international meeting on sexually transmitted infections, drawing delegates from around the globe.

Under the theme of 'The Evolving Landscape of STI and HIV Elimination', this meeting will provide an excellent opportunity for the world's most prominent researchers and health professionals to come together in the shared goal of improving global public health in the field of sexually transmitted infections, including HIV. The meeting will provide Congress attendees the opportunity to network with experts, present their research findings to an international audience, hear the latest scientific developments from world leaders in the STI/HIV field, and contribute to discussions that will shape future health policies and patient care around the world.


The STI & HIV 2019 World Congress is taking place in one of the most stunning cities in the world. Vancouver is a safe, modern, multicultural city with a vibrant local arts and culture scene and abundant opportunities for outdoor adventures amongst a setting of incomparable natural beauty.

We welcome you to Vancouver and look forward to providing you with an exceptional scientific and cultural experience!

Warm regards,



**Caroline Cameron, Chair**  
*International Society for Sexually Transmitted Diseases Research, President University of Victoria, Canada*



**Charlotte Gaydos, Co-Chair**  
*International Union Against Sexually Transmitted Infections, President Johns Hopkins University, USA*

## A Message from the Mayor

On behalf of my colleagues on Vancouver City Council and the citizens of Vancouver I want to extend my warmest greetings to the delegates of the International Society for Sexually Transmitted Diseases Research (ISSTD R) and the International Union Against Sexually Transmitted Infections (IUSTI) who are co-hosting the STI & HIV 2019 World Congress.

The opportunity to share research and scientific developments is crucial to developing policies and platforms that enhance the well-being of all citizens. With the goal of improving global public health in the field of sexually transmitted infections including HIV/AIDS, ISSTD R and IUSTI help shape discussions around future health policies and patient care around the world.

We are proud to host the STI & HIV 2019 World Congress in Vancouver and I hope that in addition to attending the conference you are able to experience the many cultural and recreational activities the City has to offer. I know everyone involved in organizing the conference will ensure your time with us is special.

Best wishes on a successful and productive conference.



**Mayor Kennedy Stewart**

Scientific Committee

Co-Chairpersons



**David Lewis**  
 Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, Australia; Westmead Clinical School, University of Sydney, Sydney, Australia; Division of Medical Virology, University of Cape Town, Cape Town, South Africa



**James Blanchard**  
 Departments of Community Health Sciences and Medical Microbiology, Centre for Global Public Health, Canada Research Chair in Epidemiology and Global Public Health, Faculty of Medicine University of Manitoba

Basic & Translational Science Track Team

Chairperson:



**Sheila Lukehart**  
 University of Washington, USA

Track Members:

- |                                  |                            |
|----------------------------------|----------------------------|
| <b>Jo-Anne Dillon</b><br>Canada  | <b>Will Geisler</b><br>USA |
| <b>Laura Sycuro</b><br>Canada    | <b>Nick Thomson</b><br>UK  |
| <b>Magnus Unemo</b><br>Sweden    | <b>Anna Wald</b><br>USA    |
| <b>David Whiley</b><br>Australia |                            |

Behavioural & Social Sciences Track Team

Chairperson:



**Jacky Jennings**  
 Johns Hopkins School of Medicine, Bloomberg School of Public Health, Center for Child and Community Health Research, USA

Track Members:

- |                                       |                                   |
|---------------------------------------|-----------------------------------|
| <b>Valeria Stuardo Avila</b><br>Chile | <b>Sarah Bernays</b><br>Australia |
| <b>Kit Fairley</b><br>Australia       | <b>Robert Lorway</b><br>Canada    |
| <b>Joe Tucker</b><br>USA              |                                   |

Clinical Science Track Team

Chairperson:



**Matthew Golden**  
 University of Washington (UW) School of Medicine, Seattle & King County HIV/STD Program, UW Public Health Capacity Building Center, USA

Track Members:

- |                                       |                               |
|---------------------------------------|-------------------------------|
| <b>Catriona Bradshaw</b><br>Australia | <b>Craig Cohen</b><br>USA     |
| <b>Julie Dombrowski</b><br>USA        | <b>Gina Ogilvie</b><br>Canada |
| <b>Daniel Richardson</b><br>Australia | <b>Janet Wilson</b><br>UK     |
| <b>Ping Yu Zhou</b><br>China          |                               |

Epidemiology & Monitoring Track Team

Chairperson:



**Gwenda Hughes**  
 National Infection Service at Public Health England, Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP), UK

Track Members:

- |                                                |                                                      |
|------------------------------------------------|------------------------------------------------------|
| <b>Michel Alary</b><br>Canada                  | <b>Kyle Bernstein</b><br>USA                         |
| <b>Viviane Bremer</b><br>Germany               | <b>Xiang-Sheng Chen</b><br>China                     |
| <b>Sinead Delaney-Moretlwe</b><br>South Africa | <b>Maria Amelia de Sousa Mascena Veras</b><br>Brazil |
| <b>Jane Hocking</b><br>Australia               |                                                      |

Policy & Community Engagement Track Team

Chairperson:



**Helen Ward**  
 Imperial College London, UK

Track Members:

- |                                  |                                  |
|----------------------------------|----------------------------------|
| <b>Patricia Garcia</b><br>Peru   | <b>Francis Ndowa</b><br>Zimbabwe |
| <b>Maryam Shahmanesh</b><br>UK   | <b>Kate Shannon</b><br>Canada    |
| <b>Morten Skovdal</b><br>Denmark |                                  |

Program & Implementation Science Track Team

Chairperson:



**Sevgi Aral**  
*US Centers for Disease Control, University of Washington, Emory University, USA, University of Manitoba, Canada*

Track Members:

- Marissa Becker**  
*Canada*
- Harrell Chesson**  
*USA*
- Sharmistha Mishra**  
*Canada*
- Anneli Uusküla**  
*Estonia*
- Parinita Bhattacharjee**  
*Kenya/Canada*
- James Hargreaves**  
*UK*
- Ian Spicknall**  
*USA*

Local Organizing Committee

Chair:

**Caroline Cameron**  
*University of Victoria, Canada*

Co-Chair:

**Charlotte Gaydos**  
*Johns Hopkins University, USA*

**Lindsay Frehlick**  
*University of Victoria, Canada*

**Mark Gilbert**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

**Troy Grennan**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

**King Holmes**  
*University of Washington, USA*

**Rupert Kaul**  
*University of Toronto, Canada*

**Mel Kraiden**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

**Nathan Lachowsky**  
*University of Victoria, Canada*

**Sheila Lukehart**  
*University of Washington, USA*

**Lisa Manhart**  
*University of Washington, USA*

**Jeanne Marrazzo**  
*University of Alabama, USA*

**Deborah Money**  
*University of British Columbia, Canada*

**Muhammed Morshed**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

**Gina Ogilvie**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

**Michael Rekart**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

**Ameeta Singh**  
*University of Alberta, Canada*

**Mark Tyndall**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

**Jason Wong**  
*University of British Columbia, British Columbia Centre for Disease Control, Canada*

néča?mat ct Indigenous Sexual Health Committee

The purpose of this committee is to raise the prominence of Indigenous sexual health within the conference and to work with the Local Organizing Committee to establish relations in a good way with the local Coast Salish peoples on whose traditional, ancestral and unceded territories the conference is held on, specifically the Skwxwú7mesh (Squamish), Selilwitulh (Tsilil-Waututh), and xʷməθkʷəy̓əm (Musqueam) Nations.

We are grateful to the Elders of the VCH Aboriginal Health Elder Advisory Council for guiding us in doing this work, including **Elder Roberta Price, Elder Doris Fox, Elder Iris Newman, Elder Iggy George, Elder Dee George, Elder Marr Dorvault, Elder Glida Morgan, Elder Lillian Daniels, and Elder Jean Wasegijig.**

The word **néča?mat ct** embodies the concept of “We are One” in the həńqəmiñəm (Musqueam) language.

Committee Members

**Jessica Chenery**  
*Penelakut, Chee Mamuk, Clinical Prevention Services, BC Centre for Disease Control*

**Sarah Chown**  
*YouthCO HIV & Hep C Society*

**Jennifer Coward**  
*Indigenous Wellness Team, First Nations Health Authority*

**Andrea Derban**  
*Indigenous Wellness Team, First Nations Health Authority*

**Mark Gilbert**  
*British Columbia Centre for Disease Control*

**Nathan Lachowsky**  
*University of Victoria & Community Based Research Centre*

**Matthew Louie**  
*Indigenous Wellness Team, First Nations Health Authority*

**Harlan Pruden**  
*First Nations Cree, Chee Mamuk, Clinical Prevention Services, BC Centre for Disease Control*

**Ameeta Singh**  
*University of Alberta*

**Larissa Wahpooseyan**  
*Yúusnewas Program, YouthCO HIV & Hep C Society*

Scholarship Committee

Chair:

**Jeanne Marrazzo**  
*University of Alabama, USA*

**Basil Donovan**  
*University of New South Wales, Australia*

**Lynn Barclay**  
*American Sexual Health Association, USA*

**Dennis Fortenberry**  
*Indiana University, USA*

**Barbara Van Der Pol**  
*University of Alabama, USA*

**Jane Hocking**  
*University of Melbourne, Australia*

**Caroline Cameron**  
*University of Victoria, Canada*

## Sponsorship Committee

## Chair:

**Caroline Cameron***University of Victoria, Canada***Charlotte Gaydos***Johns Hopkins  
University, USA***Barbara Van der Pol***University of  
Alabama, USA***Edward W. Hook III***University of  
Alabama, USA***Muhammad Morshed***University of British  
Columbia/British  
Columbia Centre for  
Disease Control, Canada***Gina Ogilvie***University of British  
Columbia/British  
Columbia Centre for  
Disease Control, Canada***Jeffrey Klausner***UCLA - David Geffen  
School Of Medicine,  
USA***Leonard Foster***University of British  
Columbia, Canada***Lindsay Frehlick***University of  
Victoria, Canada*

## Promotion Committee

## Chair:

**Nicola Low***Universität Bern, Switzerland***Caroline Cameron***University of  
Victoria, Canada***Charlotte Gaydos***Johns Hopkins  
University, USA***Thomas Quinn***Johns Hopkins  
University/National  
Institutes of Health, USA***Myron Cohen***University of North  
Carolina, USA***Heather Pedersen***British Columbia Centre  
for Disease Control/  
University of British  
Columbia/Women's  
Health Research  
Institute, Canada***Henry de Vries***University of  
Amsterdam,  
Netherlands***Karen Lithgow***University of  
Victoria, Canada***Kit Fairley***Monash  
University,  
Australia***Sean Waugh***University of  
Victoria, Canada***Troy Grennan***University of  
British Columbia/  
British Columbia  
Centre for Disease  
Control, Canada***Wilhelmina (Willi)****Huston**  
*University of  
Technology Sydney,  
Australia***Katy Turner***University of  
Bristol, UK***Lori Brotto***University of British  
Columbia/Women's  
Health Research  
Institute, Canada*

The International Society for Sexually Transmitted Diseases Research (ISSTDR) exists to promote research on sexually transmitted diseases and facilitate the timely exchange of information among research investigators. To these ends, ISSTDR sponsors a biennial, interdisciplinary scientific meeting. The ISSTDR meetings have been the premier scientific conferences that address the entire breadth of research on STDs, including HIV, and encompasses microbiology, virology, immunobiology, pathogenesis, and other basic sciences; clinical sciences, social and behavioral sciences, epidemiology, and prevention; and research in health services, public health, and prevention policy.

ISSTDR was founded in 1977 and is governed by an international Board of Directors who currently represent 6 countries. The ISSTDR Conference Support Foundation provides support in respect of the conferences of the ISSTDR.



The International Union against Sexually Transmitted Infections (IUSTI) was founded in 1923 and it is organized on both a global and regional basis. It is the oldest international organization with the objective of fostering international cooperation in the control of sexually transmitted infections including HIV/AIDS.

IUSTI is concerned with the medical, scientific, social and epidemiological aspects of sexually transmitted infections and their control.

IUSTI is on the Roster of the United Nations Economic and Social Council. It is an Official Non-Government Organization in Consultative Status with the World Health Organization. IUSTI organizes frequent international and regional conferences on sexually transmitted infections and, in collaboration with the International Journal for STD and AIDS, publishes expert clinical guidelines for their management.

## ISSTD BOARD LISTING

NAME	COUNTRY	ROLE
Caroline Cameron	Canada	President
Henry de Vries	Netherlands	President-Elect
Jeanne Marrazzo	USA	Immediate Past President and ISSTD Foundation President
Basil Donovan	Australia	Past President and Chair of the 21st Meeting, 2015
Barbara Van Der Pol	USA	Secretary General
Christopher Fairley	Australia	Member
Edward Hook III	USA	Member
Nicola Low	Switzerland	Member
Helen Ward	UK	Member
Jeff Klausner	USA	Member
Jane Hocking	Australia	Member
Charlotte Gaydos	USA	IUSTI World President, Observer
Gail Bolan	USA	CDC Observer

## IUSTI EXECUTIVE COMMITTEE LISTING

NAME	COUNTRY	ROLE
Charlotte A Gaydos	USA	President
Janet Wilson	UK	President-Elect
David Lewis	Australia	Immediate Past President
Elizabeth Foley	UK	Secretary General
Jonathan Ross	UK	Treasurer
Christopher Fairley	Australia	Assistant Secretary General & Webmaster
Bradley Stoner	USA	Membership Secretary
Francis Ndowa	Zimbabwe	Regional Director, Africa-MENA
Somesh Gupta	India	Regional Director, Asia Pacific
Airi Pöder	Estonia	Regional Director, Europe
Adele Schwartz Benzaken	Brazil	Regional Director, Latin America and the Caribbean
Cornelis Rietmeijer	USA	Regional Director, North America
Amina Hansali	Morocco	Regional Chair, Africa-MENA
Kaushal Verma	India	Regional Chair, Asia Pacific
Claudia Heller-Vitouch	Austria	Regional Chair, Europe
Angelica Espinosa Miranda	Brazil	Regional Chair, Latin America and the Caribbean
Barbara Van Der Pol	USA	Regional Chair, North America
Sarah Lowe	Zimbabwe	Elected Member
Ranmini Kularatne	South Africa	Elected Member
Keith Radcliffe	UK	Elected Member
Edward Hook III	USA	Elected Member
Dennis Fortenberry	USA	Elected Member

Sunil Sethi	India	Elected Member
Maria Eugenia Escobar	Argentina	Elected Member
Patricia Galarza	Argentina	Elected Member
Gloria Aguilar	Paraguay	Elected Member
Laith Abu-Raddad	Qatar	Elected Member
Ryoichi Hamasuna	Japan	Elected Member
Suzanne Garland	Australia	Elected Member
Marco Cusini	Italy	Elected Member
Mihael Skerlev	Croatia	Elected Member
Jo-Anne Dillon	Canada	Elected Member
Nathalie Broutet	Switzerland	WHO Liaison Officer
Caroline Cameron	Canada	ISSTDR President, Observer
Raj Patel	UK	Senior Counsellor
Chavalit Mangkalaviraj	Thailand	Senior Counsellor
Patricia Garcia	Peru	Senior Counsellor
Lew Drusin	USA	Senior Counsellor
Julius Schachter	USA	Senior Counsellor
Thomas Quinn	USA	Senior Counsellor
Sevgi Aral	USA	Senior Counsellor
Angelika Stary	Austria	Senior Counsellor
Hunter Handsfield	USA	Senior Counsellor
Mikhail Gomberg	Russia	Senior Counsellor
King Holmes	USA	Senior Counsellor

Keynote Speakers



**Rino Rappuoli**  
GSK Vaccines, Italy

Dr. Rino Rappuoli is Chief Scientist and Head of External R&D at GSK Vaccines, based in Siena, Italy and Professor at Imperial College, London, UK. Prior positions include Head of Vaccine R&D at Novartis, CSO of Chiron Corporation, and Head of R&D at Sclavo. He obtained his PhD in Biological Sciences at the University of Siena, Italy, and has been a visiting scientist at both Rockefeller University and Harvard Medical School in the United States.

He is elected member of US National Academy of Sciences (NAS), American Academy of Arts and Sciences (AAAS), the European Molecular Biology Organization (EMBO), and the Royal Society of London. Dr. Rappuoli has received numerous awards including the Gold Medal of the Italian President, the Albert B Sabin Gold Medal, the Canada Gairdner International Award and the European Inventor Award for Lifetime Achievement. He was recently nominated as the third most influential person worldwide in the field of vaccines (Terrapin). He has published more than 650 works in peer-reviewed journals.

Dr. Rappuoli has developed and implemented a number of novel scientific concepts critical for vaccine development in the areas of genetic detoxification, cellular microbiology, reverse vaccinology and the pangenome. With others, he has developed several licensed vaccines and related adjuvants/carriers, including the acellular pertussis vaccine, which contains a non-toxic mutant of pertussis toxin; the first conjugate vaccine against meningococcus C; MF59, the first vaccine adjuvant after aluminium salts, which stimulates production of CD4 memory cells following meningococcal B vaccination; and CRM 197, a non-toxic mutant of diphtheria toxin that is used as carrier protein for polysaccharides and haptens to make them immunogenic in conjugate vaccines for several diseases, including meningococcal and pneumococcal infections. Recently he used a genome-based approach, named reverse vaccinology, to discover antigens for a new vaccine against meningococcus B.





**Charlotte Watts**

*London School of Hygiene and Tropical Medicine, UK*

Professor Charlotte Watts is Chief Scientific Adviser to the UK Department of International Development (DFID). In this role she is Director of the Research and Evidence Division and Head of the Science and Engineering Profession for DFID. Professor Watts is seconded to DFID from the London School of Hygiene and Tropical Medicine, where she is Professor of Social and Mathematical Epidemiology.

Originally trained as a mathematician, with a Ph.D. in theoretical mathematics from the University of Warwick, she became interested in global health whilst conducting post-doctoral research on the epidemiology of HIV at the University of Oxford. Moving to LSHTM in 1994, after gaining further training in economics and social science, and fieldwork experience in Zimbabwe and other developing countries. she founded the Social and Mathematical Epidemiology Group. The multidisciplinary group uses mathematical, epidemiological and economic research to assess the impact of current and new HIV prevention technologies, and evaluate interventions that tackle the determinants of HIV risk.

Professor Watts is a global expert in violence prevention. She was Senior Technical Advisor to the WHO 10 country population surveys on women's health and domestic violence; led the systematic review of the global prevalence and health burden of interpersonal violence, and has been senior researcher on 5 cluster randomised controlled intervention trials in sub-Saharan Africa - showing that violence is preventable.

Professor Watts is a Fellow of the Academy of Medical Sciences, and Foreign Associate Member of the US National Academy of Medicine. She has 200 academic publications, and has served on numerous UN technical and Government advisory boards.

## Plenary Speakers



**Irin Carmon**

*New York Magazine & CNN Contributor, USA*

Contributor Irin Carmon is a journalist, the bestselling co-author of *Notorious RBG*, and a frequent speaker around the country. A New York magazine senior correspondent and on-air CNN contributor, she reports and comments on gender, politics, and the law. Carmon and her co-author were featured in the award-winning and Oscar nominated 2018 documentary *RBG*. The New York Times described Carmon as being "known for her smarts and feminist bona fides. In 2017 and 2018, Carmon teamed up with the Washington Post's investigative team to break the news of sexual harassment and assault allegations against Charlie Rose, as well as CBS's knowledge of his conduct. That work was recognized with a 2018 Mirror Award. She was also a contributing writer to the Post's Outlook section. Carmon previously served as staff reporter focusing on women's rights at MSNBC and NBC News, Salon and Jezebel. Her reporting and commentary has appeared across print, radio, television, and digital platforms. "Of *Notorious RBG: The Life and Times of Ruth Bader Ginsburg* (2015) which spent three months on the Times' bestseller list, the paper's staff book critic wrote, "That I responded so personally to it is a testimony to Ms. Carmon's storytelling and panache." She speaks frequently across the country on women's leadership and rights. In 2011, she was one of Forbes' 30 Under 30 in Media. She graduated from Harvard, magna cum laude with highest honors in literature, in 2005. Irin's key topics include: *I Dissent: How Ruth Bader Ginsburg Became the Notorious RBG*, *What Ruth Bader Ginsburg's Life & Work Can Teach Us About Reproductive Freedom*, *What's at Stake for Women at The Supreme Court*, *Reporting on #MeToo: An Account from the Journalistic Trenches*.



**Wafaa El-Sadr**

*Columbia University, USA*

Wafaa El-Sadr is the founder and director of ICAP at Columbia University, University Professor of Epidemiology and Medicine and Mathilde Krim-amfAR Professor of Global Health at Columbia University. She established ICAP at the Columbia Mailman School of Public Health, a large Center engaged in the design and implementation of programs in more than 30 countries around the world.

Dr. El-Sadr currently serves as co-principal investigator of the NIH-funded HIV Prevention Trials Network (HPTN) which supports diverse HIV prevention research studies around the world. Her research interests are diverse and include research on the prevention and treatment of HIV, tuberculosis, non-communicable diseases, maternal-child health among others. She was born in Egypt, received her medical degree from Cairo University, a master's in public health (in Epidemiology) from Columbia's Mailman School of Public Health and a master's in public administration from Harvard University's Kennedy School of Government. She was named as McArthur fellow in 2008 and is a member of the National Academy of Medicine.

**Geoff Garnett***Bill & Melinda Gates Foundation, USA*

Geoff Garnett works as a Deputy Director at the Bill and Melinda Gates Foundation on improving the effectiveness and sustainability of HIV testing, treatment and prevention programs. Prior to this Geoff was a Professor at Imperial College London researching the epidemiology, evolution and control of HIV and other sexually transmitted infections. Geoff's work combines mathematical modeling of the transmission dynamics of HIV and STIs and methods of evaluation and uses mathematical models to understand the potential impact, effectiveness, cost effectiveness and budget impact of interventions. His current research interests include the use of HIV prevention cascades in the planning and monitoring of HIV prevention interventions, understanding the drivers of HIV risk behavior and adoption of prevention interventions, and how targets and indicators can be used to improve HIV interventions.

**Kevin Hybiske***University of Washington, USA*

Dr. Kevin Hybiske is an Assistant Professor in the Division of Allergy and Infectious Diseases at the University of Washington, Seattle, USA. He has adjunct appointments in the Departments of Microbiology and Global Health at the University of Washington. His ongoing research interests concern the pathogenesis of and mechanisms of host manipulation by Chlamydia.

**Rena Janamnuaysook***The Thai Red Cross AIDS Research Center, Thailand*

Rena Janamnuaysook is a transgender woman and a health and human rights advocate from Bangkok, Thailand. She works as a program manager for transgender health at the Thai Red Cross AIDS Research Centre, where she established the Tangerine Community Health Center, the first sexual health and well-being clinic for transgender people in the region.

Rena also leads the Tangerine Academy for Transgender Health, where she provides technical assistance and capacity building interventions on key population-led health services, including HIV testing, PrEP, Same-Day ART and implementation research to community-based health centers, government partners and private sectors. Rena co-founded the Thai Transgender Alliance, the first transgender-owned human rights organization in Thailand. She received a master's degree in international development from the University of Birmingham, United Kingdom. Rena currently serves as a board member of the Asia Pacific Transgender Network and the Planned Parenthood Association of Thailand.

**Jørgen Jensen***Statens Serum Institut, Denmark*

Dr. Jørgen Skov Jensen is a consultant physician at SSI where he is heading the Research Unit for Reproductive Microbiology.

For more than 25 years, he has been working with mycoplasmas, in particular *Mycoplasma genitalium*. His current focus is on *M. genitalium* antimicrobial susceptibility aiming to improve treatment. He has been part of the European STI Guidelines Project Editorial Board since 2006 and was the lead author on the *M. genitalium* guideline – an area where hard evidence from treatment trials is limited.

**Charlotte Loppie***University of Victoria, Canada*

Dr. Charlotte Loppie is a Professor in the School of Public Health and Social Policy and Research Lead for the Faculty of Human and Social Development, University of Victoria. Dr. Loppie's research partners have included individual First Nation communities, regional and national Indigenous organizations as well as provincial and national government stakeholders. Dr. Loppie has undertaken research and published in the areas of: Indigenous health, Indigenous HIV/AIDS, social determinants of Indigenous health, racism and cultural safety, Indigenous ethics and research capacity building as well as the sexual and reproductive health of Indigenous women.

**Christina Marra***University of Washington, USA*

Dr. Marra completed residency training in Neurology and fellowship training in Infectious Diseases at the University of Washington, in Seattle, Washington, USA. She is Professor and Vice Chair for Academic Affairs in Neurology, and she has an adjunct appointment in Medicine (Infectious Diseases), at the University of Washington. Dr. Marra directs a US National Institute of Health-funded clinical and translational research program on factors that influence the clinical course of syphilis, with a particular focus on HIV and on neurosyphilis. She received the American Sexually Transmitted Diseases Association Achievement Award in 2014 for work in this area. She also participates in multi-center clinical research on the neurological consequences of HIV, and she provides general neurological care in inpatient and outpatient settings, including a multispecialty HIV clinic.

**Johan Melendez***Johns Hopkins University, USA*

Johan Melendez, MS, PhD, is a research fellow in the Division of Infectious Diseases at the Johns Hopkins School of Medicine. Dr. Melendez has almost 20 years of experience in the development and evaluation of molecular approaches for characterization of gonorrhea, chlamydia and other infectious agents, and biomarkers of human sexual behavior. His current research focuses on the development, evaluation, and implementation of rapid tests for the diagnosis of STIs and characterization of antimicrobial resistant gonorrhea.

**David Peters***Johns Hopkins University, USA*

David Peters is an internationally renowned expert in health systems who has worked as a researcher, policy advisor, educator, manager, and clinician in dozens of low and middle-income countries (LMICs). Peters' work seeks to improve the performance of health systems in LMICs through implementation science, and by building institutional capacity and creating innovations in organization, technology, and financing of health systems. He has published 8 books and monographs, more than 20 book chapters, and over 125 peer-reviewed articles. While working at the World Bank, he pioneered the Sector Wide Approaches (SWAps) in health, which is used by countries to define and implement national strategies and the allocation of foreign aid. In India, he led a research program to examine health systems and inequities, which became the basis for national policies to improve access and financing for health care. In Afghanistan, he created the first nationally implemented Balanced Scorecard to assess and manage health services.

**Tonia Poteat***University of North Carolina, USA*

Dr. Poteat is an Assistant Professor of Social Medicine at the University of North Carolina in the Center for Health Equity Research. Her research, teaching, and clinical practice focus on HIV and LGBTQ health with particular attention to the role of stigma in driving health disparities. Certified as an HIV Specialist by the American Academy of HIV Medicine, she is a leader in HIV research and care with transgender persons. She has a special interest in the intersections of gender, sexuality, race, class, and health. Dr. Poteat received a Master of Medical Science degree from Emory University's Physician Assistant (PA) Program; a Master's of Public Health from Rollins School of Public Health; and a PhD in the Social and Behavioral Interventions Program in the Department of International Health at Johns Hopkins School of Public Health.

**Helena Seth-Smith***University Hospital Basel, Switzerland*

Helena Seth-Smith uses genomic data to investigate bacterial evolution. In her current role within the Division of Clinical Microbiology at the University Hospital Basel, Switzerland, she tries to answer questions relating to emerging pathogens, outbreaks and transmission. An ongoing interest is in sexually transmitted pathogens, having worked for many years on *Chlamydia trachomatis* (in addition to *Chlamydia suis*, *abortus* and *pecorum*), published cases on sexually transmitted *Shigella sonnei*, and now exploring diversity and antibiotic resistance in *Neisseria gonorrhoeae*. She cut her genomic teeth at the Sanger Institute in Cambridge, UK, analysing the genomes of many and varied pathogens. Her PhD at the Institute of Biotechnology, University of Cambridge identified a gene cluster involved in explosive breakdown by *Rhodococcus*. As bacterial pathogens show no sign of weakening, and STIs will always transmit, she is pleased that she has chosen a fascinating and satisfying career in a field which can only expand.

**Rebecca Thurston***University of Pittsburgh, USA*

Rebecca C. Thurston, PhD. Dr. Thurston is Professor of Psychiatry, Epidemiology, Psychology, and Clinical and Translational Science, and Director of the Women's Biobehavioral Health Research Program at the University of Pittsburgh. Dr. Thurston's research interests focus on midlife women's psychosocial experiences, reproductive aging, and cardiovascular health. She takes a biopsychosocial perspective, focusing on exposures prevalent among women and important to their cardiovascular health. As such, Dr. Thurston is Principal Investigator of NIH R01-funded studies on cardiovascular disease and brain aging in women as well as a NIH K24 award supporting interdisciplinary mentoring and training in midlife women's cardiovascular health. For the past 14 years, Dr. Thurston has been an investigator of the Study of Women's Health Across the Nation, one of the largest multiethnic prospective cohort studies of midlife aging in women. Dr. Thurston is a recipient of the Henry Burger Award from the International Menopause Society, is President Elect of the North American Menopause Society, and is an elected fellow of the Academy of Behavioral Medicine Research.

**David Wilson***World Bank, USA*

David Wilson is Program Director in the World Bank's Health, Population and Nutrition global practice. He leads the World Bank's Global Solutions Groups in support of Health Systems Strengthening for UHC and also leads a Decision Science initiative focusing on technological innovation. Before joining the Bank in 2003, David worked as an academic, development practitioner and global health advisor for 20 years. David has over published over 100 scientific papers and delivered over 1,000 scientific addresses. He has worked in high- and low-income contexts in over 50 countries on all continents.

Debate Speakers



**Christopher Fairley**  
Monash University, Australia

Christopher Fairley is the Director of Melbourne Sexual Health Centre, Alfred Health and Professor of Public Health at Monash University. He holds three specialist medical fellowships from the College of Physicians (Infectious Diseases), Faculty of Public Health and Chapter of Sexual Health Medicine, and is a fellow of the Royal College of Physicians and a fellowship of the Australian Academy of Health and Medical Sciences. He is an editor of the Journal 'Sexual Health'. His principle research interests are the public health control of sexually transmitted diseases and the effectiveness of clinical services. He sits on the boards of IUSTI and ISSTDTR.



**Hunter Handsfield**  
University of Washington, USA

Dr. Handsfield is Professor Emeritus of Medicine, University of Washington. He received his medical degree from Columbia University and served his residency training in internal medicine and fellowship in infectious diseases at the University of Washington. His 40-year career has addressed the clinical aspects, epidemiology, and prevention of STDs. For 25 years he directed the Public Health—Seattle & King County STD Control Program, Seattle, Washington. Dr. Handsfield is former president of ISSTDTR and a current IUSTI Senior Counselor, former president of the American Sexually Transmitted Diseases Association, a current member of ASTDA's Executive Committee, an Associate Editor of Sexually Transmitted Diseases, and the 2010 recipient of the ASTDA's Distinguished Career Award (formerly Thomas Parran Award).

Through generous donations, the following 28 scholarship recipients have been provided with support to attend the STI & HIV 2019 World Congress. Thank you to the American, Sexually Transmitted Diseases Association (ASTDA), the International Union Against Sexually Transmitted Infections (IUSTI), International Society for Sexually Transmitted Diseases Research (ISSTDTR) Foundation, and the British Association for Sexual Health and HIV (BASHH).



**Funded by a full scholarship from the American Sexually Transmitted Diseases Association (ASTDA)**

- Raphael Ondondo, Kenya
- Beatriz Paiatto, Brazil



**Funded by a full scholarship from the International Union Against Sexually Transmitted Infections (IUSTI)**

- Anthony Ajayi, South Africa
- Natsayi Chimbindi, South Africa
- Liza Coyer, Netherlands
- Douglas Gaitho, Kenya
- Lorraine McDonagh, United Kingdom
- Avid Mohammadi, Canada



**Funded by a full scholarship from the International Society for Sexually Transmitted Diseases Research (ISSTDTR) Foundation**

- Adebola Adejimi, Nigeria
- Iyaloo Konstantinus, Namibia
- YiQiao Li, Canada
- Ismaël Maatouk, Lebanon
- Charlotte Peters, Netherlands
- Laura Thompson, Canada



**Funded by a full scholarship from the BASHH - ISSTDTR (ISON) Scholarships**

- Ling Yuan Kong, United Kingdom
- Diarmuid Nugent, United Kingdom



**Funded by a partial scholarship from the International Society for Sexually Transmitted Diseases Research (ISSTDTR) Foundation**

- Louis MacGregor, United Kingdom
- Brian van der Veer, Netherlands



**Funded by a partial scholarship from the International Union Against Sexually Transmitted Infections (IUSTI)**

- Uma Chaudhry, India



**Partial travel bursaries provided by BASHH**

- Sophie Candfield, United Kingdom
- Jessica Doctor, United Kingdom
- Deborah Goode, United Kingdom
- Emma Wallis, United Kingdom



**Funded by a STI & HIV 2019 World Congress Scholarship**

- Jonathan Gootenberg, United States
- Smarajit Jana, India
- Primrose Matambanadzo, Zimbabwe
- Mark Pakianathan, United Kingdom
- Pachara Sirivongrangson, Thailand

# ABSTRACT REVIEWERS

FIRST NAME	LAST NAME	COUNTRY
Oluwafemi	Adeagbo	South Africa
Michel	Alary	Canada
Mat	Beale	UK
Tara	Beattie	UK
Marissa	Becker	Canada
Adele	Benzaken	Brazil
Julie	Bettinger	Canada
James	Blanchard	Canada
Chris	Bourne	Australia
Viviane	Bremer	Germany
Kate	Brookmeyer	USA
Rebecca	Brotman	USA
Denton	Callander	Australia
Caroline	Cameron	Canada
Allison	Carter	Australia
Nomathemba	Chandiwana	South Africa
Xiang-Sheng	Chen	China
Marcus	Chen	Australia
Harrell	Chesson	USA
Admire	Chikandiwa	South Africa
Eric	Chow	Australia
Frances	Cowan	UK
Marco	Cusini	Italy
Alex	de Voux	USA
Henri	de Vries	Netherlands
Souleymane	Diabaté	Côte d'Ivoire
Patricia	Dittius	USA
Basil	Donovan	Australia
Mark	Drew Crosland Guimarães	Brazil
Krista	English	Canada
Nigel	Field	UK
Errol	Fields	USA
Dennis	Fortenberry	USA
Jamie	Frankis	UK
Hongyun	Fu	USA
Patricia	Galarza	Argentina
Patricia	Garcia	Peru
Suzanne	Garland	Australia
Charlotte	Gaydos	USA
Dionne	Gesink	Canada
Khalil	Ghanem	USA
Lorenzo	Giacani	USA
Jane	Goller	Australia
Sami	Gottlieb	Switzerland
Hunter	Handsfield	USA
Devon	Hensel	USA
Betsy	Herold	USA
Jane	Hocking	Australia
Matthew	Hogben	USA
Ned	Hook	USA
Gwenda	Hughes	UK
Shajy	Isac	India
Jorgen	Jensen	Denmark
Jeff	Jin	Australia
Christine	Johnston	USA
Bob	Kircaldy	USA
Patricia	Kissinger	USA
David	Koelle	USA
Fabian	Kong	Australia
Jami	Leichliter	USA
David	Lewis	Australia

# ABSTRACT REVIEWERS

Penny	Loosier	USA
Sarah	Lowe	Zimbabwe
Carla Gianna	Luppi	Italy
Laio	Magno	Brazil
Irene	Martin	Canada
Phillippe	Mayaud	UK
Nick	Medland	Australia
Supriya	Mehta	USA
Hana	Mijovic	Canada
Angelica Espinosa	Miranda	Brazil
Sharmistha	Mishra	Canada
Hamish	Mohammed	UK
Sinead Delany	Moretwe	South Africa
Christina	Muzny	USA
Landon	Myer	South Africa
Chmbindi	Natsayi	South Africa
Ndeindo	Ndeikoundam	France
Francis	Ndowa	Zimbabwe
Trang	Nguyen	USA
Abby	Norris Turner	USA
Catherine	O'Connor	Australia
Gina	Ogilvie	Canada
Jason	Ong	UK
Mark	Pakianathan	UK
Preeti	Pathela	USA
Tom	Peterman	USA
Remco	Peters	South Africa
Michael	Pickles	Canada
Ravi	Prakash	India
Alison	Quayle	USA
BM	Ramesh	Canada
Kees	Rietmeijer	USA
Anne	Rompalo	USA
Minttu	Ronn	USA
Jonathan	Ross	UK
Tariq	Sadiq	UK
Shailendra	Sawleshwarkar	Australia
Euphemia	Sibanda	Zimbabwe
Mihael	Skerlev	Croatia
Pam	Sonnenberg	UK
Ian	Spicknall	USA
Gianfranco	Spiteri	Sweden
Weiming	Tang	USA
Amanda	Tanner	USA
Meredith	Temple-Smith	Australia
Caroline	Thng	Australia
James	Thomas	USA
Peter	Timms	Australia
Elizabeth	Torrone	USA
Katy	Turner	UK
Anneli	Uusküla	Estonia
Birgit	van Benthem	Netherlands
Rick	Varma	Australia
Maria	Veras	Brazil
Lenka	Vodstrcil	Australia
Bea	Vuysteke	Belgium
Reynold	Washington	India
Janet	Wilson	UK
Rachel	Winer	USA
Gwen	Wood	USA
Iryna	Zablotska-Manos	Australia
Jonathan	Zenilman	USA

# PROGRAM AT A GLANCE

	SATURDAY   JULY 13, 2019	SUNDAY   JULY 14, 2019
7:00		
7:30		
8:00	<b>ISSTDR Board Meeting</b> (By Invitation Only) [08:00 - 12:30]	<b>Pre-Congress Symposia</b> [08:00 - 12:00]
8:30		
9:00		
9:30		
10:00		
10:30		
11:00		
11:30		
12:00		
12:30		
13:00	ISSTDR Board Member-IUSTI Executive Committee Lunch [12:30 - 13:00]	
13:30	<b>IUSTI Canada - ASTDA Career Development Symposium for Emerging Investigators and Program Leaders</b> (By Invitation Only) [08:45 - 15:30]	<b>Pre-Congress Symposia</b> [13:00 - 17:00]
14:00		
14:30		
15:00		
15:30		
16:00		
16:30	<b>1st IUSTI Executive Meeting</b> (By Invitation Only) [13:00 - 18:00]	
17:00		
17:30		<b>Welcome Ceremony</b> [17:30 - 18:30]
18:00		<b>Opening Keynote Lecture</b> [18:30 - 19:30]
18:30		
19:00		
19:30	<b>Presidents' Dinner (By Invitation Only)</b> [19:30 - 22:00]	<b>Welcome Reception</b> [19:30 - 21:00]
20:00		
20:30		
21:00		
21:30		
22:00		

# PROGRAM AT A GLANCE

	MONDAY   JULY 15, 2019	TUESDAY   JULY 16, 2019	WEDNESDAY   JULY 17, 2019
7:00			
7:30			
8:00	<b>Clinical Case Series</b> [07:00 - 08:00]	<b>Clinical Case Series</b> [07:00 - 08:00]	<b>Clinical Case Series</b> [07:00 - 08:00]
8:30	ASTDA Young Investigator Mentor/Mentee Breakfast Session [07:00 - 08:00]	ASTDA Young Investigator Mentor/Mentee Breakfast Session [07:00 - 08:00]	ASTDA Young Investigator Mentor/Mentee Breakfast Session [07:00 - 08:00]
9:00	<b>Breakfast Symposium</b> [07:00 - 08:00]	<b>Breakfast Symposium</b> [07:00 - 08:00]	<b>Breakfast Symposium</b> [07:00 - 08:00]
9:30	<b>Plenary Sessions 1 - 3</b> [08:15 - 10:00]	<b>Plenary Sessions 7 - 8</b> [08:15 - 10:00]	<b>Plenary Sessions 12 - 13</b> [08:15 - 09:25]
10:00			
10:30			
10:30	Welcome by Elder, Coast Salish Nations [10:00 - 10:15]	Welcome by Elder, Coast Salish Nations [10:00 - 10:15]	
11:00	<b>Coffee Break</b> [10:15 - 10:45]	<b>Coffee Break</b> [10:15 - 10:45]	<b>Coffee Break</b> [10:15 - 10:45]
11:30	<b>Concurrent Symposia and Abstract Sessions</b> [10:45 - 12:15]	<b>Concurrent Symposia and Abstract Sessions</b> [10:45 - 12:15]	<b>Concurrent Symposia and Abstract Sessions</b> [10:45 - 12:15]
12:00			
12:30	<b>Lunch Symposium</b> [12:30 - 13:30]	<b>ASTDA Awards Luncheon</b> [12:15 - 13:45]	<b>Lunch Symposium</b> [12:30 - 13:30]
13:00	IUSTI General Assembly [12:45 - 13:45]		
13:30	<b>Plenary Sessions 4 - 6</b> [13:45 - 15:30]	<b>Plenary Sessions 9 - 11</b> [13:45 - 15:30]	<b>Concurrent Symposia and Abstract Sessions</b> [13:45 - 15:15]
14:00			
14:30			
15:00	<b>Coffee Break</b> [15:30 - 16:15]	<b>Coffee Break</b> [15:30 - 16:15]	<b>Coffee Break</b> [15:15 - 15:45]
15:30	<b>Concurrent Symposia and Abstract Sessions</b> [16:15 - 17:45]	<b>Concurrent Symposia and Abstract Sessions</b> [16:15 - 17:45]	<b>Closing Keynote Lecture</b> [15:45 - 16:45]
16:00			<b>Closing Ceremony</b> [16:45 - 18:00]
16:30	<b>Poster Viewing</b> [17:45 - 19:00]	<b>Poster Viewing</b> [17:45 - 19:00]	<b>2nd IUSTI Executive Meeting (By Invitation Only)</b> [18:00 - 20:00]
17:00	<b>Evening Symposium</b> [18:30 - 19:30]		
17:30			
18:00	<b>Speakers' Dinner (By Invitation Only)</b> [19:30 - 22:00]	<b>Congress Dinner (Ticketed Event)</b> [19:30 - 22:00]	
18:30			
19:00			
19:30			
20:00			
20:30			
21:00			
21:30			
22:00			

# ASTDA & IUSTI North America

Join the preeminent professional association of STD researchers, practitioners, and prevention specialists in the United States and Canada.



**ASTDA AWARDS LUNCHEON  
TUESDAY, JULY 16, 12:15-13:45**

**Distinguished Career Award**  
*Charlotte Gaydos, DrPH, MPH*

**Achievement Award**  
*Patricia Kissinger, PhD, MPH*

**Young Investigator Award**  
*Yonatan Grad, MD, PhD*



**Exclusive Membership Benefits**




Joint ASTDA & IUSTI members get benefits from both organizations. These include:

- Free subscription to ASTDA's journal, *Sexually Transmitted Diseases*.
- A 40% discount on a subscription to IUSTI's journal, the *International Journal of STD and AIDS*.
- Reduced registration fees for the biannual STD Conference and most IUSTI regional and world meetings.

**Sexually Transmitted Diseases Journal**

- Submit your STD-related manuscripts.
- Read the latest peer-reviewed, original articles on current research.
- Explore the "Real World of STD Prevention," focused on clinical and prevention practice and the science-to-program interface.

Join TODAY at [www.ASTDA.org](http://www.ASTDA.org)



**American Sexually Transmitted Diseases Association**  
PO Box 12665 Research Triangle Park, NC 27709  
919-861-9399

## SCIENTIFIC PROGRAM (SATURDAY & SUNDAY)

- **Career Development Symposium for Emerging Investigators and Program Leaders** ..... Saturday, July 13
- **Pre-Congress Symposia and Opening Keynote** ..... Sunday, July 14
- **Scientific Program** ..... Monday, July 15
- **Scientific Program** ..... Tuesday, July 16
- **Scientific Program** ..... Wednesday, July 17
- **Posters**

### SATURDAY, JULY 13, 2019

- 08:45 - 15:30 **IUSTI Canada - ASTDA Career Development Symposium for Emerging Investigators and Program Leaders**  
(By Invitation Only)  
Location: MR 11+12
- 09:00 - 09:20 Introductions  
- Marc Steben
- 09:20 - 10:30 "Speed Intros"
- 10:30 - 10:45 Coffee Break
- 10:45 - 11:45 Finding Funding:  
Canada: Scott Gray-Owen Industry:  
USA: Julie Dombrowski Ajith Joseph, Abbott  
Courtney Maus, BD  
Hologic  
Chris McGowin, Roche
- 11:45 - 13:00 Lunch / Career Panel  
- Chris L. McGowin, Max Chernesky, Petra Smyczek
- 13:00 - 14:00 Manuscript Workshop  
- Bill Miller
- 14:00 - 15:00 Small Group Discussions
- Work-life balance and avoiding burnout: Abigail Norris-Turner
  - How to grow your network/increase visibility: Max Chernesky
  - Thorny issues in collaboration: Julie Dombrowski
  - Balancing clinical, research and teaching: Irene Martin
  - Community engagement, health departments & advisory boards: Marc Steben
- 15:00 - 15:30 Conclusion and Next Steps

### SUNDAY, JULY 14, 2019

- PRE-CONGRESS SYMPOSIA**
- 09:00 - 16:30 **Pre-Congress Symposium 1 - Phase specific strategies for STI and HIV control redux: Resurgence, concentrations, networks, key populations, and magic bullets**  
Location: MR 11+12
- 09:05 - 09:35 STI/HIV prevention today  
- Sevgi Aral, Centers for Disease Control and Prevention, USA
- 09:35 - 10:05 Background and progress in phase-specific strategies  
- Judy Wasserheit, University of Washington, USA
- 10:05 - 10:35 Emerging research methods and collaborations to improve program design and implementation  
- Geoff Garnett, Bill & Melinda Gates Foundation, USA

11:00 - 11:30 Appraising epidemic phases and transmission dynamics – insights from epidemiology and mathematical modeling  
- Sharmistha Mishra, University of Toronto, Canada

11:30 - 12:00 ART-based prevention: Observations on the pathway from efficacy to effectiveness  
- Myron Cohen, University of North Carolina, USA

12:00 - 12:30 Round table discussion – what have we learned from modeling about targeting for HIV prevention, and what more do we need to learn?

13:30 - 14:00 How can we improve resource allocation and management in the changing global HIV Landscape?  
- David Wilson, World Bank, USA

14:00 - 14:30 HIV and STI prevention program design: Back to the basics  
- James Blanchard, University of Manitoba, Canada

14:45 - 15:15 Challenges in the implementation of new interventions for HIV/STI  
- Helen Ward, Imperial College London, UK

15:15 - 15:45 Phase shifts in HIV and STI epidemics in Sub-Saharan Africa: Implications for programs and science  
- Richard Hayes, London School of Hygiene & Tropical Medicine, UK

15:45 - 16:15 Round table discussion - phase specific strategies and future priorities for program science

16:15 - 16:30 Wrap-up - Concluding Remarks  
- Sevgi Aral

08:00 - 12:00

**Pre-Congress Symposium 2 - The global challenges and opportunities of STIs in pregnancy**

Location: MR 9

Organized by University of California Los Angeles

08:00 - 08:10 Welcome  
- Jackie McDowell, Cepheid

08:10 - 08:30 Overview  
- Jeffrey D Klausner, UCLA - David Geffen School Of Medicine, Los Angeles, USA

08:30 - 08:55 Curable STIs in pregnant women living in Brazil; A challenge ripe for intervention  
- Nava Yeganeh, University of California, Los Angeles, USA

08:55 - 09:20 Syndromic management for STIs during pregnancy just doesn't cut it anymore: Implementing diagnostic screening to reduce adverse birth outcomes in South Africa  
- Andrew Medina-Marino, Foundation of Professional Development, South Africa

09:20 - 09:45 Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-income settings: The WANTAIM Trial, Papua New Guinea  
- Andrew Vallely, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea & The Kirby Institute, UNSW Sydney, Australia

09:45 - 10:10 Antenatal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* testing compared to syndromic management in Botswana: A cost-effectiveness study  
- Adriane Wynn, University of California, San Diego, USA

10:20 - 10:45 *Chlamydia trachomatis* screening and treatment among pregnant women in China: Evidence and challenges  
- Weiming Tang, University of North Carolina at Chapel Hill, USA

10:45 - 11:10 The ASPIRE Trial – aiming for safe pregnancies: Reducing malaria and infections of the reproductive tract in Zambia  
- Matthew Chico, London School of Hygiene & Tropical Medicine, United Kingdom

11:10 - 11:35 Enhancing nutrition and antenatal infection treatment for maternal and child health (ENAT) study: Screening and treating genitourinary tract infections to improve birth outcomes in Amhara, Ethiopia  
- Rose L. Molina, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

11:35 - 12:00 Summary and next steps  
- Nicola Low, Institute of Social and Preventive Medicine, University of Bern, Switzerland

08:00 - 12:00

**Pre-Congress Symposium 3 - Understanding variability and improving the reproducibility of genital microbiome research**

Location: MR 2+3

Chair: Jen Balkus, University of Washington, USA

08:00 - 08:15 Introductions and motivations for the Vaginal Microbiome Laboratory Variability Project (MLVP)  
- Jen Balkus, University of Washington, USA

08:15 - 08:30 Overview of the Vaginal Microbiome Laboratory Variability Project  
- David Fredricks, Fred Hutchinson Cancer Research Center, USA

08:30 - 09:00 Laboratory challenges and opportunities to reduce variability: Lessons learned from the MLVP  
- Sujatha Srinivasan, Fred Hutchinson Cancer Research Center, USA  
- Darrell Dinwiddie, University of New Mexico, USA

09:00 - 09:30 Bioinformatics challenges and opportunities to reduce variability: Lessons learned from the MLVP  
- Johanna Holm, University of Maryland, USA  
- Liam Van Der Pol, University of Alabama, USA

10:00 - 10:20 Statistical analyses and challenges for assessing variability  
- Jim Hughes, University of Washington, USA  
- Pawel Gajer, University of Maryland, USA

10:20 - 10:40 Successes and challenges of implementing the MLVP and opportunities to improve reproducibility moving forward  
- Jacques Ravel, University of Maryland, USA

10:40 - 11:30 Round table discussion with other experts engaged in vaginal microbiome research  
- Carolyn Deal, NIAUD/DMID, USA  
- Jennifer Fettweis, VCU, USA  
- Doug Kwon, Ragon Institute, USA  
- Deborah Money, UBC, Canada

08:00 - 12:00

**Pre-Congress Symposium 4 - Shaking the trees: Optimizing treatment and antimicrobial stewardship for STIs**

Location: MR 1

Facilitators: Laura Bachmann, MD, MPH - Medical Director, CDC Division of STD Prevention & Christine Johnson, MD, MPH - Associate Professor, University of Washington at Seattle; Medical Director, University of Washington STD Prevention Training Centers

Talk 1. Global STI trends and priorities for antimicrobial resistance  
- Teodora Elvira Wi, STI Department of Reproductive Health and Research, World Health Organization, Switzerland



Talk 2. Pharmacokinetics and pharmacodynamics – factors to consider for STI treatment  
- Jane Hocking, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Australia

Talk 3. Resistance emergence: Single vs combination therapies  
- George L. Drusano, Institute for Therapeutic Innovation, University of Florida, USA

Talk 4. Molecular tests for prediction of antimicrobial resistance (or susceptibility) in *N. gonorrhoeae* and *M. genitalium*  
- Magnus Unemo, WHO Collaborating Centre for Gonorrhoea and other STIs, Swedish Reference Laboratory for STIs, Örebro University Hospital, Sweden

Talk 5. Are we ready for this? - Antimicrobial stewardship for STIs  
- Arlene C. Seña, Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill; Medical Director, Durham County Department of Public Health, USA

08:00 - 12:00

**Pre-Congress Symposium 5 - The resurgence of syphilis: What have we learned and how can we respond?**

Location: MR: 8+15

Organized by David Lewis and Gwenda Hughes

Refreshments supported by Western Sydney Sexual Health, University of Sydney, Australia

08:00 - 08:10 Welcome and Introduction

08:10 - 08:30 Syphilis: A historical overview  
- David Lewis, University of Sydney, Australia

08:30 - 09:00 Keynote lecture: Syphilis: What we know and what we need to know  
- Sheila Lukehart, University of Washington, USA

09:00 - 09:20 The application of modern technologies to the goal of syphilis elimination  
- Caroline Cameron, University of Victoria, Canada

09:20 - 09:40 What can we learn about syphilis from whole genome sequencing of global *Treponema pallidum* strains  
- Nick Thomson, Sanger Institute, UK

09:40 - 10:00 Syphilis in the context of HIV co-infection  
- Khalil Ghanem, Johns Hopkins University, USA

10:00 - 10:20 Syphilis, the great imitator: Unusual case presentations of syphilis in adults  
- Somesh Gupta, All India Institute of Medical Sciences, India

10:40 - 11:00 Recent trends in syphilis in women and congenital syphilis in developed countries: A changing epidemiology?  
- Gwenda Hughes, Public Health England, UK

11:00 - 11:20 Drivers and determinants for the rising incidence of syphilis in men-who-have-sex-with-men  
- Kyle Bernstein, Centers for Disease Control and Prevention, USA

11:20 - 11:40 Responding to syphilis in China: The importance of key populations  
- Xiang-Sheng Chen, National Center for STD Control, China

11:40 - 12:00 Syphilis control efforts and public health policy: Global perspectives  
- Francis Ndowa, Skin & GU Medicine Clinic, Harare, Zimbabwe

08:00 - 12:00

**Pre-Congress Symposium 6 - The role of brief behavioural interventions in a combination prevention approach to sexually transmitted infections, including HIV**

Location: MR 7

**PART I - SRH behavioural interventions Global State of Affairs Co-chairs:**

- Igor Toskin, World Health Organization, Switzerland
- King Holmes, Dept. of Global Health & Medicine, University of Washington, USA
- Carmen Logie, University of Toronto, Canada

08:00 - 08:20 WHO perspective on behavioural interventions  
- Igor Toskin, World Health Organization, Switzerland

08:20 - 08:40 Exploring the landscape of behavioural HIV/STI prevention interventions in Canada  
- Carmen Logie, University of Toronto, Canada

08:40 - 09:00 Scientific evidence of effectiveness of behavioural interventions for shifting sexual health outcomes  
- Rob Stephenson, Center for Sexuality and Health Disparities, University of Michigan, USA

09:00 - 09:20 Delivering behavioural interventions through e-health and mHealth technologies  
- Keith Horvath, University of Minnesota, USA

09:40 - 10:00 Screening of a behavioural intervention using Motivational Interviewing (MI)

**PART II - Country perspectives behavioural interventions and WHO Brief Sexuality-related Communication (BSC) feasibility study**

**Co-chairs:**

- Igor Toskin, World Health Organization, Switzerland
- King Holmes, Dept. of Global Health & Medicine, University of Washington, USA
- Carmen Logie, University of Toronto, Canada

10:30 - 10:50 MI in France

- Experiences and results of MI-training for pharmacists
  - MI-training for counsellors of an HIV phone-service, 'SIDA-infoservice'
- Thierry Troussier, Chaire UNESCO Santé sexuelle et Droits humains, Paris, France

10:50 - 11:00 Introduction of the WHO BSC feasibility study  
- Sofia de Vasconcelos, World Health Organization, Switzerland

11:00 - 11:15 WHO BSC feasibility study in Peru: Results of the formative phase and next steps  
- Carlos Caceres, Universidad Peruana Cayetano Heredi, Peru

11:15 - 11:30 WHO BSC feasibility study in Moldova: Populations and objectives  
- Natalia Bakunina, World Health Organization, Switzerland / Larisa Boderscova, WHO, Moldova

11:30 - 11:45 Behavioural intervention showcase (video)  
- youth counselling  
- M-health intervention  
- BSC training video Peru

08:00 - 12:00

**Pre-Congress Symposium 7 - Ibero-American Network on Gay Men, others MSM and Trans Studies (RIGHT) and the Latin American Men Who Have Sex With Men Internet Survey (LAMIS)**

Location: MR 13

Talk 1. The Ibero-American network on gay men, others MSM and trans studies (RIGHT)

- Valeria Stuardo Ávila, Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Santiago, Chile

Talk 2. The methodological framework of Latin American men who have sex with men internet survey (LAMIS) in light of the prior EMIS studies

- Ulrich Marcus, Robert Koch Institute, Berlin, Germany

Talk 3. Implementation of LAMIS as a collaborative effort in Latin American countries

- Carlos Cáceres, Centro de Investigación Interdisciplinaria en Sexualidad, SIDA y Sociedad, Universidad Peruana Cayetano Heredia, Lima, Peru

Talk 4. General results - descriptive analysis of LAMIS 2018: Implications for collaborative public policies in the Latin American region

- Jordi Casabona, Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Barcelona, Spain

Talk 5. HIV among MSM and TGW in Brazil: Different approaches, same striking results

- Maria Amélia Veras, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Núcleo de Pesquisa em Direitos Humanos e Saúde LGBT, Brazil

08:00 - 12:00

**Pre-Congress Symposium 8 - The next frontier of treatment and prevention of sexually transmitted infections: Expedited partner therapy use in heterosexuals, adolescents, men who have sex with men, and transgender women**

Location: MR 14

Talk 1. Expedited partner therapy

- Okeoma Mmeje, University of Michigan, USA

Talk 2. MPH expedited partner therapy use in heterosexuals

- Jenell Coleman, Johns Hopkins University, USA

Talk 3. Expedited partner therapy use in adolescents & school-based clinics

- Nicole Speck, University of Michigan, USA

Talk 4. Support for expedited partner therapy use in men who have sex with men & transgender women

- Kristi Gamarel, University of Michigan, USA  
- Raha Richardson, University of Michigan, USA

Talk 5. Implications for expedited partner therapy use in men who have sex with men

- Julia Schillinger, Centers for Disease Control and Prevention, USA

13:00 - 15:00

**Pre-Congress Symposium 9 - Highlights of selected topics from the Canadian STI guidelines**

Location: MR 8+15

*Chair(s): Max Chernesky, McMaster University, Canada*

*Margaret Gale-Rowe, PHAC, Canada*

13:00 - 13:30 *Mycoplasma genitalium*

- Annie-Claude Labbe, Université de Montréal, Canada

13:00 - 14:00 Gonorrhoea: Approach to management in the setting of rising antimicrobial resistance

- Ameeta Singh, University of Alberta, Canada

14:00 - 14:30 Prenatal screening for STBBIs

- Mark Yudin, University of Toronto, Canada

15:00 - 17:00

**Pre-Congress Symposium 10 - IUSTI Canada Symposium: Innovative platforms and interventions against gonorrhoea**

Location: MR 8+15

Talk 1. International dissemination of ceftriaxone-resistant

*Neisseria gonorrhoeae* strain (FC428)

- Petra Smyczek, Alberta Health Services, Edmonton, Alberta, Canada

Talk 2. What's new in gonococcal antimicrobial resistance and diagnosis of AMR

- Jo-Anne Dillon, Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, Canada

Talk 3. New anti-gonococcal antibiotics, discovery and pipeline

- Gerry Wright, McMaster University, Hamilton, Ontario, Canada

Talk 4. Almost Human: Advanced preclinical models for gonococcal vaccine and drug development

- Scott Gray-Owen, University of Toronto, Toronto, Ontario, Canada

13:00 - 17:00

**Pre-Congress Symposium 11 - Proteomics**

Location: MR 14

*Chair: Leonard Foster, UBC, Canada*

Talk 1. Metaproteomics for discovering mechanisms and biomarkers in the vaginal microbiome

- Adam Burgener, University of Manitoba, Canada

Talk 2. Towards the development of a SISCAPA assay for direct measurement of *T. pallidum* proteins in bodily fluids

- Morty Razavi, SISCAPA Assay Technologies (SAT), Canada

Talk 3. When and how to bring in proteomics

- Leonard Foster, UBC, Canada

Talk 4. Practical considerations for moving proteomic tests into the clinic

- Angela Fung, Clinical Chemist, St. Paul's Hospital, Vancouver, Canada

13:00 - 17:00

**Pre-Congress Symposium 12 - Sexually transmitted infection vaccines - opportunities for research, development and implementation**

Location: MR 1

Opening remarks:

- Troy Grennan & Monika Naus, University of British Columbia & the BC Centre for Disease Control, Canada

13:10 - 13:25 The current landscape of STI vaccines  
- Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA

13:25 - 13:40 STI vaccine roadmap  
- Sami Gottlieb, World Health Organization, Switzerland

13:40 - 13:55 Will the world accept STI vaccines? Lessons from the HPV vaccine  
- Simon Dobson, University of British Columbia, Canada

13:55 - 14:55 STI vaccine development updates: Current science and future directions  
- Syphilis: Caroline Cameron, University of Victoria, Canada  
- Gonorrhoea: Rino Rappuoli, GSK Vaccines, Italy  
- Chlamydia: Kevin Hybiske, University of Washington, USA  
- HSV: Anna Wald, University of Washington, USA

15:10 - 15:55 Priority setting for future science & research (panel discussion)  
- Moderated by: Scott Lamontagne, University of Washington, USA  
- Caroline Cameron, University of Victoria, Canada  
- Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA  
- Rino Rappuoli, GSK Vaccines, Italy  
- Peter Dull, Bill & Melinda Gates Foundation

15:55 - 16:40 Implementation challenges in public health (panel discussion)  
- Moderated by: Scott Lamontagne, University of Washington, USA  
- Sami Gottlieb, World Health Organization, Switzerland  
- Bonnie Henry, Government of British Columbia, Canada  
- Manish Sadarangani, Vaccine Evaluation Centre, Canada  
- Peter Dull, Bill & Melinda Gates Foundation

Closing remarks:  
- Manish Sadarangani, Vaccine Evaluation Centre, Canada  
- Gina Ogilvie, School of Population and Public Health (SPPH), Canada

13:00 - 17:00

**Pre-Congress Symposium 13 - Accelerating development and implementation of point-of-care tests for sexually transmitted infections: Challenges, achievements, and way forward**

Location: MR 9

**PART I - STI POCT Global State of Affairs**

*Chair(s):*  
- Igor Toskin, World Health Organization, Switzerland  
- Rosanna Peeling, London School of Hygiene and Tropical Medicine, United Kingdom

13:00 - 13:15 WHO Initiative on STI POCT: vision, progress and way forward  
- Igor Toskin, World Health Organization, Switzerland

13:15 - 13:25 Epidemiology of gonococcal infections in infertile populations: Systematic review and meta-analyses  
- Hiam S. Chemaitelly, Weill Cornell Medical College, Qatar

13:25 - 13:45 POC diagnostic tests and technologies for sexually transmitted infections: A landscape analysis  
- Maurine Murtagh, World Health Organization, Switzerland

13:45 - 14:05 Policy development and Implementation successes and challenges in introducing STI POCTs  
- Rosanna Peeling, London School of Hygiene and Tropical Medicine, United Kingdom

14:05 - 14:25 Rapid AMR-test technology to enable immediate accurate treatment and enhance AMR surveillance  
- Tariq Sadiq, St George's University of London, United Kingdom

14:25 - 14:35 Sample self-collection and STI self-testing  
- Ellen Kersh, Centers for Disease Control and Prevention (CDC), Atlanta, USA

**PART II - Country Perspective and Current WHO STI POCT Evaluation Studies**

*Chair(s):*  
- Ranmini Kularatne, Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa  
- Ron Ballard, World Health Organization, Switzerland

15:15 - 15:40 Independent multi-country clinic-based evaluation of STI POCTs: Study design, methodology, research instruments, data management system and current status  
- Soe Soe Thwin, World Health Organization, Switzerland  
- Massimo Mirandola, University of Verona, UoV, Italy  
- Karel Blondeel, World Health Organization, Switzerland

15:40 - 16:00 Independent multi-country clinic-based evaluation of STI POCTs: internal quality control and external quality assurance:  
- NG/CT/TV: Ellen Kersh, Centers for Disease Control and Prevention (CDC), Atlanta, USA  
- HIV/syphilis: Kelly Andrewartha, Flinders University, Adelaide, Australia

16:00 - 16:35 Independent multi-country clinic-based evaluation of STI POCTs, implementation in selected sites:

- Italy: challenges and opportunities in piloting the study procedures and engaging with MSM in an outpatient setting  
- Maddalena Cordioli, University of Verona, UoV, Italy
- South Africa: Current status, programmatic needs and challenges  
- Ranmini Kularatne, Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
- Peru  
- Carlos Cáceres, Universidad Peruana Cayetano Heredia, Peru

16:35 - 16:45 Independent multi-country clinic-utility evaluation of STI diagnostics: study design, methodology, research instruments, data management system and current status  
- Jordi Casabona, Centre d'Estudis Epidemiològics sobre les ITS i Sida de Catalunya, CEEISCAT, Spain

13:00 - 17:00

**Pre-Congress Symposium 14 - Preparing Sexual Health Services for Antimicrobial Resistance Bacteria: A Global Perspective**

Location: MR 2+3

*Organizing committee: Dr Katy Turner, Prof Nicola Low, Dr Yonatan Grad, Prof Teodora Wi, Prof Magnus Unemo, Dr Minttu Ronn*

13:00 Session 1 - Setting the scene

Talk 1. WHO perspectives on the threat of AMR – global challenges of surveillance  
- Teodora Wi, World Health Organization, Switzerland

Talk 2. Antimicrobial resistance in *Neisseria gonorrhoeae* and *Mycoplasma genitalium*  
- Magnus Unemo, World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Sweden

Talk 3. Epidemiological trends in AMR in *Neisseria gonorrhoeae* and implications for services  
- Nicola Low, University of Bern, Switzerland

13:45 Quantifying the surveillance needed to sustain genetic marker-based antibiotic resistance diagnostics  
- Yonatan Grad, Harvard T.H. Chan School of Public Health, USA

13:50 Modelling evolution of resistance over time in *N. gonorrhoeae*  
- Liliith Whittles, Imperial College London, UK

14:00 Modelling the impact of resistance on gonorrhoea epidemiology  
- Katy Turner, University of Bristol, UK

14:00 Session 2 - Global perspective

14:30 Modelling vaccination as a way to control AMR  
- Laith Abu Raddad, Weill Cornell Medical College, Qatar

14:45 Impact of vaccination on the sustainable transmission of *Neisseria gonorrhoeae* [*Neisseria gonorrhoeae* in italics] drug-resistant strains  
- Shaheen Seedat, Stellenbosch University, South Africa

14:55 The Brazilian public health policy for gonorrhoea  
- Pâmela Cristina Gaspar, Ministry of Health, Brazil

15:10 Gonorrhoea in the era of AMR, diagnostic needs for improved antimicrobial stewardship in low and middle income countries  
- Cecilia Ferreyra, FIND, Switzerland

13:00 - 17:00

**Pre-Congress Symposium 15 - Understanding the costs and benefits of sexual health services and interventions: A guide for clinicians and researchers**

Location: MR 13

Organized by Dr Louise Jackson

13:00 - 13:15 The economics of sexual health services and interventions – a service perspective  
- Jonathan Ross, University of Birmingham, UK

13:15 - 14:00 Overview of key principles in analysing costs and benefits in Sexual Health  
- Tracy Roberts, University of Birmingham, UK

14:00 - 14:45 A practical guide to collecting and analysing data on costs and benefits  
- Louise Jackson, University of Birmingham, UK

15:00 - 16:00 Activity – analysing an economic study

16:00 - 16:40 Workshop – developing an evaluation

16:40 - 17:00 Synthesis & next steps  
- Jonathan Ross, University of Birmingham, UK  
- Tracy Roberts, University of Birmingham, UK

13:00 - 17:00

**Pre-Congress Symposium 16 - BS21 Network: Behavioural surveillance for HIV and STIs in the 21st century**

Location: MR 7

Talk 1. Introduction to contemporary behavioural surveillance  
- Lisa McDaid, University of Glasgow, UK  
- Nathan Lachowsky, University of Victoria, Canada

Talk 2. The current state of behavioural surveillance (panel discussion)  
- Nathan Lachowsky, University of Victoria, Canada  
- Patrick Sullivan, Emory University, USA  
- Benjamin Bavinton, Kirby Institute, Australia  
- Peter Saxton, University of Auckland, New Zealand  
- Jamie Frankis, Glasgow Caledonian University, UK

Talk 3. Changing HIV epidemics and representativeness of behavioural surveillance research (panel discussion)  
- Peter Saxton, University of Auckland, New Zealand  
- Nathan Lachowsky, University of Victoria, Canada  
- Jamie Frankis, Glasgow Caledonian University, UK

Talk 4. Why do we still need behavioural surveillance in the age of biomedical HIV prevention? (panel discussion)  
- Benjamin Bavinton, Kirby Institute, Australia  
- Jamie Frankis, Glasgow Caledonian University, UK  
- Patrick Sullivan, Emory University, USA

Talk 5. Neglected populations and regions (panel discussion)  
- Jacqueline Gahagan, Dalhousie University, Canada  
- Tyrone Curtis, University College London, UK  
- Harlan Pruden, BC Centre for Disease Control, Canada  
- Patrick Sullivan, Emory University, USA  
- Jamie Frankis, Glasgow Caledonian University, UK  
- John Kim, Public Health Agency of Canada, Canada

Talk 7. Community engagement in behavioural surveillance research (panel discussion)  
- David Brennan, University of Toronto, Canada  
- Jeff Morgan, CBRC - Community Based Research Centre for Gay Men's Health, Canada  
- Lisa McDaid, University of Glasgow, UK

Talk 8. Application of theoretical models to periodic behavioural surveillance and what is missed if you do not have one (panel discussion)  
- Paul Flowers, Glasgow Caledonian University, UK  
- Kiffer Card, Simon Fraser University, Canada

**LOCATION: BALLROOM**

17:30 - 18:30

**Welcome Ceremony**

Chairpersons: Caroline Cameron, ISSTD President and Congress President, and Charlotte Gaydos, IUSTI President and Congress Co-President

18:30 - 19:30

**K01 Opening Keynote Lecture**

Chairpersons: Caroline Cameron, President, International Society for Sexually Transmitted Diseases Research, University of Victoria, Canada and Henry de Vries, STI & HIV 2021 World Congress President, Amsterdam University Medical Centers, The Netherlands

**2019 ISSTD PRESTIGIOUS LECTURE: BACTERIAL STI VACCINES - ETERNAL DREAM OR FUTURE REALITY?**

Rino Rappuoli, GSK Vaccines, Italy

19:30 - 21:00

**Welcome Reception**

Location: Exhibit Hall A

Key to tracks (colours)

- Basic Science & Translational Research (BSTR)
- Clinical Science (CS)
- Epidemiology & Monitoring (EM)
- Behavioural & Social Science (BSS)
- Policy & Community Engagement (PCE)
- Program & Implementation Science (PIS)
- Special Symposia

MONDAY, JULY 15, 2019

07:00 - 08:00

**CCS01 Clinical Case Series - Syphilis: The great imitator**

Location: MR 8+15

*Chairpersons: Stephanie Cohen, San Francisco Department of Public Health, USA and Khalil Ghanem, Johns Hopkins University, USA*

CCS01.1 Neurosyphilis is more common among malignant syphilis: Based on case series evidence  
- Pingyu Zhou, Shanghai Skin Disease Hospital, China

CCS01.2 A case series of syphilis masquerading as thoracic malignancy  
- Jessica Doctor, Guys' and St Thomas's NHS Foundation Trust, UK

CCS01.3 Syphilis as fibromyalgia with unexplained hepatosplenomegaly  
- Jackie Sherrard, Buckinghamshire Healthcare NHS Trust, UK

**LOCATION: BALLROOM**

08:15 - 08:50

**PL01.1 Plenary 1**

*Chairperson: Sheila Lukehart, University of Washington, USA*

**The role of genomics in the diagnosis and management of STIs**  
**Helena Seth-Smith, University Hospital Basel, Switzerland**

08:50 - 09:25

**PL02.1 Plenary 2**

*Chairperson: Edward Hook, University of Alabama at Birmingham, USA*

**Identification and management of complicated syphilis**  
**Christina Marra, University of Washington, USA**

09:25 - 10:00

**PL03.1 Plenary 3**

*Chairperson: James Ward, South Australian Health and Medical Research Institute, Australia*

**Engaging indigenous communities in health programs**  
**Charlotte Loppie, University of Victoria, Canada**

10:00 - 10:15

**Welcome by Elder, Coast Salish Nations**

*Chairperson: Mark Gilbert, BCCDC, Canada*

10:15 - 10:45

**Coffee Break**

Location: Exhibit Hall A

10:45 - 12:15

**S01 Symposium 1**

**Program science/implementation science methods: Moving beyond the traditional RCT**

*Chairpersons: Nicola Low, Institute of Social and Preventative Medicine, Switzerland and Marissa Becker, University of Manitoba, Canada*

Location: MR 11+12

S01.1 Must the evaluation of complex interventions be complex? Learning from the impact evaluation of DREAMS  
- Isolde Birdthistle, The London School of Hygiene & Tropical Medicine, UK

S01.2 HPTN 071 (PopART): Findings and lessons from a non-traditional RCT  
- Richard Hayes, The London School of Hygiene & Tropical Medicine, UK

S01.3 Using multiple data sources for program evaluation: Integration of program monitoring data with other research studies  
- Banadakoppa Ramesh, University of Manitoba, Canada

S01.4 Evaluating complex public health issue violence - understanding and measuring violence and evaluating violence interventions - lessons from STRIVE  
- Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, South Africa

10:45 - 12:15

**S02 Symposium 2**

**HIV and syphilis self-testing and self-collection: Empowerment, agency and implementation**

*Chairpersons: Judith Wasserheit, University of Washington, USA and Adele Schwartz Benzaken, Tropical Medicine Foundation, Brazil*

Location: MR 1

S02.1 HIV self-testing in Eastern and Southern Africa: The STAR project  
- Maryam Shahmanesh, Institute for Global Health, University College London, UK

S02.2 Syphilis self-testing: A nationwide pragmatic study among men who have sex with men in China  
- Cheng Wang, Southern Medical University, China

S02.3 HPV self-collection in Peru: Project HOPE  
- Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru

S02.4 Empowerment and approaches for stigma reduction: Implementation of HIV self-testing among female sex workers  
- Catherine Oldenburg, University of California, San Francisco, USA

10:45 - 12:15

**S03 Symposium 3**

**Epidemiological aspects of STI transmission in MSM**

*Chairpersons: Gwenda Hughes, Public Health England, UK and Maarten Schim van der Loeff, Center for Infection and Immunity Amsterdam, Academic Medical Center, Amsterdam, The Netherlands*

Location: Ballroom

S03.1 Impact of HIV PrEP on risk compensation and STI epidemiology – what does the evidence show?  
- Helen Ward, Imperial College London, UK

S03.2 The role of oral-anal transmission in persistence of chlamydial infection  
- Henry de Vries, University of Amsterdam, Netherlands

S03.3 Sexual transmission of *N. meningitidis* in MSM and implications for public health  
- Anna McNulty, Sydney Sexual Health Centre, Australia

S03.4 Hepatitis C in HIV-negative MSM – a growing concern?  
- Axel J. Schmidt, London School of Hygiene & Tropical Medicine, UK

**S04 Symposium 4**  
**The impact of advances in diagnostic technology on policy, program and practice (ISSTD Special Symposium)**

Chairpersons: *Barbara van der Pol, University of Alabama at Birmingham, USA and Rosanna Peeling, London School of Hygiene & Tropical Medicine, UK*  
 Location: MR 2+3

- S04.1 Resistance-guided therapy for *M.genitalium*: Impact of diagnostic resistance assays on practice and policy  
 - Catriona Bradshaw, Central Clinical School, Monash University, Australia
- S04.2 Point of care and home testing opportunities: Implications for quality public health practice  
 - Patricia Dittus, Centers for Disease Control and Prevention, USA
- S04.3 Home based testing: Unintended consequences and implications for antimicrobial stewardship – should we be concerned?  
 - Paddy Horner, Population Health Sciences, University of Bristol, UK
- S04.4 Implementing molecular testing to predict *Neisseria gonorrhoeae* susceptibility in clinical practice  
 - Jeffrey D. Klausner, UCLA - David Geffen School Of Medicine, USA

**O01 Oral Presentation Session 1**  
**Development of vaccines for bacterial STIs**

Chairpersons: *Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA and Kate Seib, Griffith University, Australia*  
 Location: MR 8+15

- O01.1 Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine  
 - Henju Marjuki, Centers for Disease Control and Prevention, USA
- O01.2 Genetic, structural, and surface antigenic variation of *Treponema pallidum*'s OMPeome: Steps towards a global syphilis vaccine  
 - Kelly Hawley, Connecticut Children's Medical Center, USA
- O01.3 Engineering hybrid bacterial transferrin receptor-based vaccines to confer broad protection against *Neisseria gonorrhoeae*  
 - Scott Gray-Owen, University of Toronto, Canada
- O01.4 Rabbit immunization with *B. burgdorferi* expressing *T. pallidum* TprK and Tp0435 as a novel vaccine design for syphilis  
 - Lorenzo Giacani, University of Washington, USA
- O01.6 A meningococcal native outer membrane vesicle vaccine as a platform for presenting conserved gonococcal antigens  
 - Gregory Moe, UCSF Benioff Children's Hospital Oakland, USA
- O01.6 Meningococcal vesicle vaccines deleted for major outer membrane proteins enhance gonococcal clearance in a murine model  
 - Kathryn Matthias, US Food and Drug Administration, USA

**O02 Oral Presentation Session 2**  
**Extragenital bacterial STIs: Epidemiology, natural history, testing and antimicrobial resistance**

Chairpersons: *Jackie Sherrard, Bucks Healthcare NHS Trust, UK and Remco Peters, Anova Health Institute and University of Pretoria, South Africa*  
 Location: MR 13

- O02.1 What Is the optimal testing strategy for oropharyngeal *Neisseria gonorrhoeae* in women visiting STI clinics?  
 - Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), The Netherlands

10:45 - 12:15

12:15 - 13:45

13:45 - 14:20

- O02.2 Oropharyngeal and genital gonorrhoea among heterosexuals who report sexual contact with partners with gonorrhoea  
 - Eric Chow, Monash University, Australia
- O02.3 Antimicrobial resistance in pharyngeal *Neisseria gonorrhoeae* infection: A cross-sectional study in men who have sex with men  
 - Hester Allen, Public Health England, UK
- O02.4 Incidence and duration of pharyngeal and rectal gonorrhoea and chlamydia among high-risk men who have sex with men (MSM)  
 - Lindley Barbee, University of Washington, USA
- O02.5 Inflammatory cytokines in rectal gonorrhoea/chlamydia infection and treatment: Towards STI control as HIV prevention for MSM  
 - Jesse Clark, UCLA Geffen School of Medicine, USA
- O02.6 Extragenital *Mycoplasma genitalium* infections amongst men who have sex with men  
 - Rosie Latimer, Monash University, Australia

**O03 Oral Presentation Session 3**  
**Persistence and resistance**

Chairpersons: *Anna Maria Geretti, University Of Liverpool, UK and Ranmini Kularatne, National Institute for Communicable Diseases, South Africa*  
 Location: MR 9

- O03.1 Natural history of genital and oral herpes simplex virus-1 (HSV-1) shedding after first episode genital HSV-1 infection  
 - Christine Johnston, University of Washington, USA
- O03.2 Detection of glycosylated *Treponema pallidum* proteins: Relevance for diagnostic assays and importance for infection  
 - Alloysius Gomez, University of Victoria, Canada
- O03.3 The European gonococcal antimicrobial surveillance programme findings 2017  
 - Michaela Day, Public Health England, UK
- O03.4 Modelling intervention strategies for preventing spread of extensively drug resistant gonorrhoea strains among Australian MSM  
 - Qibin Duan, University of New South Wales, Sydney, Australia
- O03.5 Utility of real-time whole genome sequencing in partner notification and control of *Neisseria gonorrhoeae* infection  
 - Ling Yuan Kong, Leeds Teaching Hospitals NHS Trust, UK
- O03.6 Vaginal bacteria and risk of incident and persistent infection with high risk sub-types of human papillomavirus  
 - Kayla Carter, University of Washington, USA

Break

**LOCATION: BALLROOM**

**PL04.1 Plenary 4**

Chairperson: *Janet Wilson (IUSTI President-Elect), Leeds Teaching Hospitals NHS Trust, UK*

**2019 IUSTI Prestigious Lecture - Revising STI treatment guidelines in times of rapidly evolving antimicrobial resistant STIs**  
**Jørgen Jensen, Statens Serum Institut, Denmark**

14:20 - 14:55

**PL05.1 Plenary 5**

Chairperson: *Maria Amelia de Sousa Mascena Veras, Faculdade De Ciências Médicas Da Santa Casa De São Paulo, Brazil*

**Priorities for research and programmes for trans communities**  
**Tonia Poteat, University of North Carolina, USA**

14:55 - 15:30

**PL06.1 Plenary 6**

Chairperson: *Sevgi Aral, CDC, USA*

**Mathematical modelling, a luxury or a necessity in STD control?**  
**Geoff Garnett, Bill & Melinda Gates Foundation, USA**

15:30 - 16:15

**Coffee Break**

Location: Exhibit Hall A

16:15 - 17:45

**S05 Symposium 5**

**Community engagement, mobilization and empowerment**

Chairpersons: *Maryam Shahmanesh, Institute for Global Health, University College London, UK and Igor Toskin, WHO, Switzerland*  
 Location: MR 2+3

S05.1 Working with community to control HIV/STI: A U.S. local health department perspective  
 - Matthew Golden, University of Washington, USA

S05.2 Mobilising for health and rights: A history of sex worker activism in India  
 - Smarajit Jana, Sonagachi Research and Training Institute, India

S05.3 Mobilization and empowerment of sex workers: Can self-help groups bring about sustained change?  
 - Primrose Matambanadzo, CeSHHAR, Zimbabwe

S05.4 #SaveSexy: A gamified approach to harnessing the power of community activism for HIV testing promotion  
 - Benedict Bernabe, Red Whistle, Philippines

16:15 - 17:45

**S06 Symposium 6**

**Improved models and tools for STI infections**

Chairpersons: *Nicholas Thomson, Wellcome Sanger Institute, UK and Lorenzo Giacani, University of Washington, USA*  
 Location: MR 9

S06.1 Use of cervical explants to study gonococcal pathogenesis  
 - Daniel Stein, University of Maryland, USA

S06.2 *Bringing culture to the uncultured: Long-term culture of the syphilis spirochete, Treponema pallidum*  
 - Steven Norris, University of Texas, USA

S06.3 Pigtailed macaque model of STIs  
 - Dorothy Patton, University of Washington, USA

S06.4 Chlamydia, trichomonas and syphilis infections in macaques: Effects on simian HIV acquisition  
 - Sundaram Ajay Vishwanathan, Center for Disease Control and Prevention, USA

16:15 - 17:45

**S07 Symposium 7**

**Sexual health at the intersection of substance use and social inequality**

Chairpersons: *Mark Pakianathan, The London School of Hygiene & Tropical Medicine, UK and Vincent Cornelisse, Kirketon Road Centre, Australia*  
 Location: Ballroom

S07.1 The North American overdose crisis: How structural violence, prohibition and stigma have paralyzed our response  
 - Mark Tyndall, BC Centre for Disease Control, Canada

S07.2 Chemsex and new STI/HIV diagnoses among gay, bisexual and other men who have sex with men attending sexual health clinics  
 - Aseel Hegazi, St George's University Hospital Foundation Trust, UK

S07.3 Challenges in defining Chemsex. Answers for surveillance from EMIS-2017  
 - Axel Schmidt, London School of Hygiene & Tropical Medicine, UK

S07.4 Review of sexualized drug use associated with sexually transmitted infections (STI) in men who have sex with men (MSM)  
 - Fiona Guerra, Public Health Ontario, Canada

16:15 - 17:45

**O04 Oral Presentation Session 4**

**Antimicrobial resistance in STI pathogens**

Chairpersons: *Jo-Anne Dillon, University Of Saskatchewan, Canada and Tariq Sadiq, St George's, University of London, UK*  
 Location: MR 1

O04.1 Novel pathway to ceftriaxone resistance in clinical isolates of *N. gonorrhoeae* via point mutations in the RNA polymerase  
 - Yonatan Grad, Harvard T.H. Chan School of Public Health, USA

O04.2 Phylogenomic analysis reveals persistence of *Neisseria gonorrhoeae* clades with reduced susceptibility to cephalosporins  
 - Jesse Thomas, US Centers for Disease Control and Prevention, USA

O04.3 Prioritizing novel drug targets based on genomics and proteomics approach in *Neisseria gonorrhoeae*  
 - Daman Saluja, University of Delhi, India

O04.4 *Mycoplasma genitalium parC* and *gyrA* mutations associated with moxifloxacin and sitafloxacin treatment failure  
 - Gerald Murray, The Royal Women's Hospital, Australia

O04.5 Point-of-care magnetofluidic assay cartridge for *Neisseria gonorrhoeae* detection and antimicrobial resistance determination  
 - Alexander Trick, Johns Hopkins University, USA

O04.6 Prediction of available drug targets of *Neisseria gonorrhoeae* based on codon usage parameter  
 - Uma Chaudhry, Bhaskaracharya College of Applied Sciences, University of Delhi, India

**O05 Oral Presentation Session 5**

**Female genital infections, immunology and microbiome**

Chairpersons: *Rebecca Brotman, University of Maryland School of Medicine, USA and Yaw Adu Sarkodie, Kwame Nkrumah University of Science and Technology, Ghana*  
 Location: MR 13

O05.1 Lower genital tract predictors of acute endometritis among women with signs and symptoms of pelvic inflammatory disease (PID)  
 - Sharon Hillier, University of Pittsburgh and Magee-Womens Research Institute, USA

005.2 Characterizing the impact of penile-vaginal sex on HIV-susceptible CD4+ T Cell subsets in the female genital tract  
- Avid Mohammadi, University Of Toronto, Canada

005.3 The combined contraceptive vaginal ring increases Th17-related cytokines in the genital tract: A randomized crossover trial  
- Iyaloo Konstantinus, University of Cape Town, South Africa

005.4 The effect of the combined oral contraceptive pill on the vaginal microbiota of women treated for bacterial vaginosis  
- Larissa Ratten, Monash University, Australia

005.5 A case control study to examine the cervico-vaginal microbiota associated with pelvic inflammatory disease  
- Sally Sweeney, Family Planning New South Wales, Australia

005.6 Cervicovaginal metabolic profiling reveals the interplay between HPV, microbiota and inflammation in cervical carcinogenesis  
- Melissa Herbst-Kralovetz, University of Arizona, USA

16:15 - 17:45

**006 Oral Presentation Session 6  
STI/HIV treatment efficacy and effectiveness**

*Chairpersons: Jonathan Ross, University of Birmingham, UK and Catriona Bradshaw, Melbourne Sexual Health Centre, Australia*  
Location: MR 11+12

006.1 Gentamicin for pharyngeal gonorrhoea: A single-arm, non-blinded clinical trial  
- Lindley Barbee, University of Washington, USA

006.2 In vitro combination testing and selection of resistance to zoliflodacin combined with six antimicrobials for *N. gonorrhoeae*  
- Magnus Unemo, World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Sweden

006.3 Efficacy of resistance guided therapy for *Mycoplasma genitalium* using doxycycline followed by azithromycin or moxifloxacin  
- Duygu Durukan, Monash University, Australia

006.4 Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac)  
- Richard Gilson, University College London, UK

006.5 Do treatment rates suffer in a low-touch screening model? New York City sexual health clinics, 2017-2018  
- Kelly Jamison, New York City Department of Health and Mental Hygiene, USA

006.6 Reduction in adherence to antiretroviral therapy during postpartum: Findings from a prospective cohort study  
- Anthony Ajayi, University of Fort Hare, South Africa

16:15 - 17:45

**007 Oral Presentation Session 7  
Bugs, behaviour and beyond: New challenges for STI control among gay, bisexual and other men who have sex with men**

*Chairpersons: Nigel Field, University College London, UK and Chris Bourne, Centre For Population Health, Australia*  
Location: MR 8+15

007.1 Multiple lineages of multiresistant shigella in Australia  
- Deborah Williamson, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Australia

007.2 Use of whole-genome sequencing to identify sexual transmission of shigella in men who have sex with men in England  
- Holly Mitchell, University College London, UK

007.3 Sexually transmissible enteric infections in men who have sex with men: Preliminary findings from a cross-sectional study  
- Holly Mitchell, University College London, UK

007.4 Incidence of sexual behaviors and relationship to the urethral microbiota among men who have sex with men (MSM) in Seattle  
- Laura Chambers, University of Washington, USA

007.5 The index case's partnership status is important in predicting the likelihood of persistence of introduced XDR NG among MSM  
- Ben Hui, University of New South Wales, Sydney, Australia

007.6 A RCT to facilitate psychosocial care among high risk MSM in Amsterdam, a SYNdemic BASEd Intervention (Syn.bas.In Study)  
- Roel Achterbergh, Public Health Service of Amsterdam, The Netherlands

17:45 - 19:00

**PS01 Poster Viewing Session**  
Location: Exhibit Hall A

**TUESDAY, JULY 16, 2019**

07:00 - 08:00

**CCS02 Clinical Case Series  
Clinical cases from experts**

*Chairpersons: Julie Dombrowski, University of Washington, USA and Kees Rietmeijer, Rietmeijer Consulting, USA*  
Location: MR 8+15

CCS02.1 Dequalinium chloride vaginal tablets for recalcitrant *Trichomonas vaginalis* (TV): A case report  
- Deborah Goode, Leeds Teaching Hospitals Trust, UK

CCS02.2 Penile intraepithelial neoplasia: Myriad presentations and intractable course  
- Suresh Gupta, All India Institute of Medical Sciences, India

CCS02.3 Persisting urethritis in an immunocompromised patient  
- William Geisler, University of Alabama at Birmingham, USA

**LOCATION: BALLROOM**

08:15 - 08:50

**PL07.1 Plenary 7**

*Chairperson: Thomas Quinn, NIH, USA*

**Global trends in HIV in the era of combination prevention – what progress have we made towards elimination?**  
**Wafaa El-Sadr, Columbia University, USA**

08:50 - 10:00

**PL08 Plenary 8**

**#MeToo movement, systems of power and sexual health and wellbeing: The widening of the #MeToo movement**  
*Moderator: Jacky Jennings, Johns Hopkins School of Medicine, USA*

**Panel:**

- **Rebecca Thurston, University of Pittsburgh, USA**  
- **Irin Carmon, New York Magazine & CNN Contributor, USA**



10:00 - 10:15

**Welcome by Elder, Coast Salish Nations**  
*Chairperson: Ameeta Singh, University of Alberta, Canada*

10:15 - 10:45

**Coffee Break**  
 Location: Exhibit Hall A

10:45 - 12:15

**S08 Symposium 8**  
**"Elders teach and youth reach": Indigenous conversations on sexual health**  
*Chairpersons: Elder Roberta Price, Indigenous Co-Lead for the Family Medicine Residency Program, Canada and Larissa Wahpooseyan, Youthco, Canada*  
 Location: MR 2+3

The idea for this symposium was developed through discussion with Elders from the Aboriginal Health Elders Advisory Council at Vancouver Coastal Health. This Council includes Elders from the Coast Salish peoples on whose land this conference is held, specifically the Skwxwú7mesh (Squamish), Selilwitulh (Tsleil-Waututh), and xʷməθkʷəy̓əm (Musqueam) Nations, and from Nations from the Four Directions.

The Aboriginal Health Elders Advisory Council will be leading this symposium in partnership with the Yuúusnewas program at YouthCO HIV & Hep C Society. The Yuúusnewas program is an Indigenous youth-led program that centres Indigenous teachings in conversations about sexual health and harm reduction. Through workshops and cultural activities, this team of educators creates spaces for all Indigenous young people to develop solutions to the impacts of HIV and Hep C stigma on youth in what is now called British Columbia.

**Support:**  
 Organization of this symposium is supported by members of the Conference nécaʔmat ct Indigenous Sexual Health Committee. Financial support for this symposium is provided by the BC Centre for Disease Control, First Nations Health Authority, Indigenous Services Canada, and the Vancouver Foundation.

10:45 - 12:15

**S09 Symposium 9**  
**Prevention and care cascades**  
*Chairpersons: Rebecca Guy, Kirby Institute, Australia and Nathan Lachowsky, University of Victoria / CBRC, Canada*  
 Location: MR 11+12

S09.1 The relationship between demographics, health needs and the HIV care cascade outcomes: From infection to viral suppression  
 - Abigail Kroch, Ontario HIV Treatment Network (OHTN), Canada

S09.2 Cascade of HIV prevention: A powerful tool to improve the implementation of DREAMS combination prevention in rural South Africa  
 - Maryam Shahmanesh, Institute for Global Health, University College London, UK

S09.3 Application of a cascade approach for guiding prevention of congenital syphilis  
 - Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru

S09.4 Cascades and other approaches to guide PrEP programming  
 - Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute,

10:45 - 12:15

**S10 Symposium 10**  
**STIs in low and middle-income countries: Resurgent infections and evolving control measures**  
*Chairpersons: Craig Cohen, UCSF, USA and Teodora Wi, World Health Organization, Switzerland*  
 Location: MR 8+15

S10.1 High rates of curable STIs in low and middle income countries  
 - Connie Celum, University of Washington, USA

S10.2 Building STD clinical infrastructure in LMIC – role of general vs. specialized infrastructure  
 - Ligang Yang, Southern Medical University, China

S10.3 Cervical cancer prevention in LMICs: Are we on the path to elimination?  
 - Megan Huchko, Duke University, USA

S10.4 Self-care interventions for sexual and reproductive health and rights  
 - Manjulaa Narasimhan, World Health Organization, Switzerland

10:45 - 12:15

**S11 Symposium 11**  
**Research on the vaginal microbiome: Advances & controversies**  
*Chairpersons: Jeanne Marrazzo, University of Alabama at Birmingham, USA and Sharon Hillier, University of Pittsburgh School of Medicine, USA*  
 Location: MR 1

S11.1 Introduction to the vaginal microbiome preconference symposium  
 - Jeanne Marrazzo, University of Alabama at Birmingham School of Medicine, USA

S11.2 Lessons learned from the pre-meeting symposium on characterizing the vaginal microbiota through a blinded multi-laboratory collaboration  
 - Jen Balkus, University of Washington, USA

S11.3 The vaginal microenvironment prior to incident STI  
 - Rebecca Brotman, University of Maryland School of Medicine, USA"

S11.4 Role of the genital tract microbiome in sexual and reproductive health: Report from the Keystone Symposium in Cape Town, 2018  
 - Janneke van de Wijger, University of Liverpool, UK and University Medical Center Utrecht, The Netherlands

10:45 - 12:15

**O08 Oral Presentation Session 8**  
**Getting real with implementing PrEP 1: Gay, bisexual and other men who have sex with men**

*Chairpersons: Susan Blank, NYC Dept Of Health & Mental Hygiene, USA and Gilbert Yang, Skin/STD Clinic, Philippines*  
 Location: Ballroom

O08.1 Pre-exposure prophylaxis in Brazil: Opportunities and challenges for men who have sex with men, Brazil, 2018  
 - Diego Calixto, Ministry of Health of Brazil, Brazil

O08.2 Sexual behaviour, risk and sexually transmitted infections before and after the introduction of the PrEP impact trial  
 - Louis MacGregor, University of Bristol, UK

O08.3 Rates of chlamydia and gonorrhoea testing and positivity before and after initiation of PrEP among MSM in US private settings  
 - Guoyu Tao, Centers for Disease Control and Prevention, USA

O08.4 Influence of HIV-status and PrEP use on high STI prevalences in MSM in Germany, 2018  
 - Klaus Jansen, Robert Koch Institute, Germany

O08.5 Trends in bacterial STI incidence and impact of PrEP use among MSM attending Western Sydney Sexual Health Centre (2013-2018)  
 - David Lewis, Western Sydney Local Health District, Australia

O08.6 Frequency and determinants of switching between daily or event-driven PrEP and discontinuing each regimen in Amsterdam MSM  
 - Liza Coyer, Public Health Service of Amsterdam, The Netherlands

10:45 - 12:15

**O09 Oral Presentation Session 9**

**Epidemiology and surveillance to inform practice and policy**

*Chairpersons: Viviane Bremer, Robert Koch-institute, Germany and Hannelore Götz, Public Health Service Rotterdam-Rijnmond, The Netherlands*  
Location: MR 13

- O09.1 The Netherlands chlamydia cohort study: Pregnancies in women with and without a previous chlamydia infection  
- Bernice Hoenderboom, National Institute for Public Health and the Environment, The Netherlands
- O09.2 Declines in chlamydia-associated PID at SSHS in England since 2007: What might this tell us about chlamydia control?  
- Paddy Horner, University of Bristol, UK
- O09.3 Potential *Neisseria gonorrhoeae* outbreak in heterosexuals younger than 25 revealed three clusters by culture-free genotyping  
- Brian Van Der Veer, Maastricht University Medical Center (MUMC+), The Netherlands
- O09.4 HIV and HCV among clients of female sex workers in Dnipro, Ukraine  
- Marissa Becker, University of Manitoba, Canada
- O09.5 Hepatitis C incidence rate among people who inject drug (PWID) in British Columbia from 2000 to 2015  
- YiQiao Li, British Columbia Center for Disease Control, Canada
- O09.6 Development of an integrated data mart for surveillance of sexually transmitted and bloodborne infections (STIBBI)  
- Jason Wong, BC Centre for Disease Control, Canada

12:15 - 13:45

**ASTDA Awards Luncheon**

Location: Ballroom C (West Building)

**LOCATION: BALLROOM**

13:45 - 14:20

**PL09.1 Plenary 9**

*Chairperson: William Geisler, University of Alabama at Birmingham, USA*

**Understanding chlamydia pathogenesis**

**Kevin Hybiske**, University of Washington, USA

14:20 - 14:55

**PL10.1 Plenary 10**

*Chairperson: Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, South Africa*

**The global HIV response at 40**

**David Wilson**, World Bank, USA

14:55 - 15:30

**PL11.1 Plenary 11**

*Chairperson: King Holmes, University of Washington, USA*

**Global health legacies, sustainable development goals, and implications for sexual & reproductive health**

**David Peters**, Johns Hopkins University, USA

15:30 - 16:15

**Coffee Break**

Location: Exhibit Hall A

16:15 - 17:45

**S12 Symposium 12**

**New approaches for STI vaccines**

*Chairpersons: Anna Wald, University of Washington, USA and Sami Gottlieb, World Health Organization, Switzerland*

Location: MR 2+3

- S12.1 Progress towards a gonorrhoea vaccine  
- Kate Seib, Griffith University, Australia
- S12.2 A tri-antigen protective syphilis vaccine design that enhances treponemal clearance and inhibits pathogen dissemination  
- Lorenzo Giacani, University of Washington, USA
- S12.3 Therapeutic vaccination to treat HPV disease: Lessons learned from high grade intraepithelial lesions  
- Margaret Madeleine (STI & HIV 2019 World Congress Scholarship Recipient), Fred Hutchinson Cancer Research Center, USA
- S12.4 A mucosal *Chlamydia trachomatis* vaccine stimulates protective memory T cells  
- Michael Starnbach, Harvard University, USA

16:15 - 17:45

**S13 Symposium 13**

**Controversies in clinical STI care**

*Chairpersons: Matthew Golden, University of Washington, USA and Christopher Fairley, Monash University, Australia*

Location: MR 11+12

- S13.1 Does azithromycin have a future in the treatment of gonorrhoea and chlamydial infection?  
- Jane Hocking, University of Melbourne, Australia
- S13.2 Should enteric infections in MSM always be treated?  
- Mark Pakianathan, The London School of Hygiene & Tropical Medicine, UK
- S13.3 Do rectal bacterial STIs in women matter? Who should we test and when?  
- Christine Khosropour, University of Washington, USA
- S13.4 HPV vaccination in MSM: Who should be vaccinated and is there a role for vaccination of older and/or HIV-positive MSM in preventing initial, persistent and recurrent HPV and related diseases?  
- David Templeton, University of Sydney, Australia

16:15 - 17:45

**S14 Symposium 14**

**Sexual networks and STI transmission: From modelling to practice**

*Chairpersons: Katy Turner, University of Bristol, UK and Laith Abu-Raddad, Weill Cornell Medicine, Qatar*

Location: Ballroom

- S14.1 Sexual contact networks, STI transmission and the effectiveness of interventions: Insights from mathematical modelling  
- Christian Althaus, University of Bern, Switzerland
- S14.2 Use of whole genome sequencing to explore transmission between sexual networks in an STI outbreak  
- Helen Fifer, Public Health England, UK

S14.3 Maximizing the acceptability, feasibility and validity of sexual network studies: Lessons from the field  
- Abby Norris Turner, Ohio State University, USA

S14.4 The role of sexual networks in the global spread of antimicrobial-resistance enteric infections  
- Nigel Field, University College London, UK

16:15 - 17:45

**O10 Oral Presentation Session 10**  
**Getting real with implementing PrEP 2**

*Chairpersons: Bradley Stoner, St. Louis STD/HIV Prevention Training Center, USA and Catherine O'Connor, Kirby Institute, Australia*  
Location: MR 8+15

O10.1 HIV pre-exposure prophylaxis (PrEP) indications and uptake vary by race, gender and insurance in a large clinic network  
- Maria Pyra, Howard Brown Health, USA

O10.2 Impact of HIV-PrEP for female-sex-workers on community-wide awareness, uptake and perceptions in a rural-area Kwazulu-Natal  
- Natsayi Chimbindi, Africa Health Research Institute (AHRI), South Africa

O10.3 High curable STI prevalence and incidence among young African women initiating PrEP in HPTN 082  
- Sinead Delany-Moretlwe, University of the Witwatersrand, South Africa

O10.4 Scaling up HCV screening and treatment for eliminating HCV among MSM in UK in the era of HIV pre-exposure prophylaxis  
- Louis MacGregor, University of Bristol, UK

O10.5 Patterns of HIV pre-exposure prophylaxis care one year after initiating PrEP, Baltimore City, Maryland 2015-2018  
- Linxuan Wu, Johns Hopkins University School of Medicine, USA

O10.6 A longitudinal analysis of men who have sex with men's condom use and attitudes during HIV antiretroviral prevention scale-up  
- Nathan Lachowsky, University of Victoria, Canada

16:15 - 17:45

**O11 Oral Presentation Session 11**  
**Improving the equity and effectiveness of sexual health care**

*Chairpersons: Elizabeth Foley, Solent NHS Trust, UK and Peter Saxton, University of Auckland, New Zealand*  
Location: MR 1

O11.1 An update on the performance of STI services for gay and bisexual men across 40 cities: Preliminary results from EMIS-2017  
- Jason Doran, London School of Hygiene & Tropical Medicine, UK

O11.2 How do the sexual networks of men who have sex with men in one mid-Atlantic city differ by race/ethnicity?  
- Jessica Wagner, Johns Hopkins University School of Medicine, USA

O11.3 "You feel invisible": A qualitative exploration of young LGBT+ people's attitudes towards STI/HIV testing in primary care  
- Lorraine McDonagh, University College London, UK

O11.4 Trans & gender diverse people's experiences of sexual health care are associated with sexual health screening uptake  
- Denton Callander, New York University, USA

O11.5 Impact of HIV self-testing on the promotion of HIV testing among men who have sex with men in China: A randomized controlled trial  
- Weibin Cheng, Dermatology Hospital of Southern Medical University, China

O11.6 Trends in chlamydia screening and pap testing among US females by age and race; National Survey of Family Growth, 2006-2017  
- Laura Haderxhanaj, Centers for Disease Control and Prevention, USA

16:15 - 17:45

**O12 Oral Presentation Session 12**  
**Understanding relationships and partner strategies for STI control**

*Chairpersons: John Saunders, University College London, UK and Matthew Hogben, Centers for Disease Control and Prevention, USA*  
Location: MR 13

O12.1 Exploring relationship duration among gay and bisexual men: A longitudinal event-level analysis  
- Kiffer Card, University of Victoria, Canada

O12.2 Partnership context and consistent condom use among young African American men  
- Megan Clare Craig-Kuhn, Tulane University School of Public Health and Tropical Medicine, USA

O12.3 Epidemiological impact of expedited partner therapy for men who have sex with men: A modeling study  
- Kevin Weiss, Emory University, USA

O12.4 Effects of enhanced STI partner notification counselling in Cape Town: Randomized controlled trial  
- Catherine Mathews, South African Medical Research Council, South Africa

O12.5 Partner notification outcomes for chlamydia/gonorrhoea cases diagnosed through clinics vs GetCheckedOnline in British Columbia  
- Arina Zamanpour, British Columbia Centre for Disease Control, Canada

O12.6 Contact tracing vs patient-delivered partner treatment for African American heterosexual men with chlamydia  
- Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

17:45 - 19:00

**PS02 Poster Viewing Session**  
Location: Exhibit Hall A

19:30 - 22:00

**Congress Dinner** (Ticketed Event)  
Location: Ballroom C + D (West Building)

**WEDNESDAY, JULY 17, 2019**

07:00 - 08:00

**CCS03 Clinical Case Series - Cases from the clinic**  
*Chairpersons: David Hawkins, Chelsea and Westminster Hospital, UK and Laura Bachmann, Centers for Disease Control and Prevention, USA*  
Location: MR 8+15

CCS03.1 Rapid PrEP reinitiation in a patient with ongoing risk  
- Negusse Ocbamichael PA-C, STD Clinic/Public Health-Seattle & King County at Harborview, USA

CCS03.2 Neonatal HSV: Could this transmission have been prevented?  
- Elizabeth Foley, Solent NHS Trust, UK

CCS03.3 Zoon balanitis in HIV-infected patient  
- Mauro Ramos, Ambulatório de Dermatologia Sanitária, Brazil

LOCATION: BALLROOM

08:15 - 08:50

**PL12.1 Plenary 12**

Chairperson: Magnus Unemo, WHO CC for STIs, Örebro University Hospital, Sweden

**Overview on the development of point-of-care tests for detection of antimicrobial resistance – challenges and opportunities**  
**Johan Melendez**, Johns Hopkins University, USA

08:50 - 09:25

**PL13.1 Plenary 13**

Chairperson: David Lewis, Western Sydney Sexual Health Centre/University of Sydney, Australia

**The role of key population-led health services in addressing the challenge of STI and HIV**  
**Rena Janamnuaysook**, The Thai Red Cross AIDS Research Centre, Thailand

09:25 - 10:15

**D01 Debate**

**Among men who have sex with men, pharyngeal infection contributes more to population levels of gonorrhea transmission than urethral infection, rectal infection, or both?**

**Chairperson:**

**Kyle Bernstein**, Centers for Disease Control and Prevention, USA

**Speaker(s):**

**D01.1** For the motion: **Kit Fairley**, Monash University, Australia

**D01.2** Against the motion: **Hunter Handsfield**, University of Washington, USA

10:15 - 10:45

**Coffee Break**

Location: Exhibit Hall A

10:45 - 12:15

**S15 Symposium 15**

**New approaches to STI diagnosis and prevention**

Chairpersons: **Laura Scyuro**, University of Calgary, Canada and **Ameeta Singh**, University of Alberta, Canada

Location: Ballroom

S15.1 Four *Treponema pallidum* proteins detected in urine from syphilis-infected individuals using mass spectrometry  
 - Chris Kenyon, Institute of Tropical Medicine, Belgium

S15.2 CRISPR Diagnostics: Expanding the nucleic acid detection toolbox by harnessing microbial diversity  
 - Jonathan Gootenberg, Massachusetts Institute of Technology, USA

S15.3 Reducing the global burden of infectious diseases through precision infection management (PIM)  
 - Ian Lewis, University of Calgary, Canada

S15.4 Combatting HIV with nanomaterials  
 - Kim Woodrow, University of Washington, USA

10:45 - 12:15

**S16 Symposium 16**

**Anatomical sites of infection: Biomedical, modeling, behavioral, and programmatic considerations for STI prevention**

Chairpersons: **Thomas Gift**, Centers For Disease Control And Prevention, USA and **Parinita Bhattacharjee**, University of Manitoba, Canada

Location: MR 2+3

S16.1 Anatomical sites of infection: Biomedical considerations for STI prevention  
 - Jane Hocking, University of Melbourne, Australia

S16.2 Modeling considerations related to multi-site infection  
 - Ian Spicknall, Centers for Disease Control and Prevention, USA

S16.3 Anatomical sites of infection: Behavioural considerations for STI prevention  
 - Catherine Mercer, University College London, UK

S16.4 Designing an approach to deal with extragenital sexually transmitted infections: Do we have the data we need?  
 - Jeanne Marrazzo, University of Alabama, USA

10:45 - 12:15

**S17 Symposium 17**

**Clinical issues in women's health and STI**

Chairpersons: **Gina Ogilvie**, University of British Columbia, Canada and **Anne Rompalo**, Johns Hopkins University School of Medicine, USA

Location: MR 11+12

S17.1 HPV screening – new evidence and current state of the art  
 - Suzanne Garland, The Royal Women's Hospital, Australia

S17.2 Treatment of bacterial vaginosis: How, when and how much?  
 - Caroline Mitchell, Harvard University, USA

S17.3 Screening women for bacterial STIs: Should we scale-back?  
 - Jonathan Ross, University of Birmingham, UK

S17.4 Prematurity and STI – value of screening and treatment  
 - Deborah Money, University of British Columbia, Canada

10:45 - 12:15

**S18 Symposium 18**

**Regional responses to global HIV/STI trends (IUSTI Special Symposium)**

Chairpersons: **Charlotte Gaydos**, Johns Hopkins University, USA and **Kaushal Verma**, Indian Institute of Science, India

Location: MR 13

S18.1 An update on the status of HIV/STIs in IUSTI's five regions  
 - Francis Ndowa, Skin & GU Medicine Clinic, Harare, Zimbabwe

S18.2 Bridging the gap - best practice global examples of integration of HIV and STI services  
 - Janet Wilson, National Health Service, UK

S18.3 Improving the sexual and reproductive health of women living with HIV  
 - Angelica Espinosa Miranda, Universidade Federal do Espirito Santo, Brazil

S18.4 Engaging culturally and linguistically diverse populations in HIV/STI services: Challenges and opportunities  
 - Shailendra Sawleshwarkar, University of Sydney, Australia

10:45 - 12:15

**O13 Oral Presentation Session 13**

**Working towards sexual health equity: Understanding context**

*Chairpersons: Dennis Fortenberry, Indiana University School of Medicine, USA and Airi Pöder, Tartu University Clinics Foundation (Clinic of Dermatology), Estonia*

Location: MR 1

O13.1 Factors associated with safer sex efficacy among Northern and indigenous youth in the Northwest Territories, Canada  
- Carmen Logie, University of Toronto, Canada

O13.2 Mixed methods analysis: Role of parents, peers and perceived severity of sexual health outcomes among Native American youth  
- Lauren Tingey, Johns Hopkins University, USA

O13.3 High prevalence of cervico-vaginal infections among female adolescents in four urban regions of Panama  
- Amanda Gabster, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama

O13.4 Patterns of drug use among MSM in Amsterdam and sexually transmitted infections, The Netherlands: A cluster analysis  
- Roel Achterbergh, Public Health Service of Amsterdam, The Netherlands

O13.5 Reaching home-based female sex workers with preventive sexual health care services in The Netherlands  
- Charlotte Peters, South Limburg Public Health Services, The Netherlands

O13.6 Precarious legal immigration status linked to client condom refusal among sex workers in Metro Vancouver (2010-2018)  
- Bronwyn McBride, Centre for Gender and Sexual Health Equity, Canada

10:45 - 12:15

**O14 Oral Presentation Session 14**

**Improving the access and impact of STI testing**

*Chairpersons: Angelika Stary, Outpatients Centre for STI, Austria and Sunil Sethi, PGIMER, India*

Location: MR 8+15

O14.1 Optimizing screening for chlamydia: Is there a role for screening heterosexual men?  
- Minttu Rönn, Harvard T.H. Chan School of Public Health, USA

O14.2 Can community *Chlamydia trachomatis* screening of young heterosexual men help identify infected networks?  
- Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

O14.3 Disparities in access to HIV point-of-care testing: The non-urban Canadian context  
- Jacqueline Gahagan, Dalhousie University, Canada

O14.4 Implementation of point of care gonorrhea and chlamydia testing in an STD clinic PrEP program, San Francisco, 2017-2018  
- Stephanie Cohen, San Francisco Department of Public Health, USA

O14.5 *Chlamydia trachomatis* testing: A national evaluation of internet based self-sampling in Sweden  
- Björn Herrmann, Uppsala University Hospital, Sweden

O14.6 mAfrica: Zenzele, a mobile-phone enabled HIV testing and linkage to care pathway for young people in rural South Africa  
- Maryam Shahmanesh, University College London, UK

10:45 - 12:15

**O15 Oral Presentation Session 15**

**Understanding perceptions and beliefs: Improving STI/HIV interventions and outcomes**

*Chairpersons: Lynn Barclay, American Sexual Health Association, USA and Charlotte Bell, Royal Adelaide Hospital, Australia*

Location: MR 9

O15.1 "A PrEP user is someone who has a lot of bareback": A qualitative study of acceptability of PrEP in MSM in Lebanon  
- Ismael Maatouk, Clemenceau Medical Center, Lebanon

O15.2 Interested? Why or why not? STI clinic client perceptions of bacterial STI vaccines in British Columbia, Canada  
- Kara Plotnikoff, University of British Columbia, Canada

O15.3 Development of a scale measuring stigma towards alcohol abstinence among people living with HIV in Vietnam  
- Kathryn Lancaster, The Ohio State University, USA

O15.4 Predictors of incorrect HIV care initiation beliefs among people living with HIV/AIDS in Chókwè District, Mozambique  
- Christine Hara, Public Health Institute, Mozambique

O15.5 Syphilis risk perceptions among repeatedly infected men who have sex with men in Beirut, Lebanon  
- Ismael Maatouk, Clemenceau Medical Center, Lebanon

O15.5 Women's approaches to involving others in making HIV trial enrollment decisions while pregnant in the US and Malawi  
- Kristen Sullivan, University of North Carolina at Chapel Hill, USA

12:15 - 13:45

**Break**

13:45 - 15:15

**S19 Symposium 19**

**Global public health approaches to gonorrhea prevention and the threat of antibiotic resistance**

*Chairpersons: Rupert Kaul, University of Toronto, Canada and Helen Fifer, Public Health England, UK*

Location: MR 11+12

S19.1 Perspectives from North America  
- Karen Schlanger, Center for Disease Control and Prevention, USA

S19.2 Perspectives from Brazil and Latin America  
- Adele Schwartz Benzaken, Tropical Medicine Foundation, Manaus, Amazonas

S19.3 Perspectives from Thailand  
- Pachara Sirivongrangson, Thailand Ministry of Public Health, Thailand

S19.4 Public health approaches to gonorrhea prevention and the threat of antibiotic resistance – perspectives from Europe  
- Otilia Mårdh, European Centre for Disease Prevention and Control (ECDC), Sweden

13:45 - 15:15

**S20 Symposium 20**

**Criminalization, the law and sexual health**

*Chairpersons: Helen Ward, Imperial College London, UK and Michel Alary, CHU de Québec - Université Laval, Canada*

Location: Ballroom

S20.1 Understanding how laws and policies affect HIV prevention practices: A theoretical approach  
- Morten Skovdal, University of Copenhagen, Denmark

S20.2 Intersectionality, criminalisation and sexual health  
- Carmen Logie, University of Toronto, Canada

S20.3 The health impacts of sex work criminalization: A review of the evidence  
- Lucy Platt, London School of Hygiene & Tropical Medicine, UK

S20.4 Criminalisation of HIV transmission in the era of U=U  
- Michael Brady, Kings College Hospital/Terrence Higgins Trust, UK

13:45 - 15:15

**S21 Symposium 21**  
**Building a human infrastructure for STI prevention: Beyond community engagement, consultation and advisory boards**  
*Chairpersons: Deborah Money, University of British Columbia, Canada and Gail Bolan, Centers for Disease Control and Prevention (CDC), USA*  
Location: MR 2+3

S21.1 Youth and community based research  
- Sarah Flicker, York University, Canada

S21.2 Addressing anti-LGBT stigma and medical mistrust through a data-informed approach to community engagement  
- Errol Fields, Johns Hopkins University, USA

S21.3 Authentic and successful community engagement for STI/HIV prevention, screening and treatment in rural and urban settings  
- Scott Rhodes, University of North Carolina, USA

S21.4 Spurring innovation in improving community engagement for STI prevention  
- Weiming Tang, University of North Carolina Project-China, China

13:45 - 15:15

**O16 Oral Presentation Session 16**  
**Host-pathogen interactions**  
*Chairpersons: Juan Salazar, UCONN School of Medicine, USA and Lyle McKinnon, University of Manitoba, Canada*  
Location: MR 9

O16.1 Therapeutic effect of indoleamine 2,3-dioxygenase (IDO) inhibitor in the male genital inflammation  
- Shin Ohira, Kawasaki Medical School, Japan

O16.2 Mapping regions of host attachment in the *T. pallidum* adhesin Tp0751; Function-informed vaccine design  
- Sean Waugh, University of Victoria, Canada

O16.3 Cytokine immune response against natural human papillomavirus infection among men in Kisumu, Kenya  
- Raphael Ondondo, Masinde Muliro University of Science and Technology, Kenya

O16.4 Structural similarity of *Treponema pallidum* protein Tp0225 with human toll-like receptor 2  
- Simon Houston, University of Victoria, Canada

O16.5 Targeting complement receptor 3 on primary human cervical cells has the potential to cure *Neisseria gonorrhoeae* infection  
- Jennifer Edwards, The Research Institute at Nationwide Children's Hospital and The Ohio State University, USA

O16.6 Basic science aids syphilis vaccine development: Bloodstream spreading by the syphilis spirochete *Treponema pallidum*  
- Karen Lithgow, University of Victoria, Canada

13:45 - 15:15

**O17 Oral Presentation Session 17**  
**Screening and vaccination**  
*Chairpersons: Basil Donovan, Kirby Institute, Australia and Marc Steben, INSPQ, Canada*  
Location: MR 1

O17.1 HPV FOCAL 48 month exit results by age for women HPV or LBC negative at baseline screening  
- Gina Ogilvie, University of British Columbia, Canada

O17.2 Women's experiences with primary human papillomavirus (HPV) testing for cervix screening: HPV FOCAL exit survey results  
- Laurie Smith, BC Cancer, Canada

O17.3 Declining rates of cervical intraepithelial neoplasia after introduction of the HPV vaccine in British Columbia, Canada  
- Robine Donken, BC Children's Research Institute, Canada

O17.4 Impact of the human papillomavirus immunization program on rates of anogenital warts in British Columbia, Canada 2000-2017  
- Christine Lukac, University of British Columbia, Canada

O17.5 Declining trends in anogenital warts since HPV vaccine introduction in a large urban health system, 2013-2017  
- Linda Niccolai, Yale School of Public Health, USA

O17.6 Parents'/healthcare providers' knowledge, attitude and perception of school-based HPV vaccination program in Lagos, Nigeria  
- Adebola Adejimi, College of Medicine, University of Lagos, Nigeria

13:45 - 15:15

**O18 Oral Presentation Session 18**  
**Pills of white mercury: Syphilis prevalence, screening and prevention**  
*Chairpersons: Troy Grennan, BC Centre for Disease Control, Canada and Pingyu Zhou, Shanghai Skin Disease Hospital, China*  
Location: MR 13

O18.1 Prevalence of active syphilis among transwomen in São Paulo, Brazil  
- Beatriz Paiatto, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil

O18.2 Estimating disease burden of maternal syphilis and associated adverse pregnancy outcomes in China  
- Yajie Wang, Dermatology Hospital of Southern Medical University, China

O18.3 Development of a syphilis serum repository for research and evaluation of syphilis diagnostics tests in the United States  
- Mayur Shukla, Centers for Disease Control and Prevention, USA

O18.4 Evaluation of routinized syphilis screening with HIV viral loads among men living with HIV  
- Ann Burchell, St. Michael's Hospital, Canada

O18.5 HIV seropositivity and early syphilis stage predictive of ocular syphilis diagnosis in British Columbia, Canada: 2010-2018  
- Hasan Hamze, University of British Columbia, Canada

O18.6 Prenatal care entry among pregnant women with syphilis who use methamphetamines: A key to congenital syphilis prevention  
- Rosalyn Plotzker, California Department of Public Health, USA

13:45 - 15:15

**O19 Oral Presentation Session 19**  
**Models, networks and transmission dynamics: New insights for programs**  
*Chairpersons: David Regan, University of New South Wales, Australia and Peter White, Imperial College London, UK*  
 Location: MR 8+15

- O19.1 Model-based study design for estimation of route-specific gonorrhoeal transmission probabilities  
 - Ethan Romero-Severson, Los Alamos National Laboratory, USA
- O19.2 Bridging of *Neisseria gonorrhoeae* across diverse sexual networks in the HIV PrEP era  
 - Deborah Williamson, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Australia
- O19.3 Partner services for gonorrhoea can decrease new HIV among MSM in King County, Washington: A mathematical modeling study  
 - Gui Liu, University of Washington, USA
- O19.4 Molecular epidemiology of HIV among foreign-born residents of King County, Washington, USA; Using HIV surveillance data  
 - Diana Tordoff, University of Washington, USA
- O19.5 The influence of risk group turnover in STI/HIV epidemics: Mechanistic insights from transmission modeling  
 - Jesse Knight, St. Michael's Hospital, Canada
- O19.6 Professional injectors, injection networks, and HIV: Case studies from five cities in Pakistan  
 - Laura Thompson, University of Manitoba, Canada

15:15 - 15:45

**Coffee Break**  
 Location: Exhibit Hall A

**LOCATION: BALLROOM**

15:45 - 16:45

**K02.1 Closing Keynote Lecture**  
*Chairpersons: James Blanchard, University of Manitoba, Canada and Henry de Vries, Amsterdam University Medical Centers, The Netherlands*

**MAKING SCIENCE WORK TO DELIVER EFFECTIVE PROGRAMMES AT SCALE**

**Charlotte Watts**, UK Department of International Development, UK

16:45 - 18:00

**Closing Ceremony**

**Monday, July 15, 2019**

**17:45 - 19:00 PS01 Poster Viewing Session**  
 Location: Exhibit Hall A

- P004** - The nationwide antimicrobial resistance surveillance system of sexually transmitted infections - South Korea, 2017-2018  
 Chang Hee Han, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Republic of Korea
- P005** - Gonorrhoea in the era of AMR, diagnostic needs for improved antimicrobial stewardship in low and middle income countries  
 Cecilia Ferreyra, FIND, Switzerland
- P006** - "First test along then together" - the practice of couple's HIV testing in Ethiopia  
 Tewodros Getachew Hailemariam, The University of New South Wales, Australia
- P007** - Uptake of couples HIV testing and counselling in Sub-Saharan Africa: A systematic review and meta-analysis  
 Tewodros Getachew Hailemariam, The University of New South Wales, Australia
- P008** - Diagnostic accuracy of Xpert MTB/RIF in detecting pulmonary tuberculosis among people living with HIV in western Nigeria  
 Saheed Usman, APIN Public Health Initiatives, Nigeria
- P012** - A process evaluation of an incentivized home-based intervention to test and start (HITS) in rural Kwazulu-Natal, South Africa  
 Oluwafemi Adeagbo, Africa Health Research Institute, South Africa
- P013** - Screening practices related to inconclusive *Neisseria gonorrhoea* and *Chlamydia trachomatis* nucleic acid amplification testing  
 Cherie Blair, University of California, Los Angeles, USA
- P014** - Validating a clinical prediction rule for chlamydia and gonorrhoea infection among online testers in British Columbia, Canada  
 Aidan Ablona, BC Centre for Disease Control, Canada
- P015** - Introduction of chlamydia and gonorrhoea opt-out testing in a short-term correctional facility in Alberta, Canada  
 Petra Smyczek, Alberta Health Services, Canada
- P017** - Effect of time change on adolescent and young people accessibility to AYFHC in Akure, Ondo state Nigeria  
 Onesimus Aiwanfo, Federal university of Technology Akure, Nigeria
- P018** - Pay-it-forward gonorrhoea and chlamydia testing among Chinese men who have sex with men: A cluster randomized controlled trial  
 Tiange Zhang, University of North Carolina Project-China, China
- P019** - Implementing home-sampling strategies to engage young heterosexuals in *Chlamydia trachomatis* re-testing and peer-testing  
 Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands
- P020** - Urison™ facilitate urine collection and transportation for the detection of STD with the Anyplex™ II STI-7 assay  
 Santina Castriciano, Copan Italia Spa, Canada
- P021** - Use of non-FDA cleared assays for detection of STIs in children being evaluated for suspected sexual abuse  
 Margaret Hammerschlag, State University of New York Downstate Medical Center, USA
- P022** - Antenatal testing for curable STIs compared to syndromic management in Botswana: A cost-effectiveness study  
 Adriane Wynn, UCSD, USA
- P023** - A mixed-methods analysis of a pay-it-forward gonorrhoea/chlamydia testing program among men who have sex with men in China  
 Wenting Huang, University of North Carolina at Chapel Hill Project-China, China

- P024** - Targeted point-of-care testing compared to syndromic management of urogenital infections in Rwandan women  
 Janneke Van De Wijgert, University Medical Center Utrecht, Netherlands
- P025** - Automation and optimization strategies in a molecular lab result in an improved workflow for STI surveillance studies  
 Carsten Tiemann, Krone Laboratory / LABCON-OWL, Germany
- P026** - Frequency of STD testing services among commercially-insured patients with high risk sexual behaviors  
 Sagar Kumar, Centers for Disease Control and Prevention, USA
- P027** - Safety and effectiveness of same-day screening and treatment among youth in Los Angeles, California  
 Erin Keizur, UCLA, USA
- P029** - Multi-target PCRs - the new multi-tool of STI diagnostics  
 Carsten Tiemann, Krone Laboratory / LABCON-OWL, Germany
- P030** - Pilot implementation of a home-care program for chlamydia, gonorrhoea and syphilis testing in HIV positive MSM  
 Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands
- P031** - Using intervention mapping to develop a home-care program for men who have sex with men to get themselves tested for HIV/STI  
 Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands
- P032** - Alone but supported with an innovative HIV self-testing app: Qualitative results from a large cohort study in South Africa  
 Ricky Janssen, Maastricht University, Netherlands
- P033** - Differentiation of common genital ulcer disease pathogens using sequential or parallel molecular testing  
 Chris McGowin, Roche Diagnostics Corp, USA
- P034** - HIV self-testing and potential linkage to care among men who have sex with men in China: A cross-sectional online survey  
 Cheng Wang, Social Entrepreneurship to Spur Health (SESH) Team, China
- P035** - Impact of mass media exposure in getting HIV testing among urban women in Nepal  
 Bikesh Bajracharya, Support to the Health Sector Programme, Nepal
- P036** - Predictors of lost to follow-up in a "test and treat" programme among women with high-risk sexual behaviour in Kampala, Uganda  
 Onesmus Kamacooko, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Uganda
- P038** - Comparison of Anyplex™II STI-7e v1.1 to Allplex™ CT/NG/MG/TV for the detection of STI from urine collected with UriSponge™  
 Santina Castriciano, Copan Italia Spa, Canada
- P039** - A central reference laboratory for antimicrobial resistant *Neisseria gonorrhoeae* in the US Department of Defense June Early, Infectious Disease Clinical Research Program, USA
- P040** - Making sense of HIV self-testing: Social representation in young Nigerians narratives for promoting HIV self-testing  
 Chisom Obiezu-Umeh, Saint Louis University, USA
- P041** - How is the value of point-of-care tests for STIs negotiated in the context of a nationalised health system?  
 Agata Pachó, St George's, University of London, UK
- P043** - Regional differences in STI testing barriers among online testers in British Columbia, Canada  
 Mark Gilbert, BC Centre for Disease Control, Canada
- P044** - Regional differences in use of GetCheckedOnline and client characteristics across British Columbia, Canada  
 Aidan Ablona, BC Centre for Disease Control, Canada

**P045** - Is chlamydia testing in general practice sustained when financial incentives or audit + feedback are removed: A cluster RCT  
Jane Hocking, University of Melbourne, Australia

**P046** - Ensuring quality-assured and personalized online self-testing within a market-driven context  
Hanna Bos, Soa Aids Nederland, Netherlands

**P047** - The three Rs: recalls, reminders and retesting for chlamydia – views of GPs and young adults  
Alaina Vaisey, University of Melbourne, Australia

**P048** - Improving 'home-based' STI/HIV self-sampling and boosting sample return rates  
Paul Flowers, University of Glasgow, UK

**P049** - STI testing and documentation via a phone application (app): Experience with the safe app  
Kenneth Fife, SAFE Health, USA

**P050** - Sexual Health London online testing: A review of service users and outcomes  
Ryan Kinsella, Preventx, UK

**P051** - Accuracy of sexually transmitted infections testing on self-collected vaginal samples versus cervical samples  
Clementina Cocuzza, University of Milano-Bicocca, Italy

**P052** - HIV case finding and linkage to care in Eleme local government area, Rivers state  
Atochi Emenike, Pathfinder International, Nigeria

**P053** - Detection of sexually transmitted pathogens from sediment of first-void urine in patients from greater Zagreb Area  
Jasmina Vranas, Institute of Public Health "Dr. Andrija Stampar", Croatia

**P055** - London Sexual Health Programme – Developing innovative solutions to open access sexual health services  
Ryan Kinsella, Preventx, UK

**P056** - The acceptability of different HIV testing options among young men living in Vancouver, Canada: A qualitative study  
Caroline Mniszak, BC Centre on Substance Use, Canada

**P057** - The Brazilian strategy for HIV self-tests free distribution in public health  
Pâmela Gaspar, Ministry of Health of Brazil, Brazil

**P058** - Design and performance of the alinity m STI assay for the detection of CT, NG, TV, and MG  
Kevin Nelson, Abbott Molecular, USA

**P059** - Quantitative detection of bacteria associated with BV in urine versus swab samples using droplet digital PCR  
Deshanta Naicker, Nelson R Mandela School of Medicine, South Africa

**P060** - Performance of 3-in-1 pooled samples from anal, rectal, and throat of GeneXpert® CT/NG in Bali, Indonesia  
Irvin Romyco, FHI360-LINKAGES, Indonesia

**P066** - A mobile clinic model to care for women engaging in exchange sex who are opiate dependent and living unhoused in Seattle  
Jenell Stewart, University of Washington, USA

**P067** - Drug use during sex among Dutch swingers and associated sexual risk behavior: A hidden phenomenon?  
Christian Hoeb, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), Netherlands

**P068** - STD screening and diagnosis among 15-24 year old diagnosed with prescription opioid related disorder  
Chirag Patel, Centers for Disease Control and Prevention, USA

**P069** - Do cannabis use and social support mediate the relationship between intersectional stigma and bodily pain and functioning?  
Carmen Logie, University of Toronto, Canada

**P070** - Determination of antibiotic susceptibility and efficacy by VITA-PCR  
Nicole Lima, University of New South Wales, Australia

**P071** - Police harassment and HIV/STI risk behaviors among a sample of people who inject drugs on the U.S.-Mexico border  
Oscar Beltran, Programa Compañeros, A.C., Mexico

**P073** - From silos to buckets: A qualitative study of how sexual health clinics can address mental health & substance use needs  
Travis Salway, BC Centre for Disease Control, Canada

**P075** - STI and HIV infections among MSM reporting exposure to gonorrhoea or chlamydia: implications for expedited partner therapy  
Julia Schillinger, Centers for Disease Control and Prevention, USA

**P076** - Do prescriptions for expedited partner therapy get filled? Findings from a multi-jurisdictional evaluation, US, 2017-2018  
Julia Schillinger, Centers for Disease Control and Prevention, USA

**P077** - Piloting an algorithm to guide clinical treatment decisions for syphilis notified partners in Rotterdam, the Netherlands  
Hannelore Götz, 1 Public Health Service Rotterdam Rijnmond; 2 Erasmus MC University Medical Center Rotterdam; 3 National Institute for Public Health and the Environment (RIVM), Netherlands

**P078** - Barriers and facilitators to expedited partner therapy: a survey of family physicians in British Columbia, Canada  
Jason Wong, BC Centre for Disease Control, Canada

**P079** - Using theory and evidence to optimise an accelerated partner therapy intervention in a chlamydia partner notification trial  
Paul Flowers, University of Glasgow, UK

**P080** - Investigating the effects of accelerated partner therapy on chlamydia transmission in Britain: a mathematical modelling study  
Christian Althaus, University of Bern, Switzerland

**P083** - Designing online HIV information, testing and clinical care pathways to address users' expectations and emotions  
Jo Gibbs, University College London, UK

**P084** - Geographical proximity as barrier in sexual health clinic utilization, even in infrastructure rich countries  
Denise Twisk, Municipality of Rotterdam / Public Health Service Rotterdam-Rijnmond / Erasmus Medical Center, Netherlands

**P085** - Relative contribution of general practices and sexual health centres in STI consultations in the Netherlands  
Hannelore Götz, 1 Public Health Service Rotterdam Rijnmond; 2 Erasmus MC University Medical Center Rotterdam; 3 National Institute for Public Health and the Environment (RIVM), Netherlands

**P086** - Social bonds as a strategy of practical assistance for sex worker healthcare  
Ana Amélia Bones, UFCSPA, Brazil

**P087** - Providers' views on barriers and facilitators of bacterial STI testing among gbMSM living with or at risk for HIV  
Charlie Guiang, St. Michael's, University of Toronto, Canada

**P088** - Using electronic screening and feedback with adolescents to decrease sexual health risks in the emergency department  
Siobhan Thomas-Smith, Seattle Children's Hospital/University of Washington School of Medicine, USA

**P089** - Evaluating onlie and clinic-based STI screening services: A case study of Umbrella Sexual Health Services, UK  
Louise Jackson, University of Birmingham, UK

**P090** - Understanding young people's priorities for sexually transmitted infection (STI) screening  
Louise Jackson, University of Birmingham, UK

**P091** - Estimating neonatal herpes simplex virus infections using Chapman's Capture-Recapture Method, Florida, 2011-2017  
James Matthias, Centers for Disease Control and Prevention, USA

**P092** - Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: systematic review and meta-analyses  
Manale Harfouche, Weill Cornell Medicine-Qatar, Qatar

**P093** - Performance of four diagnostic assays for detecting herpes simplex virus type 2 antibodies in Middle East and North Africa  
Soha Dargham, Weill Cornell Medicine-Qatar, Qatar

**P094** - An assessment of risk factors for HSV-2 infection in Malawian women using two classifications for the Herpesect 2 test  
Payal Chakraborty, The Ohio State University, USA

**P095** - Age disparity and sociodemographic correlates of herpes simplex virus type 2 (HSV-2) seropositivity in South India  
Makella Coudray, Florida International University, USA

**P096** - Vulvar Zoster  
Christine Remar Concepcion, University of the Philippines, Philippines

**P099** - Risk of acquiring HIV infection among exposed infants in selected primary health care facilities in Ibadan Oyo State  
Nigeria  
Aishat Usman, AFRICAN FIELD EPIDEMIOLOGY NETWORK, Nigeria

**P100** - Bidirectional association between Human Immunodeficiency Virus and psoriasis: Systematic review of cohort studies  
Yi-Yu Chen, Taiwan

**P103** - Optimization of data audits to achieve epidemic control and quality of care in Kajjajo Central sub-county  
PRECIOUS Mbabazi, NATIONAL AIDS & STI CONTROL PROGRAMME, Kenya

**P107** - Socio-cultural factors influencing condom use intentions among African migrant youth in South Africa  
Johannes John-Langba, University of Kwazulu-Natal, South Africa

**P108** - Prevalence of alexithymia among a cohort of well-controlled HIV infected and normal children  
Ragas Dental College and Hospital, Chennai, India

**P113** - Risk behaviors following Hepatitis C treatment among gay and bisexual men living with HIV in Melbourne, Australia  
Brendan Harney, Burnet Institute, Australia

**P115** - Socio-demographic profile of HIV seropositivity in a tertiary care North Indian hospital: A ten year retrospective study  
Nikhil Sharma, Guru Nanak Dev University, India

**P122** - Treatment outcomes in HIV care among children and adult in high volume ART sites in Rivers State, Nigeria  
Atochi Emenike, Nigeria  
**P124** - Attitudes and beliefs regarding HIV and AIDS among immigrants in Mopani District, South Africa  
Hilda Shilubane, University of Venda, South Africa

**P125** - Low rate of HIV testing among prisoners in Iran: Findings from nationwide repeated behavioral surveys  
Mohammad Karamouzian, BC Center on Substance Use, Canada

**P127** - Disparities between HIV testing levels and the self-reported HIV-negative status of sexually active college students  
Edmond Pui Hang Choi, The University of Hong Kong, Hong Kong PRC

**P128** - HIV+ women 50+ stigmatized and discriminated  
Chantal Mukandoli, APAA(African In Partnership Against AIDS), Canada

**P137** - Modelling factors determining Pakistan's heterogeneous HIV epidemic in people who inject drugs  
Aaron Lim, University of Bristol, UK

**P138** - High STI prevalence among HIV-exposed women planning for pregnancy in rural, southwestern Uganda  
Pooja Chitneni, Brigham and Women's Hospital, USA

**P139** - The racial impact of AIDS trends among women in Sao Paulo, Brazil  
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

**P140** - The rising HIV epidemic among key populations: An urgent need for a focused targeted prevention response in Pakistan  
Baseer Achakzai, National AIDS Control Program, Pakistan

**P141** - Factors associated with HIV-related stigma among individuals accessing antiretroviral therapy in British Columbia, Canada  
Andrea Bever, BC Centre for Excellence in HIV/AIDS, Canada

**P142** - Characteristics of HIV-1 pretreatment drug resistance and its impact on combined antiretroviral therapy in Beijing  
Ruolei Xin, Beijing Center for Disease Prevention and Control, China

**P143** - Medication reviews for people living with HIV (PLWHIV)  
Bronagh McBrien, Manchester Foundation Trust, UK

**P145** - An intra-familial transmission of HIV-1 CRF02\_AG was reconstructed by molecular epidemiology  
Chun Huang, Beijing Center for Disease Prevention and Control, China

**P146** - Gender, sexual relationship power equity, and HIV-risk among sub-Saharan African youth: A comprehensive literature review  
Angela Kaida, Simon Fraser University, Canada

**P148** - Transcontinental dissemination of the major HIV-1 CRF01\_AE lineages circulating in China  
Minghui An, AIDS Institute, China

**P149** - Evolution: A text messaging powered intervention for connection, support and HIV eradication  
Katie Plax, Washington University School of Medicine, USA

**P151** - HIV epidemic among crack users in central Brazil: Epidemiological basis for interventions  
Márcia Souza, Universidade Federal de Goias, Brazil

**P152** - The epidemiology of HIV infection among young adults in Brazil  
Natalia Kops, Hospital Moinhos de Vento, Brazil

**P153** - Are parturient women on anti-retroviral therapy complying with the recommended six-months exclusive breastfeeding?  
Anthony Ajayi, University of Fort Hare, South Africa

**P154** - Diffuse skewing of Th17/Treg ratio in the anorectal mucosa of HIV+MSM with HPV-associated dysplasia  
Rupert Kaul, University of Toronto, Canada

**P156** - Study on the effect of slanDC-mediated ADCC in HIV-1-infected patients  
Wengqing Geng, the First Affiliated Hospital, China Medical University, China

**P157** - Crowdsourcing methods to enhance HIV and sexual health services: A qualitative scoping review of evidence  
Weiming Tang, UNC Project-China, China

**P159** - Influence of HIV status and opioid misuse on STI risk and infection: Results of a pilot study  
Wiley Jenkins, Southern Illinois University School of Medicine, USA

**P161** - Adopting a political economy approach to HIV research: A case study of ongoing conflict in Ukraine  
Nicole Herpai, Canada

**P162** - Unsuppressed viral load (VL) by HIV exposure category among people living with HIV in British Columbia(BC), Canada: 2005-2015  
David Moore, BC Centre for Excellence in HIV/AIDS, Canada

**P163** - HIV care and treatment services for female sex workers: utilisation of and satisfaction with the services in Kampala, Uganda  
Gertrude Namale, MRC/UVRI & LSHTM, Uganda



**P166** - Determinants of viral non-suppression among children in a HIV program in Kenya: A cross-sectional study  
Douglas Gaithe, Christian Health Association of Kenya, Kenya

**P167** - PCR detection of HIV proviral DNA in brain tissues from dead HIV/AIDS in Zambia  
Lishi Bai, Beijing Center for Disease Prevention and Control, China

**P168** - Multidrug resistant tuberculosis in TB/HIV co-infected patients in Rivers State, Nigeria  
Mary Alex-Wele, University of Port Harcourt teaching Hospital, Nigeria

**P169** - Association between CXCR4 and TRAIL pathway expression in CD4 T lymphocytes from HIV+ ART-naïve patients  
Sarah Ratkovich-Gonzalez, Universidad de Guadalajara, Mexico

**P170** - Efavirenz based anti-retroviral regimens in paediatrics: A peep into neuropsychiatric and biochemical derangements  
Purba Chakrabarty, India

**P171** - Zbtbs gene expression in CD4+ T cells and systemic pro-inflammatory cytokines in naïve and treated HIV patients  
Judith De Arcos Jimenez, Universidad de Guadalajara, Mexico

**P172** - Association between short-chain fatty acids producing bacteria and CD4 T cells recovery in HIV positive patients  
Mariana Ruiz Briseño, Universidad de Guadalajara, Mexico

**P173** - Investigating varicella-zoster virus-specific T cells through the lenses of HIV  
Carolina Moreira, University of Manitoba, Canada

**P176** - HIV acquisition and antiretroviral therapy initiation in a youth cohort in Soweto and Durban, South Africa  
Angela Kaida, Simon Fraser University, Canada

**P179** - Community based local rapid HIV testing campaigns to expand HIV diagnostic coverage  
Ana Amélia Bones, Brazil

**P180** - Virtual academic detailing to improve quality of HIV health care  
Ana Amélia Bones, UFCSPA, Brazil

**P181** - Epidemiological information on HIV in the management of the cascade of care in health services  
Ana Amélia Bones, UFCSPA, Brazil

**P183** - Predictors of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* asymptomatic infection in HIV patients  
Cátia Caldas, Centro Hospitalar e Universitário de São João, Portugal

**P184** - Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV  
Elisabeth McClymont, University of British Columbia, Canada

**P186** - *Neisseria gonorrhoeae* infections among people living with HIV on ART at STI clinic in Kumasi, Ghana  
Thomas Agyarko-Poku, Suntreso Government Hospital, Ghana Health Service, Ghana

**P187** - Anal cancer and precursor lesions in HIV-infected persons: A clinical cohort study  
Yuanfan Ye, University of Alabama at Birmingham, USA

**P189** - Evaluation of Aptima HIV-1 quant assay performance using plasma and dried blood spots  
Julie Nelson, University of North Carolina at Chapel Hill, USA

**P190** - The role of helpline counseling in HIV status disclosure among sexual partners: A case study of toll free helpline in Uganda  
Julius Ssekinkuse, Communication for Development Foundation Uganda, Uganda

**P191** - South Indian long-distance truck drivers still at high-risk for HIV/STI  
Karl Krupp, Florida International University, USA

**P192** - Healthcare worker related stigma and discrimination towards people living with HIV in one of the government hospital in Bohol.  
LYdette Galimba, Gov.Celestino Gallares Memorial Hospital, Philippines

**P195** - Creation of an HIV case definition to assess the quality of HIV care in the primary healthcare setting in Canada  
Sarah Boyd, Memorial University Centre for Rural Health Studies, Canada

**P196** - WIR-Center for Sexual Health and Medicine: A care model to counter HIV/STI in Germany  
Norbert Brockmeyer, Walk In Ruhr - WIR - Center for Sexual Health., Germany

**P198** - Dolutegravir rollout and expected prevalence of pretreatment drug resistance to antiretroviral therapy among Kenyan women  
Horacio Duarte, University of Washington, USA

**P199** - Trends in motivation and setting for HIV testing among people newly diagnosed with HIV in British Columbia, Canada, 2003-2007  
Jason Wong, BC Centre for Disease Control, Canada

**P202** - Developing a database with sensitive health information: A profile of people living with HIV in Newfoundland and Labrador  
Sarah Boyd, Memorial University Centre for Rural Health Studies, Canada

**P204** - Serodiscordance and sex partner concurrency: evidence for racial disparities in HIV among gay and bisexual men (MSM)  
Carla Tilchin, Johns Hopkins University School of Medicine, USA

**P205** - HIV Non-B subtypes in San Francisco: Migration but little local transmission  
Hong-Ha Truong, University of California, San Francisco, USA

**P206** - The specific contribution of each data source in a population-based administrative data cohort from Manitoba, Canada.  
Souradet Shaw, University of Manitoba, Canada

**P207** - Burden of ophthalmia neonatorum among babies of PLHIV at a district hospital in Kumasi, Ghana  
Thomas Agyarko-Poku, Suntreso Government Hospital, Ghana Health Service, Ghana

**P208** - Testing and treating genital and extra genital bacterial infections in HIV infected patients: Lessons learned  
Cátia Caldas, Centro Hospitalar e Universitário de São João, Portugal

**P209** - Productive impact of assisted referrals and incentivized enrollment on the uptake of HIV services in Lagos state, Nigeria  
Felix Iwuala, Association for Reproductive and Family Health (ARFH), Nigeria

**P210** - Alinity m HIV-1 assay: Design and performance  
Jeffrey Wuitschick, Abbott Molecular, USA

**P211** - Reproductive outcome and fetal growth in HIV-infected pregnant women at a university hospital in Vitória, Brazil  
Angelica Miranda, Universidade Federal do Espírito Santo, Brazil

**P212** - Psychosocial factors affecting the caregivers of pediatric HIV patients in returning for treatment  
Kelsey Buehler, Touro University, USA

**P216** - Gender-based violence and the associated psychosocial and mental health issues among Filipino HIV-positives  
Evangeline Castronuevo-Ruga, De La Salle University-Dasmariñas, Philippines

**P217** - "Stigma and Level of Care Among Health Care Providers to HIV/AIDS patients"  
Félisse Julien Jegonia, Philippine College Of Physicians, Philippines

**P218** - Determining the Neurocognitive status and functional ability to screen for HIV-Associated Neurocognitive Disorder (HAND)  
Ritika Agarwal, Chandra Laxmi Hospital, India

**P219** - Profile of patients who underwent rapid STI tests at a health unit in the Brazilian capital city with the highest HIV rate  
Ana Amélia Bones, UFCSPA, Brazil

**P220** - Opportunities and challenges to the rituals of care that circumvent misdiagnosis amongst rapid HIV testers in Zimbabwe  
Morten Skovdal, University of Copenhagen, Denmark

**P222** - Living with HIV/AIDS in adolescence: factors for adherence to therapeutics.  
Shirley Coelho, Centro Estadual Especializado em Diagnostico, HIV/AIDS e Hepatites Virais, Brazil

**P223** - Prevalence of Reproductive Tract Infections and HIV on pregnant women in some areas in Indonesia, 2016-2017  
Luxi Pasaribu, National Institute of Health Research and Development, Indonesia

**P225** - Practical cognitive screening for patients with HIV  
Gwen Levitt, District Medical Group, USA

**P226** - Self-esteem, body image, and subculture identification among gay, bisexual, and other men who have sex with men  
Kiffer Gard, University of Victoria, Canada

**P227** - Perceived stress and socioeconomic factors associated with vaginal microbiota in the Longitudinal Study of Vaginal Flora  
Rodman Turpin, University of Maryland, USA

**P228** - From 2017 positive voices data: Is self-reported health associated with depressive symptoms among people with HIV in England?  
Natasha Ratna, Public Health England, UK

**P233** - Genital tract infection of women with and without tubal pathology  
Svetlana Dubrovina, Rostov Medical State University, Russian Federation

**P235** - Vaginal and rectal *M. genitalium* (MG), *C. trachomatis* (CT), and *N. gonorrhoeae* (GC) Co-Infection Among Women in Seattle, WA  
Christine Khosropour, University of Washington, USA

**P237** - Enzyme complexes of alcohol metabolism protect against liver injury in animal models fed acute alcohol and anti-HIV drugs  
Cheng Ji, University of Southern California, USA

**P239** - Genital HSV-2 suppression is not associated with alterations in the vaginal microbiome: a one-way, cross-over study  
Christine Johnston, University of Washington, USA

**P241** - Detection of Y-chromosomal DNA correlates with last unsafe sexual exposure  
Petra Wolffs, Maastricht University Medical Center (MUMC+), Netherlands

**P242** - Co-infections with cytomegalovirus (CMV) and sexually transmitted infections (STIs) in pregnant women  
Swetha Pinninti, University of Alabama at Birmingham, USA

**P243** - High prevalence of Ureaplasma spp. in women visiting an STI clinic although no azithromycin resistance was discovered  
Inge Van Loo, Maastricht University Medical Center, Netherlands

**P245** - Integration of HIV testing with tuberculosis and sexually transmitted infections at a tertiary care hospital in Delhi  
Tanisha Bharara, Dr Baba Saheb Ambedkar Hospital and Medical College, India

**P246** - Community perceptions, experiences and preferences for partner notification services in North Carolina  
Humberto Gonzalez Rodriguez, UNC-CH Gillings School of Global Public Health, USA

**P247** - Partner notification for syphilis in Chile: Realities from two regional health services - a qualitative case study  
Jane Tomnay, The University of Melbourne, Australia

**P248** - STI risk reduction strategies among individuals with multiple sex partners and perceived partner non-monogamy in the US  
Casey Copen, Centers for Disease Control and Prevention, USA

**P249** - What works in partner notification for sexually transmitted infections, including HIV? Systematic review and meta-analysis  
Nicola Low, University of Bern, Switzerland

**P250** - Interim analysis of individual risk factors, sexual networks, and STI risk in a military population  
Eric Garges, USUHS, USA

**P251** - Developing partner notification outcomes for bacterial STI by sex-partner type: International perspectives  
Claudia Estcourt, Glasgow Caledonian University, UK

**P252** - Predictability of Prevalence of Sexually Transmitted Infection on Complex Sexual Network  
Ryosuke Omori, Hokkaido University, Japan

**P253** - HPV vaccine knowledge and acceptability among MSM in Lebanon: A qualitative study  
Ismael Maatouk, Clemenceau Medical Center, Lebanon

**P254** - Barriers to sexual assault disclosure within sexual health services: A mixed method/population study  
Jane Meyrick, University of the West of England, UK

**P257** - Patterns and correlates of gender-based violence (GBV) in rural and urban South African communities  
Saheed Usman, APIN Public Health Initiatives, Nigeria

**P259** - Seeking clickthroughs: Using cell phone applications in preventing STDs  
Rachel Kachur, Centers for Disease Control and Prevention, USA

**P260** - Risk perception, safer sex practices, and PrEP enthusiasm: Exploring PrEP with black and minority ethnic women in the UK  
Sarah Nakasone, USA

**P262** - PrEP utilization among young transgender women, transgender men, and MSM in an urban community-based setting  
Doreen Dankerlui, Henry Ford Health System, USA

**P264** - Community perspectives on bacterial STI testing for gay, bisexual and other men who have sex with men in Toronto, Canada  
Dionne Gesink, U of Toronto, Canada

**P265** - CD4 count as parameter to estimate the time of infection in HIV positive men having sex with men and its social implications  
Patrick Eustaquio, LoveYourself, Inc., Philippines

**P270** - Health rights: LGBTIQ community  
Tyronne Havnar, Zimbabwe

**P271** - A community perspective on the immediate prescribing of antiretroviral therapy at time of a HIV diagnosis (ARTATD)  
David Crawford, Positive Life NSW, Australia

**P272** - Research to resource: Booklet for people living with HIV associated neurocognitive disorder (HAND)  
David Crawford, Positive Life NSW, Australia

**P273** - Understanding the mental health issues and service needs of the transgender community in Delhi, India  
Ramita Iyer, Singapore

**P274** - Leveraging multi-level monitoring to achieve stakeholder buy-in: Descriptive lessons from key population mapping in Nigeria  
Chukwuebuka Chukwukadibia Ejeckam, Centre for Global Public Health, University of Manitoba (Nigeria Country Office), Nigeria

**P275** - Towards the management of HIV/AIDS patients in pentecostal churches in Uganda: A case of Eden and Bethel churches in Kampala  
Rebecca Nantalo Namige, Vamutulo Women Group, Uganda

**P276** - A national action plan to advance the sexual and reproductive health and rights of women living with HIV in Canada  
Angela Kaida, Simon Fraser University, Canada

**P277** - Reducing HIV self-testing barriers in black African communities using collect: A PHE HIV innovation fund project  
Louise Logan, Public Health England, UK

**P278** - Strategies developed by ministry of health of Brazil to increase HIV diagnosis since 2012  
Pâmela Gaspar, Ministry of Health of Brazil, Brazil

**P279** - Development and validation of sexually transmitted infections decision modelling software in cooperation with policy makers  
John Saunders, UCL, UK

**P280** - Use of mobile healthcare units in rapid test events in combating sexually transmitted infections  
Ana Amélia Bones, Brazil

**P281** - Reaching out to MSM who fled for war and LGBT oppression for HIV and STI testing, HBV vaccination and counselling  
Hanna Bos, Soa Aids Nederland, Netherlands

**P283** - The Alberta 2016-2020 STBBI Operational Strategy and Action Plan: collective impact to address the provincial STI outbreak  
Cari Egan, Alberta Health Services, Canada

**P285** - Factors associated with mother-to-child HIV transmission in western Nigeria: Importance of 90-90-90 goals in the elimination  
Saheed Usman, APIN Public Health Initiatives, Nigeria

**P288** - Sexually transmitted infections among pregnant women in rural Mysore, India  
Sandra Kiplagat, Florida International University, USA

**P290** - Temporal discounting and engagement in care among HIV-infected pregnant and breastfeeding women  
Jessica Londeree Saleska, Ohio State University College of Public Health, USA

**P291** - Impact of PMTCT service uptake on outcome of care among women attending anti natal care in Nigeria  
Chidiebere Ezeakafor, National Agency for the Control of AIDS, Nigeria

**P295** - Prevalence of STIs among Nepalese women population  
Prasanna Upreti, Prabhat Kiran Sewa Samaj (NGO, NPO), Nepal

**P299** - Epidemiology of sexually transmitted infections at Gabriel Toure Teaching Hospital, Bamako, Mali  
Ibrahim Teguété, Mali

**P300** - Neighborhood violent crime and HIV transmission risk: A temporal and spatial exploration of their association  
Aruna Chandran, Johns Hopkins University School of Medicine, USA

**P302** - Achieving the third 90: Keeping pregnant and breastfeeding women living with HIV virally suppressed in western Nigeria  
Ibiwumi Usman, Kids & Teens Resource Centre, Nigeria

**P304** - Achieving the third 90: Keeping adolescents living with HIV virally suppressed in rural Nigeria in the era of test and treat  
Saheed Usman, APIN Public Health Initiatives, Nigeria

**P305** - Poor adherence predictors and factors associated with treatment failure among HIV seropositive patients in western Nigeria  
Ibiwumi Usman, Kids & Teens Resource Centre, Nigeria

**P306** - Vaccine development & AMP; Participation in sub-Saharan Africa: How willing are young people in Western Nigeria?  
Saheed Usman, APIN Public Health Initiatives, Nigeria

Page 66

**P307** - Linkage to HIV care from sexual health center Rotterdam: Timely entrance to care, but worrying loss to follow-up in migrants  
Hannelore Götz, 1 Public Health Service Rotterdam Rijnmond; 2 Erasmus MC University Medical Center Rotterdam; 3 National Institute for Public Health and the Environment (RIVM), Netherlands

**P308** - Timing of initiation of HIV treatment and level of adherence among pregnant women under option B+ programme in Nigeria  
Olumuyiwa Omonaiye, Deakin University, Australia

**P309** - Going deeper - MSM peer cliques and not peer groups promotes behaviour change in HIV prevention interventions in Nigeria  
Lawrence Ukponahiusi, Edo State Agency for the Control of HIV and AIDS, Nigeria

**P311** - Examining interactions with online outreach workers for gay, bisexual and other men who have sex with men  
David Brennan, University of Toronto, Canada

**P312** - Evaluation of an antiretroviral therapy (ART) interruption alert and referral system in British Columbia (BC), Canada  
Jon Kremer, BC Centre for Excellence in HIV/AIDS, Canada

**P313** - The role of temporal discounting in a conditional cash transfer intervention to improve engagement in HIV-care  
Jessica Londeree Saleska, Ohio State University College of Public Health, USA

**P314** - Identifying key stakeholders and their roles in the integration of POCs for STIs into clinical services  
Agata Pacho, St George's, University of London, UK

**P316** - Structure-based drug design for *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and *Mycoplasma genitalium*  
Kayode Ojo, University of Washington, USA

**P317** - Implementation of continuous quality initiative for improving key indicators in HIV treatment cascade in western Nigeria  
Saheed Usman, APIN Public Health Initiatives, Nigeria

**P318** - The implications of effective school-based prevention for risk of STD acquisition  
Kathleen Ethier, Centers for Disease Control and Prevention, USA

**P319** - Randomized Controlled Trial of 1% and 5% 5-Fluorouracil Compared to 90% Trichloroacetic Acid for Anogenital Wart Treatment  
Ika Anggraini, Universitas Indonesia, Indonesia

**P320** - Incentive testing and treatment for STBBI in hard to reach populations in Edmonton, Alberta, Canada  
Petra Smyczek, Alberta Health Services, Canada

**P321** - The sexual and reproductive health needs of the hard to reach populations in Uganda  
SAMUEL Mukasa, Uganda Martrys University, Uganda

**P322** - A Brief Clinic-Based Peer-to-Peer Education Intervention to Improve Prevention Practices Among Sexual Minority Males  
Nathan Lachowsky, University of Victoria, Canada

**P323** - Unexpected rising trend of sexually transmitted infection in Bangkok, Thailand  
Alisra Tattakorn, BMA, Thailand

**P324** - How do the psychosocial characteristics of women attending sexual health services differ from those attending primary care?  
Natalie Edelman, University of Brighton, UK

**P326** - Syndemic patterns of risk for sexually transmitted infections  
Ashley Hill, Texas A&M University, USA

**P327** - Pattern of sexually transmitted infections in the interior part of Sindh Province of Pakistan  
Mour Khan, Chandka Medical College & SMBB Medical University, Pakistan

**P328** - Sexual health care: Professional development for rural practitioners  
Siobhan Bourke, The University of Melbourne, Australia

**P329** - Stress, post-traumatic stress disorder, and sexual and reproductive health in a nationally-representative sample of US women  
Joy Scheidell, NYU School of Medicine, USA

**P330** - The sexual and reproductive health needs of hard to reach groups in Uganda  
SAMUEL Mukasa, Uganda Martrys University, Uganda

**P331** - Quantitative evaluation of an innovation contest to enhance a sexual health campaign in China  
Ye Zhang, Kirby Institution, University of New South Wales, Australia

**P334** - Acceptance of contraceptive vaginal ring among women with bacterial vaginosis and their male partners in Kenya  
Jeanne Marrazzo, University of Alabama at Birmingham, USA

**P335** - E-devices usage in order to promote mHealth for young key population: Hackhealth outcomes  
Diego Calixto, Ministry of Health of Brazil, Brazil

**P336** - The sexual health knowledge, attitudes and behaviour of women living with HIV in Banten Province, Indonesia  
Dyah Juliatusti, The University of Queensland, Australia

**P337** - A study on how sexual empowerment under mixed-gender dyads influences sexual health among women in India  
Raman Mishra, International Institute for Population Sciences, India

**P338** - Prevalence and mucosal impact of STIs in young women from Mombasa, Kenya with varying exposure to sex work  
Lyle McKinnon, University of Manitoba, Canada

**P339** - Factors of risky sexual behavior among long-haul truckers in a Southern Nigerian town  
Paul Okojie, Liberty University, USA

**P340** - Trends in high-risk sexual risk behaviors in the United States, 2002-2015  
Patricia Dittus, Centers for Disease Control and Prevention, USA

**P341** - Trends in condom use among a nationally representative sample of women and men with opposite-sex partners in the U.S.  
Patricia Dittus, Centers for Disease Control and Prevention, USA

**P343** - Primary outcomes from implementing a behavioral counseling intervention program in four federally qualified health centers  
Kathryn Brookmeyer, Centers for Disease Control and Prevention, USA

**P345** - Correlates of consistent condom use among urban adolescents attending high-school in Panama  
Indira Ranaweera, University of South Florida, USA

**P346** - Psychosocial factors associated with chlamydia retesting among young people in the UK  
Lorraine McDonagh, University College London, UK

**P347** - Does HPV vaccine initiation influence sexual behavior? Findings from the second Australian study of health and relationships  
Anna Yeung, St. Michael's Hospital, Canada

**P348** - Intracluster correlations of STI and sexual behaviour outcomes: Estimates from a community-based cluster RCT  
Jane Hocking, University of Melbourne, Australia

**P349** - Sexual behavior and STI risk among MSM and transgender women participating in a study of timing of antiretroviral therapy  
Michalina Montano, University of Washington, USA

**P350** - What is the optimum method for collecting robust data to understand a nation's sexual health needs?  
Catherine Mercer, University College London, UK

**P351** - Down to test: Music festivals to improve attitudes & social norms to STI testing & condoms in high-risk young people  
Chris Bourne, NSW Health, Australia

**P352** - STD, HIV, and pregnancy testing behaviors among internet and mobile dating application users and non-users, 2016  
Matthew Hogben, Centers for Disease Control and Prevention, USA

**P353** - Social apps and the evolving risk environment: A cross-sectional survey among men who attend STDs clinics in Guangdong, China  
Changchang Li, Dermatology Hospital of Southern Medical University, China

**P356** - HIV-related stigma and discrimination in Western Nigeria: Experiences of people living with HIV and rights issues  
Ibiwumi Usman, Kids & Teens Resource Centre, Nigeria

**P357** - Interlinking stigma, violence and STI/HIV among injecting drug users in India  
Santosh Sharma, International Institute for Population Sciences, India

**P360** - Improving health care worker understanding of LGBTQ+ patients through storytelling and empathy  
Errol Fields, Johns Hopkins University, USA

**P361** - Prevalence of bacterial vaginosis among women attending Sexual Health Clinics in New York City, 2017-2018  
Alissa Davis, Columbia University, USA

**P363** - Combined oral and topical antibiotic therapy for male partners of women with bacterial vaginosis: A pilot study  
Erica Plummer, Monash University, Australia

**P364** - Gardnerella vaginalis clade distribution is associated with behaviours and Nugent score in women who have sex with women  
Erica Plummer, Monash University, Australia

**P365** - Microbial risk factors for acquisition of symptomatic bacterial vaginosis (BV)  
May Beamer, Magee-Womens Research Institute, USA

**P366** - An evaluation of the BD MAX™ vaginal panel compared to the Nugent Score for diagnosis of bacterial vaginosis (BV)  
Lisa Cosentino, Magee-Womens Research Institute, USA

**P367** - Hormonal contraception and risk of STIs and bacterial vaginosis in South African adolescents: A randomized trial  
Christina Balle, University of Cape Town, South Africa

**P368** - Low prevalence of vaginal dysbiosis in Kenyan adolescent girls  
Anna Wald, University of Washington, USA

**P369** - Incidence of vaginal infections in Kenyan women randomized to continuous or cyclic contraceptive ring (CVR)  
Jeanne Marrazzo, University of Alabama at Birmingham, USA

**P370** - Prevalence of chlamydia, gonorrhoea, M. genitalium and T. vaginalis in the general population of Slovenia, 2016-2017  
Irena Klavs, National Institute of Public Health, Slovenia

**P371** - Effect of metronidazole treatment on recurrent and persistent bacterial vaginosis: A pilot study  
Makella Coudray, Florida International University, USA

**P372** - Bacterial vaginosis and high-risk human papillomavirus coinfection among African American women in the United States  
Purnima Madhivanan, Florida International University, USA

**P373** - Co-occurrence of bacterial vaginosis and Trichomonas vaginalis among young African American women  
Purnima Madhivanan, Florida International University, USA

**P374** - Overlap between Amsel's criteria, Nugent's Gram stain score, and vaginal microbiota community state types  
Susan Tuddenham, Johns Hopkins University School of Medicine, USA

**P375** - Risk factors for incident bacterial vaginosis among heterosexual women  
Christina Muzny, University of Alabama at Birmingham, USA

**P380** - The association between social support, violence experience, and social service needs among a select sample of urban adults  
Aruna Chandran, Johns Hopkins University School of Medicine, USA

**P382** - Factors affecting hepatitis C care in prisons in England: A qualitative analysis of stakeholders in London and England  
Sophie Candfield, The Mortimer Market Centre, UK

**P384** - Extension for community healthcare outcomes (ECHO) implemented for Hepatitis C (HCV)/HIV co-infected patients in Texas, USA  
Waridibo Allison, UT Health San Antonio, USA

**P386** - Cancer risk among people with HIV, HBV and/or HCV infections  
Maryam Darvishian, BC CDC, Canada

**P387** - Assessment of the performance of WHO prequalified HIV rapid tests and HCV rapid technology on Dried blood spot eluats  
Hicham Oumzil, Institut National d'Hygiène, Morocco

**P388** - Evolution of hepatitis C care cascades among HIV and hepatitis B co-infected patients in British Columbia, Canada  
Geoff McKee, Vancouver Coastal Health, Canada

**P390** - Improving the uptake of HIV-centered preventative and treatment services by adolescents  
Chantal Smith, MatCH, South Africa

**P391** - Young people's experiences with clinical care and preferences for delivery of new point-of-care tests for STIs in England  
Sebastian Fuller, St George's, University of London, UK

**P392** - Teens' experiences following sexual assault: A systematic review of qualitative research  
Jonathan Ross, University Hospital Birmingham NHS Trust, UK

**P393** - Situation analysis of adolescent and young females in Akure, Ondo State, Nigeria  
Onesimus Aiwanfo, Federal university of Technology Akure, Nigeria

**P395** - Acceptability of point of care testing for *Chlamydia trachomatis* in adolescents: If we make it, will they take it?  
Margaret Hammerschlag, State University of New York Downstate Medical Center, USA

**P397** - Intra-vaginal practices among adolescent girls and young women in South Africa: Risk for HIV acquisition  
Lorato Maje, Simon Fraser University, Canada

**P398** - Can video-consultations contribute to diminishing waiting lists? A demonstration project in the Netherlands  
Filippo Zimble, Soa Aids Nederland (STI Aids The Netherlands), Netherlands

**P399** - HIV prevention among young key population: Community-based strategy outcomes, Brazil  
Diego Calixto, Ministry of Health of Brazil, Brazil

**P400** - Quality improvement initiatives to strengthen viral suppression among ALHIVs in Institute of Human Virology sites in Abuja  
Henrietta Ezegbe, Simon Fraser University, Canada

**P401** - Provision of online and offline HIV self-testing kits for students attending universities: experience from Sichuan, China  
Song Fan, Sun Yat-sen University, China

**P402** - Large Dutch study reveals low-educated youngsters are an important target group for sexual health prevention activities  
Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), Netherlands

**P405** - Social learning theory and health belief model as a predictor and influencer of youth behavior in HIV testing  
Grace Gatimu, Women Fighting HIV/AIDS in Kenya, Kenya

**P407** - 'MTV Shuga': Mass media communication, HSV2 and sexual health in adolescent girls and young women in rural South Africa  
Maryam Shahmanesh, University College London, UK

**P408** - Does stigma around HIV contribute to testing habits among young people? A qualitative analysis  
Chisom Obiezu-Umeh, Saint Louis University, USA

**P410** - Program evaluation to provide HIV and STI information in junior high schools in Kpando, Ghana  
Edem Richard Adjordor, HardtHaven Children's Home, Ghana

**P411** - Acceptability of a phone app-based motivational interviewing intervention for young men's sexual health  
Alexis Guzman, Columbia University Irving Medical Center, USA

**P412** - An exploratory analysis of associations between psycho-social factors and systemic inflammation among South African youth  
Ashley Henry, Canada

**P413** - A dyadic intervention for STI prevention in youth: Feasibility, acceptability & preliminary effectiveness  
Pamela Matson, Johns Hopkins School of Medicine, USA

**P415** - The decision-making process of self-initiated HIV testing among youth: A qualitative study  
Oluwamuyiwa Adebayo, The Pennsylvania State University, USA

**P416** - Longitudinal relationship and sexual health outcomes for adolescent and young adults with pelvic inflammatory disease  
Maria Trent, Johns Hopkins University School of Medicine, USA

**P818** - Prevalence of HPV in teenage heterosexual males after the introduction of the gender-neutral vaccination program in Australia  
Eric Chow, Monash University, Australia

**P819** - Influence of knowledge, attitude, motivation on willingness of mothers for their daughters to undergo HPV vaccination  
Sybil Lizanne Bravo, University of the Philippines, Philippines

**P821** - Sexual behavior in adolescents before and after introduction of the HPV vaccination in Canada  
Robine Donken, University of British Columbia, Canada

**P822** - Factors associated with oncogenic human papillomavirus prevalence among Australian women following vaccine introduction  
Dorothy Machalek, The Royal Women's Hospital, Australia

**P823** - Comparison of Copan UriSponge™ to Colli-Pee for the collection of urine for HPV detection with molecular assays  
Santina Castriciano, Copan Italia Spa, Canada

**P824** - Accuracy of cervical cancer screening using a self-collected vial for HPV DNA testing among adult women in sub-Saharan Africa  
Ralph Sydney Mboumba Bouassa, Ecole Doctorale d'Infectiologie Tropicale, Gabon

**P825** - HPV seroprevalence and seroconversion among HIV-positive men: Cohort study in South Africa  
Admire Chikandiwa, Wits RHI, University of the Witwatersrand, South Africa

**P826** - High prevalence of cervical HR-HPV in immigrant women originating from Sub-Saharan Africa and living in Orléans, France  
Ralph Sydney Mboumba Bouassa, Ecole Doctorale d'Infectiologie Tropicale, Gabon

**P827** - A very high prevalence of human papillomavirus in hidden population of swingers: A Dutch case-control study  
Fleur Koene, Amsterdam UMC, Netherlands

**P828** - Use of hormonal contraceptives and genital human papillomavirus infection: A national multicenter study  
Marina Bessel, Hospital Moinhos de Vento, Brazil

**P829** - Human papillomavirus types distribution in head and neck: A meta-analysis from infection to cancer  
Yong Lu, School of Public Health, Sun Yat-sen University, Guangzhou, PR China, China

**P830** - Feasibility of an online HPV self-collection screening program in Canada: digital health literacy in South Asian women  
Sandy Zhang, Canada

**P831** - Characteristics associated with HPV-related external genital lesions among young adults in Brazil  
Marina Bessel, Hospital Moinhos de Vento, Brazil

**P832** - Effectiveness of the quadrivalent HPV vaccine against HSIL and CIN: A data-linkage study  
Robine Donken, University of British Columbia, Canada

**P833** - HSV-2 serostatus and HPV incidence, persistence, and precancerous lesions in a cohort of HPV-vaccinated women living with HIV  
Elisabeth McClymont, University of British Columbia, Canada

**P834** - Epidemiology of human papillomavirus among women in Guangdong, China 2008-2017  
Ganfeng Luo, Sun Yat-sen University, China

**P835** - Quantitative oral HPV16 and HPV18 detection in patients attending dental clinics  
Helen Stankiewicz Karita, University of Washington, USA

**P836** - Trends in anogenital warts since introduction of human papillomavirus vaccines in Connecticut, USA  
Linda Nicolai, Yale School of Public Health, USA

**P837** - HPV16 / 18 vaccine: influence on the systemic and local TH1 / TH2 cytokine profile  
Rose Luce Do Amaral, UNICAMP, Brazil

**P839** - A chemically modified  $\beta$ -lactoglobulin (JB01) is effective in treating HPV infection and preventing sexual transmission of HIV  
Shibo Jiang, Fudan University, China

**P840** - The HPV Screening and Vaccine Evaluation (HPV-SAVE) Study in men living with HIV: early pathologic and acceptability outcomes  
Troy Grennan, BC Centre for Disease Control, Canada

**P841** - Barriers to HPV vaccination among gay, bisexual, and other men who have sex with men (gbMSM) in Canada: A CIRN study  
Ramandip Grewal, St. Michael's Hospital, Canada

**P842** - Healthcare engagement and HPV vaccination among gay, bisexual, and other men who have sex with men (gbMSM): A CIRN study  
Ramandip Grewal, St. Michael's Hospital, Canada

**P843** - The transmission of HPV in the sexual networks of swingers, a multilevel network approach  
Anne-Marie Niekamp, South Limburg Public Health Service, Netherlands

**P844** - The burden of HPV and HSV-related anogenital diseases in a Southeastern US urban HIV clinic  
Yuanfan Ye, University of Alabama at Birmingham, USA

**P846** - Biomarkers of HIV exposure and condomless receptive anal sex in men who have sex with men using self-collected rectal swabs  
Maria Lemos, Fred Hutchinson Cancer Research Center, USA

**P848** - Revisiting enfuvirtide's mechanism and designing its analog with improved activity by targeting triple sites in gp41  
Shibo Jiang, Fudan University, China

**P850** - Gender identify and self-reported HPV vaccination among youth living with or at high-risk for HIV  
Elizabeth Arnold, UT Southwestern Medical Center, USA

**P851** - Performance disk diffusion method in identifying gonococcal resistance  
Wenqi Xu, National Center for STD Control, Chinese Center for Disease Control and Prevention, Chinese Academy of Medical Sciences & Peking Union Medical College, China

**P852** - Evaluation of PLEXPCR VHS For diagnosis of genital lesions  
Litty Tan, Speedx Pty Ltd., Australia

**P853** - Human factors engineering to drive the development of a next generation Colli-Pee home-based first-void urine collection  
Vanessa Vanckerkhoven, Novosanis N.V., Belgium

**P859** - Genotyping gyrA and penA from remnant *Neisseria gonorrhoeae* positive Cepheid Xpert® clinical specimens  
Sakina Qadir, University of California Los Angeles, USA

## Tuesday, July 16, 2019

17:45 - 19:00 PS02 Poster Viewing Session

Location: Exhibit Hall A

**P417** - High interest in syphilis pre- and post-exposure prophylaxis among gay, bisexual and other MSM in Vancouver and Toronto  
Laura Fusca, Li Ka Shing Knowledge Institute, Canada

**P418** - Uptake of HIV pre-exposure prophylaxis (PrEP) in western Nigeria: are healthcare providers prepared for the key populations?  
Ibiwumi Usman, Kids & Teens Resource Centre, Nigeria

**P419** - Patterns of group sex activity among gay and bisexual men in Melbourne and Sydney in Australia, 2013-2018  
Eric Chow, Monash University, Australia

**P420** - Understanding PrEP service delivery preferences among black women in urban and rural counties in the US deep south  
Latesha Elore, University of Alabama at Birmingham, USA

**P421** - "The promise of PrEP": Motivations for taking PrEP among early-adopting New Zealand gay and bisexual men  
Peter Saxton, University of Auckland, New Zealand

**P422** - Use of doxycycline prophylaxis against STI among gay and bisexual men taking pre-exposure prophylaxis in Melbourne  
Eric Chow, Monash University, Australia

**P423** - Pre-exposure prophylaxis as an alternative to PEP for electives: Survey assessing medical students' knowledge and beliefs  
Zayn Majeed, GKT School Of Medical Education, UK

**P424** - High prevalence and incidence of bacterial STIs in young women at high risk of HIV prior to PrEP scale-up in Kenya  
Jenell Stewart, University of Washington, USA

**P425** - Capturing missed opportunities for PrEP prescription in patients diagnosed with other STIs  
Stephanie McLaughlin, New York University, USA

**P426** - Risk factors associated with Gonorrhea infection among PrEP patients in a Montreal clinic  
Réjean Thomas, Clinique médicale l'Actuel, Canada

**P427** - SUPPLEx: Appearance and performance-enhancing supplements use in people on pre-exposure Prophylaxis  
Isaac Bogoch, University Health Network, Canada

**P428** - HIV incidence, and pre- and post-exposure prophylaxis (PrEP and PEP) among PEP users at New York City sexual health clinics  
Preeti Pathela, New York City Department of Health and Mental Hygiene, USA

**P429** - Does HIV pre-exposure prophylaxis (PrEP) initiation in sexual health clinics impact subsequent HIV risk?  
Preeti Pathela, New York City Department of Health and Mental Hygiene, USA

**P430** - Predictors of interest in switching from daily to on-demand HIV pre-exposure prophylaxis (PrEP) among Australians  
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

**P431** - Effect of targeted intervention on condom use and among men who have sex with men (MSM) taking PrEP in Nairobi Kenya  
Maureen Akolo, Partners for Health and Development in Africa, Kenya

**P432** - High prevalence and incidence of curable STIs among young women initiating PrEP in a township in South Africa  
Katherine Gill, Desmond Tutu HIV Foundation, South Africa

**P433** - Low HIV incidence among women diagnosed with syphilis or gonorrhoea does not support PrEP recommendations, King County, WA  
Anna Berzkalns, Public Health – Seattle & King County, USA

**P434** - Substance use patterns and HIV prevention among gay and bisexual men in the 2014-2015 sex now survey  
Kiffer Card, University of Victoria, Canada

**P435** - Use of condoms for the prevention of sexually transmitted infections (STIs) among HIV pre-exposure prophylaxis (PrEP) users  
Benjamin Bavinton, University of New South Wales, Sydney, Australia

**P436** - Barriers to adherence to HIV treatment among adolescents and youth enrolled in ARV in two district hospitals in rural Rwanda  
Naome Nyirahabimana, Partners In Health/Inshuti mu Buzima (Rwanda), Rwanda

**P438** - Gay, bisexual and other men who have sex with men prefer sexual health clinic nurses over family physicians for PrEP delivery  
Darrell Tan, St. Michael's Hospital, Canada

**P439** - Insurance coverage, financial strain, and adherence to pre-exposure prophylaxis among gay/bisexual men in the United States  
Tyler Wray, Brown University School of Public Health, USA

**P440** - Assessment of potential pre-exposure prophylaxis (PrEP) compliance in intravenous drug users accessing outreach services  
Jane Champion, University of Texas at Austin, USA

**P442** - Implementing pre-exposure prophylaxis for HIV: Experiences in a health department based STI clinic  
Andrea Lewis, Wake Forest Baptist Medical Center, USA

**P443** - Eligibility for and use of HIV pre-exposure prophylaxis among Australian gay and bisexual men over time  
Benjamin Bavinton, University of New South Wales, Sydney, Australia

**P444** - A case series of pre-exposure prophylaxis failures in men using event-based-dosing in London, UK  
Naomi Fitzgerald, Guy's and St Thomas' NHS Trust, UK

**P445** - Anxiety about HIV and use of HIV pre-exposure prophylaxis among gay and bisexual men  
Peter Saxton, University of Auckland, New Zealand

**P446** - Use of antibiotic prophylaxis for sexually transmitted infections among gay and bisexual men in Australia  
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

**P447** - Awareness and acceptability of pre-exposure prophylaxis among MSM: Results from Scotland's gay bar survey  
Jamie Frankis, Glasgow Caledonian University, UK

**P448** - Are we enrolling men who have sex with men with greatest HIV acquisition risk in a pre-exposure prophylaxis program?  
Errol Fields, USA

**P449** - Who's got PrEP? Association between race, recent STI and receipt of PrEP prescription among MSM enrolled in a PrEP Program  
Errol Fields, USA

**P450** - Prep use, STD acquisition and sexual risk behavior  
Amy Burrell, Chase Brexton Health Services, USA

**P452** - A Nurse-Led HIV Pre-Exposure Prophylaxis Program at Cool Aid Community Health Centre for Men Who Have Sex with Men  
Karen Lundgren, Cool Aid Community Health Centre, Canada

**P453** - Incidence and Predictors of Urethral and Rectal Chlamydia and Gonorrhoea among Men Who Have Sex with Men Taking PrEP in Kenya  
Supriya Mehta, University of Illinois at Chicago, USA

**P454** - Emergency Department (ED)-Based HIV Pre-Exposure Prophylaxis (PrEP) Referral Program—Using EDs as a Portal for PrEP Services  
Zezhou Zhao, Johns Hopkins University, USA

**P455** - Awareness, Knowledge and Willingness to use HIV PrEP among MSM and TG People in Bali, Indonesia  
Irvin Romyco, FHI360-LINKAGES, Indonesia

**P457** - A single dose of behaviour change: The impact of testing on behaviour and chlamydia transmission  
Daphne Van Wees, National Institute for Public Health and the Environment (RIVM), Netherlands

**P458** - Genital *Chlamydia trachomatis* and *Mycoplasma genitalium* among infertile women in University College Hospital, Ibadan  
Tinuade Ajani, Babcock University Teaching Hospital, Nigeria

**P459** - Towards a universal tool for estimating chlamydia prevalence from surveillance data: A systematic comparison of models  
Jonathan Roberts, Imperial College London, UK

**P460** - Assessment of tubal factor infertility attributable to chlamydia with Pgp3 serology  
Gloria Anyalechi, Centers for Disease Control and Prevention, USA

**P461** - Bacterial load of chlamydia in the oropharynx and saliva among gay and bisexual men with untreated oropharyngeal chlamydia  
Kate Maddaford, Alfred Health, Australia

**P462** - Re-testing for chlamydia in the National Chlamydia Screening Programme in Bristol, England: An analysis of surveillance data  
Katherine Davis, Imperial College London, UK

**P463** - Participation and retention of women in a prospective multicenter study on *Chlamydia trachomatis* infections (FemCure)  
Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands

**P464** - Treatment failure in rectal *Chlamydia trachomatis* azithromycin treated women driven by high viable bacterial load (FemCure)  
Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands

**P465** - Chlamydia-screening for women under the age of 25 years in Germany – how are we doing?  
Martyna Gassowski, Robert Koch-Institute, Germany

**P466** - High prevalence of extragenital *Chlamydia trachomatis* (CT) in heterosexual women: validation of pooled samples  
Selena Singh, UK

**P467** - Factors associated with anorectal chlamydia or gonorrhoea test positivity in women – a systematic review and meta-analysis  
Andrew Lau, University of Melbourne, Australia

**P468** - The association of symptoms with viable vaginal or rectal *Chlamydia trachomatis* load: Multicenter cohort study (FemCure)  
Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands

**P469** - Spontaneous resolution to negative and non-viable status of vaginal and rectal *Chlamydia trachomatis* infection (FemCure)  
Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands

**P470** - Screening rates and follow-up of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections during pregnancy  
Annie-Claude Labbé, Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est-de-l'Île-de-Montréal, Canada

**P471** - *Lymphogranuloma venereum* in Quebec, Canada: five years of epidemiological survey, 2013-2017  
Karine Blouin, Institut National de Santé Publique du Québec, Canada

**P472** - Do chlamydia testing patterns in New Zealand explain the high diagnosis rates?  
Peter Saxton, University of Auckland, New Zealand

**P473** - Epidemiology of *Chlamydia trachomatis* in Ontario and implications for changes to practice guidelines  
Gayane Hovhannisyan, Niagara Public Health Department, Canada

**P474** - Cases of *Lymphogranuloma venereum* in Chicago, IL, July 2016 – April 2017  
Irina Tabidze, Chicago Department of Public Health, USA

**P475** - *Chlamydia trachomatis* and *Neisseria gonorrhoeae*: Prevalence and factors associated among women with HIV in São Paulo, Brazil  
Valdir Pinto, Municipal Health Secretariat of São Paulo, Brazil

**P476** - Prevalence of chlamydia and gonorrhoea among youth in Los Angeles and New Orleans receiving frequent testing  
Erin Keizer, UCLA, USA

**P477** - Prenatal screening and treatment of *Chlamydia trachomatis* infection to prevent adverse pregnancy outcomes - a pilot study  
Changchang Li, Dermatologic Hospital of Southern Medical University, China

**P478** - Is chlamydia and gonorrhoea testing associated with pregnancy outcomes? A retrospective data-linkage cohort study  
Torrington Callan, University of Technology Sydney, Australia

**P479** - Immunoprofiling of *Chlamydia trachomatis* combining whole-proteome microarrays and high-throughput multiplex serology  
Katrin Hufnagel, German Cancer Research Center (DKFZ), Germany

**P480** - Enhanced prevalence of *Chlamydia trachomatis* DNA in clinical samples of patients with STIs co-infection  
Valentina Feodorova, Federal Research Center for Virology and Microbiology, Branch in Saratov, Russian Federation

**P481** - Patients with repeat *Chlamydia trachomatis* and *Neisseria gonorrhoeae* are different compared to those with single infections  
Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands

**P482** - Women visiting general practitioners have higher *Chlamydia trachomatis* bacterial loads than women visiting the STI clinic  
Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands

**P483** - A lower genital *Chlamydia trachomatis* bacterial load is associated with coinfections with *Neisseria gonorrhoeae* and HIV  
Nicole Dukers-Muijers, Public Health Service South Limburg, Netherlands

**P484** - The impact of *Chlamydia trachomatis* NAAT detection probability on test-of-cure results  
Petra Wolffs, Maastricht University Medical Center (MUMC+), Netherlands

**P485** - Predictors of loss-to-follow-up among HIV infected MSM on treatment at a (trusted) community health centre in Lagos, Nigeria  
Adebola Adejimi, College of Medicine, University of Lagos, Nigeria

**P486** - Population structure of *Lymphogranuloma venereum* in Belgium: Surveillance data from 2010 until 2017  
Irith De Baetselier, Institute of Tropical Medicine, Belgium

**P487** - A novel rapid real-time PCR test for the detection of *Chlamydia trachomatis* in patient samples  
Clare Cornwell, QuantuMDx, UK

**P488** - Putting the U.S. Army's rising rates of chlamydia and gonorrhoea in perspective: A comparison with U.S. trends  
Nikki Jordan, Army Public Health Center, USA

**P489** - *Chlamydia trachomatis* -specific gene transcripts as a more accurate marker for infection status  
Petra Wolffs, Maastricht University Medical Center (MUMC+), Netherlands

**P490** - LGV in patients attending an STI outpatient clinic in Berlin: An urban emergence with high proportion of HIV-coinfections  
Heiko Jessen, Praxis Jessen2 + Kollegen, Germany

**P491** - Determining recommended chlamydia and gonorrhoea treatment using linked medical claims, prescription and laboratory data  
Guoyu Tao, Centers for Disease Control and Prevention, USA

**P492** - Predicting Chlamydia reinfection in African American women using immunogenetic determinants in a Bayesian model  
Kristin Olson, University of Alabama at Birmingham, USA

**P493** - Determination of *Chlamydia trachomatis* organism load in men with Nongonococcal Urethritis (NGU)  
James Williams, Indiana University School of Medicine, USA

**P494** - Diagnosis and management of lymphogranuloma venereum (LGV) in a municipal STD Clinic, San Francisco, 2016-18  
Stephanie Cohen, San Francisco Department of Public Health, USA

**P495** - HIV, STIs and sexual health screening in men who have sex with men in Lebanon: A retrospective study  
Ismael Maatouk, Clemenceau Medical Center, Lebanon

**P497** - A meta-synthesis of men who have sex with men (MSM)'s experiences and perceptions of Human Papillomavirus (HPV) vaccination  
Lewis Clarke, Edinburgh Napier University, UK

**P499** - Human papillomavirus detection in residual samples from STI tests in men who have sex with men  
Richard Gilson, University College London, UK

**P500** - Barriers and opportunities for partner services related to syphilis among men who have sex with men in Anchorage, Alaska  
Laura Quilter, Centers for Disease Control and Prevention, USA

**P501** - Low prevalence of high-risk anal HPV in young gay and bisexual males after the universal HPV vaccination program in Australia  
Eric Chow, Monash University, Australia

**P503** - Trends in awareness and use of PrEP among HIV-negative men who have sex with men in Vancouver, Toronto, and Montreal  
Heather Armstrong, University of British Columbia, Canada

**P505** - The impact of gonorrhoea vaccination in men who have sex with men on prevalence and resistance: mathematical modelling study  
Janneke Heijne, National Institute for Public Health and the Environment (RIVM), Netherlands

**P507** - Disclosure of same-sex behavior and extragenital STI testing among men who have sex with men – American Men's internet survey  
Alex De Voux, Centers for Disease Control and Prevention, USA

**P508** - Hepatitis C reinfection rates after cure or clearance among HIV-infected and uninfected men who have sex with men  
Maryam Darvishian, British Columbia Centre for Disease Control, Canada

**P509** - Use of internet/mobile dating apps to find sex partners among a nationally representative sample of men who have sex with men  
Rachel Kachur, Centers for Disease Control and Prevention, USA

**P510** - Chemsex among men who have sex with men in a mixed urban-non-urban area and associations with sexually transmitted infections  
Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), Netherlands

**P511** - Surveillance of Lymphogranuloma venereum among men who have sex with men attending STI clinics in Alberta, Canada, 2018  
Petra Smyczek, Alberta Health Services, Canada

**P512** - Quantifying sexual mixing by HIV status and pre-exposure prophylaxis (PrEP) use among men who have sex (MSM) with men  
Jesse Knight, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Canada

**P513** - Convection mixing and the social geography of partner selection among sexual minority men in Toronto, Canada  
Dionne Gesink, University of Toronto, Canada

**P516** - Low immunity to hepatitis A amongst men who have sex with men attending a large sexual health clinic in Melbourne, Australia  
Lenka Vodstrcil, Monash University, Australia

**P517** - Do sexual practices differ by age among gay and bisexual men? A cross-sectional study in Melbourne, Australia  
Eric Chow, Monash University, Australia

**P518** - Sexual practices and healthcare use of men who have sex with men only and men who have sex with men and women  
Alaina Vaisey, University of Melbourne, Australia

**P519** - Is chemsex among men who have sex with men perceived as problematic? A cross-sectional study in the Netherlands  
Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), Netherlands

**P520** - HPV infections and flat penile lesions of the penis in men who have sex with men  
Maarten Schim Van Der Loeff, Public Health Service Amsterdam, Amsterdam University Medical Center (UMC), Netherlands

**P521** - Increases in the estimated number of reported gonorrhoea cases among men who have sex with men (MSM): The role of testing  
Emily Weston, US Centers for Disease Control and Prevention, USA

**P522** - Disparities in HIV/STI testing and diagnosis among urban and non-urban US men who have sex with men from 2013 to 2017  
Maria Zlotorzynska, Emory University Rollins School of Public Health, USA

**P523** - Urethral microbiota in idiopathic nongonococcal urethritis (NGU) in men who have sex with men and men who have sex with women  
Sujatha Srinivasan, Fred Hutchinson Cancer Research Center, USA

**P524** - Gays, government and big data: Should routine health records include sexual orientation?  
Peter Saxton, University of Auckland, New Zealand

**P525** - Prevalence of *Mycoplasma genitalium* by anatomical site in men who have sex with men: A systematic review and meta-analysis  
Rosie Latimer, Melbourne Sexual Health Centre, Australia

**P526** - High prevalence and incidence rate of rectal chlamydia and gonorrhoeae infection among men who have sex with men in Tokyo  
Daisuke Mizushima, National Center for Global Health and Medicine, Japan

**P527** - HIV testing uptake among young men who have sex with men in Myanmar: Self-efficacy and HIV testing behavior  
Minh Pham, Burnet Institute, Australia

**P528** - Rates of primary and secondary syphilis among men who have sex with men by HIV status – 24 states, 2011–2015  
Jeremy Grey, Centers for Disease Control and Prevention, USA

**P529** - Early sexual debut and non-consensual sex among Chinese men who have sex with men: A multi-city cross-sectional study  
Weiming Tang, UNC Project-China, China

**P530** - Addressing underserved men who have sex with men (MSM): Advancing the sexual health approach for MSM in Vancouver, Canada  
Nathan Lachowsky, University of Victoria, Canada

**P531** - Chemsex and STI clinic use among MSM: results from a large online survey in England  
Paula Blomquist, Public Health England, UK

**P532** - The sexual behaviour and health of heterosexual-identifying men who have sex with men: A systematic review  
Tyrone Curtis, University College London, UK

**P533** - Hepatitis A vaccine uptake among men who have sex with men from a targeted vaccination program in Melbourne in 2018  
Lenka Vodstrcil, Monash University, Australia

**P535** - Chemsex & sexual consent: A quantitative study on sexualized drug use in men who have sex with men and non-consensual sex  
Martijn Van Rooijen, Public Health Service of Amsterdam, Netherlands

**P538** - High HIV incidence among men who have sex with men in eight Chinese cities: Results from a cohort study  
Weiming Tang, UNC Project-China, China

**P539** - Prevalence of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* among MSM in Morocco  
Amina Hançali, Institut National d'Hygiène, Morocco

**P540** - HPV (sero) prevalence among young MSM visiting the STI clinic: Opportunities for targeted HPV vaccination  
Petra Woestenberg, RIVM, Netherlands

**P541** - To pool or not to pool STI samples in MSM using PrEP? Results of the CohMSM-PrEP Study (ANRS 12369 - Expertise France)  
Irith De Baetselier, Institute of Tropical Medicine, Belgium

**P542** - Prevalence of STIs among MSM initiating PrEP in West-Africa (CohMSM-PrEP ANRS 12369 - Expertise France)  
Irith De Baetselier, Institute of Tropical Medicine, Belgium

**P543** - Cost-effectiveness of pre-exposure prophylaxis in MSM with event-driven and daily regimens  
Maarten Reitsema, RIVM, Netherlands

**P544** - Trends in recreational drug use and associations with CAS, HIV and STI among HIV-negative MSM in Amsterdam between 2008-2017  
Liza Coyer, Public Health Service of Amsterdam, Netherlands

**P545** - Trends in HIV infection and AIDS in men who have sex with men (MSM): Adults compared to young people in Sao Paulo, Brazil  
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

**P546** - "STIs are everyone's responsibility": A new conceptual model of sexual health among gay and bisexual men  
Denton Callander, New York University, USA

**P547** - Relationship length of gay male couples and sexually transmitted infections  
Silver Vargas, Universidad Peruana Cayetano Heredia, Peru

**P548** - Acute gastroenteritis in men-who-have-sex-with-men in Seattle, Washington, 2017-2018  
Gretchen Snoeyenbos Newman, University of Washington, USA

**P549** - What is the optimal testing strategy for oropharyngeal *Neisseria gonorrhoeae* in MSM visiting STI clinics?  
Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), Netherlands

**P550** - High awareness but low uptake of HPV vaccine among GBMSM in Ontario, Canada: Results from the #Cruise Study  
Anna Yeung, St. Michael's Hospital, Canada

**P551** - Extragenital gonorrhoea positivity among men who have sex with men – STD Surveillance Network, 2015–2017  
Winston Abara, CDC, USA

**P553** - Initiating a sexual network study among men who have sex with men: A mixed-methods pilot study  
JaNelle Ricks, The Ohio State University, USA

**P554** - Adherence and sexually transmitted infections among MSM receiving care in a community-based HIV PrEP clinic in the deep South  
Paul St. Clair, USA

**P555** - Monitoring HIV and syphilis co-infection among men who have sex with men in Brazil, 2009-2016  
MARK Guimaraes, Brazil

**P556** - History of STI therapy and willingness of prep among HIV-negative MSM cohort in Japan  
Misao Takano, National Center for Global Health and Medicine, Japan

**P557** - "Flux NZ": An online national cohort investigating HIV, STI and drug-related practices among New Zealand gay and bisexual men  
Peter Saxton, University of Auckland, New Zealand

**P558** - Sexual health, syndemics and assets among men who have sex with men: Secondary analysis of multi-national surveys  
Paul Flowers, University of Glasgow, UK

**P559** - Incarceration, stress and sexual risk-taking: An intersectional analysis of black men who have sex with men in the deep south  
Denton Callander, New York University, USA

**P560** - HIV preventive behaviour during last sex with a non-steady partner – self-reported data from 113,000 MSM from 66 countries  
Ulrich Marcus, Robert Koch-Institut, Germany

**P561** - Developing surveillance tools to measure MSM's HIV infection risk in the era of complex biobehavioural prevention strategies  
Jamie Frankis, Glasgow Caledonian University, UK

**P562** - Health seeking behaviour and acceptability of online outreach efforts among MSM using sex-seeking apps/websites  
David Brennan, University of Toronto, Canada

**P563** - MSM predictive modeling within a large, linked database of laboratory, surveillance, and administrative healthcare records  
Travis Salway, BC Centre for Disease Control, Canada

**P564** - Outcomes of anal HPV screening in HIV+ men who have sex with men attending high resolution anoscopy clinic in Canada  
Angel Chu, Alberta Health Services, Canada

**P565** - Personalized cognitive counseling (PCC) to reduce HIV risk following rectal gonorrhoea/chlamydia diagnosis among MSM in Peru  
Jesse Clark, UCLA Geffen School of Medicine, USA

**P566** - The uptake of non-occupational HIV postexposure prophylaxis among MSM: A systematic review and meta-analysis  
Zhenyu Wang, School of Public Health, Sun Yat-sen University, China

**P567** - Factors influencing gay and queer men's acceptability of integrating substance use care within sexual healthcare settings  
Caroline Mniszak, BC Centre on Substance Use, Canada

**P568** - Positivity of syphilis, rectal gonorrhoea and rectal chlamydia among MSM PrEP users in Baltimore City, Maryland  
Christina Schumacher, Johns Hopkins School of Medicine, USA

**P569** - Seroadaptive behaviors influenced by partner-level and environmental-level factors among IPREX participants  
Hong-Ha Truong, University of California, San Francisco, USA

**P570** - Demographic, healthcare, and psychosocial factors related to STI diagnosis in a sample of young MSM: The P18 cohort study  
Stephanie McLaughlin, USA

**P571** - Prevalence of extragenital gonorrhoea and chlamydia among venue-attending men who have sex with men – San Francisco, 2017  
Trang Nguyen, San Francisco Department of Public Health, USA

**P572** - High prevalence of anal human papillomavirus infection in HIV-infected males having sex with males in Turkey  
Alper Gunduz, Sisli Etfal Training and Research Hospital, Turkey

**P573** - Geographic effects of incarceration on multiple partnerships and STI among black men who have sex with men  
Maria Khan, New York University School of Medicine, USA

**P574** - Rectal and pharyngeal M. genitalium among Men who have Sex with Men (MSM): Results from a Longitudinal Cohort Study  
Lindley Barbee, University of Washington, USA

**P575** - Prevalence and Risk Factors of Anal Human papillomavirus (HPV) Infections among MSM in Bali, Indonesia  
Irvin Romyco, FHI360-LINKAGES, Indonesia

**P577** - Associations between penile-anal intercourse and oral sex and viral STIs in the United States, 2011-2015  
Melissa Habel, Centers for Disease Control and Prevention, USA

**P578** - Drivers of sexual health knowledge for two-spirit, gay, bi and/or native men who have sex with men (gbMSM)  
Harlan Pruden, BCCDC, Canada

**P579** - High prevalence and correlates of syphilis and HIV infection among adolescents of the Comarca Ngäbe-Buglé, Panama  
Amanda Gabster, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama

**P580** - Predictors of sexually transmitted infection screening among binge alcohol using Native American adults  
Lauren Tingey, Johns Hopkins School of Public Health, USA

**P583** - The role of parents in predicting sexual health and substance use risk among Native American youth  
Lauren Tingey, Johns Hopkins University, USA

**P584** - Factors predicting lifetime sexual experience among rural, reservation-based Native American youth  
Lauren Tingey, Johns Hopkins University, USA

**P585** - Inuit community readiness: Adapting the community readiness model with Inuit communities for HIV prevention  
Audrey Steenbeek, Dalhousie University, Canada

**P586** - Ikajurniq: An Inuit cascade of care framework for sexually transmitted and blood borne infections  
Savanah Ashton, Pauktuutit Inuit Women of Canada, Canada

**P587** - Association between vaginal bacteria and HIV acquisition risk among African women participating in the VOICE study  
Sujatha Srinivasan, Fred Hutchinson Cancer Research Center, USA

**P588** - A multi-site comparative study to understand sources of variability in studies of the vaginal microbiota  
Jennifer Balkus, University of Washington, USA

**P589** - The influence of preconception vaginal microbiota on preterm birth  
Catherine Haggerty, University of Pittsburgh, USA

**P590** - Vaginal microbiota and douching cessation: A cross-over pilot study  
Sarah Brown, University of Maryland, USA

**P591** - The effect of hormonal contraception on the vaginal microbiota over 2 years  
Susan Tuddenham, Johns Hopkins University, USA

**P592** - Microbiota concordance between mid-vaginal swabs and both clean- and random-catch urine samples  
Courtney Robinson, University of Maryland, USA

**P593** - A cross-sectional study of birth mode and vaginal microbiota in reproductive-age women  
Rebecca Brotman, University of Maryland, USA

**P595** - Vaginal Microbiota Among Adolescent and Young Adult Women with Pelvic Inflammatory Disease  
Maria Trent, Johns Hopkins University School of Medicine, USA

**P597** - Comparison of assays and specimen types for the diagnosis of *Mycoplasma genitalium* and macrolide resistant mutations  
Max Chernesky, McMaster University / St. Joseph's Research Institute, Canada

**P598** - Detection of chlamydia, gonorrhoea and *Mycoplasma genitalium* in semen and in ESwab medium using Hologic Aptima assays  
Cécile Bébéar, University of Bordeaux, France

**P599** - *Mycoplasma genitalium* detection in male and female urogenital specimens using a standardized molecular assay  
Rodney Arcenas, Roche Molecular Systems, USA

**P600** - *Mycoplasma genitalium* positivity rates in the US  
Barbara Van Der Pol, University of Alabama at Birmingham, United States Minor Outlying Islands

**P601** - Macrolide and fluoroquinolone resistance-associated mutations in *Mycoplasma genitalium*: A systematic review and meta-analysis  
Dorothy Machalek, The Royal Women's Hospital, Australia

**P602** - Molecular screening and quantification of *Mycoplasma genitalium* in infertility patients  
Sunil Sethi, Postgraduate Institute of Medical Education & Research Chandigarh, India

**P603** - Estimating Population Burden of Pelvic Inflammatory Disease Due to *Mycoplasma genitalium* in England: An Evidence Synthesis  
Joanna Lewis, Imperial College London, UK

**P604** - Platform-agnostic reagents for detection of *Mycoplasma genitalium*  
Barbara Van Der Pol, University of Alabama at Birmingham, United States Minor Outlying Islands

**P605** - Testing and treatment strategies for limiting drug resistance in *Mycoplasma genitalium*  
Peter White, Imperial College London, UK

**P606** - Oh MG! The symptoms of *Mycoplasma genitalium* in Women  
Rosie Latimer, Melbourne Sexual Health Centre, Australia

**P607** - Detection of *Mycoplasma genitalium* macrolide resistance using the open channel of the Panther Fusion® system  
Carsten Tiemann, Krone Laboratory / LABCON-OWL, Germany

**P608** - SimpleProbe PCR assay for detection of mutations associated with macrolide resistance in *Mycoplasma genitalium* samples  
Marianne Gossé, Norwegian University of Science and Technology, Norway

**P609** - Clinical evaluation of three commercial PCR assays for the detection of *Mycoplasma genitalium* and macrolide resistance  
Sabine Pereyre, University of Bordeaux, France

**P610** - *Mycoplasma genitalium* in clients visiting two Dutch STI clinics: Very high prevalence and resistance to azithromycin  
Sylvia Bruisten, Public Health Service Amsterdam, Amsterdam University Medical Center (UMC), Netherlands

**P611** - High seroprevalence of *Mycoplasma genitalium* in the general adult population of Germany  
Felix Reichert, Robert Koch-Institute, Germany

**P612** - Antimicrobial susceptibility data of *Mycoplasma genitalium* strains isolated in Japan  
Ryoichi Hamasuna, Shin-Kokura Hospital, Japan

**P613** - Prevalence and clinical features of *Mycoplasma genitalium* in patients attending a STI Outpatient Clinic in Berlin: 2013-2017  
Heiko Jessen, Praxis Jessen2 + Kollegen, Germany

**P614** - Macrolide Resistance in *Mycoplasma genitalium* is strongly associated with STI co-infection  
Martina Furegato, St George's, University of London, UK

**P615** - Clinical improvement after standard treatment for urethritis: the role of *Mycoplasma genitalium*  
Clarissa Vergunst, Public Health Service of Amsterdam, Netherlands

**P616** - Predictive macrolide and fluoroquinolone resistance markers in *Mycoplasma genitalium* from the UK and Ireland  
Michaela Day, Public Health England, UK

**P617** - Molecular typing of *Mycoplasma genitalium* shows a diverse epidemic with limited azithromycin resistance in South Africa  
Remco Peters, University of Pretoria, South Africa

**P618** - *Mycoplasma genitalium* testing in clinical practice: Prevalence and resistance rates in a South London sexual health clinic  
Emma Wallis, Guy's and St Thomas' NHS Trust, UK

**P619** - Macrolide and quinolone resistance in *Mycoplasma genitalium*: Data from a UK sexual health clinic  
Ruairi Conway, Brighton and Sussex Medical School, UK

**P620** - Inclusivity, exclusivity, stability and prospective testing of two real-time PCR assays for *Mycoplasma genitalium*  
Justin Hardick, Johns Hopkins University School of Medicine, USA

**P621** - Prevalence of *Mycoplasma genitalium* infection, antimicrobial resistance, and symptom resolution following treatment  
Laura Bachmann, Centers for Disease Control and Prevention, USA

**P622** - The use of Seegene's Allplex™ MG & AziR assay for the detection of *Mycoplasma genitalium* and macrolide resistance in Wales  
Andrew Barratt, Room 166, 6th floor Main Building, University Hospital of Wales, UK

**P623** - Post-transcriptional regulation of genes by non-coding RNA in *Neisseria gonorrhoeae*, an obligate human pathogen  
Pooja Tanwer, University of Delhi, India

**P624** - Culture for urethral gonorrhoea from asymptomatic men positive for *Neisseria gonorrhoeae* by urine Aptima Combo 2 testing  
Melanie Bissessor, Melbourne Sexual Health Centre, Australia

**P625** - Trends in symptomatic presentation among reported gonorrhoea cases, STD Surveillance Network (SSuN), 2010 – 2017  
Mark Stenger, U.S. Centers for Disease Control and Prevention, USA

**P626** - *Neisseria Gonorrhoea* as an Unrecognized Cause of Preseptal Cellulitis  
Paul Adamson, UCLA - David Geffen School of Medicine, USA

**P627** - Changing of molecular characterization of gonococcal isolates in Guangdong, China: In a background of a rising epidemic  
He-ping Zheng, Dermatology Hospital of Southern Medical University, Guangdong Center for STD Control & Prevention, China

**P628** - The impact of including throat and rectal swabs for chlamydia and gonorrhoea testing online in British Columbia, Canada  
Aidan Ablona, BC Centre for Disease Control, Canada

**P629** - Gonorrhoea acquisition after infection with the US NmNG urethritis clade: a prospective, chart-based study  
Abigail Norris Turner, Ohio State University, USA

**P630** - Estimating the potential impact of realistic vaccination strategies against antibiotic resistant *Neisseria gonorrhoeae*  
Lilith Whittles, Imperial College London, UK

**P631** - Cases of gonorrhoea with multiple anatomic sites of infection in Canada, 2016 to 2017  
Pam Sawatzky, Public Health Agency of Canada, Canada

**P632** - Regional differences in gonorrhoea antimicrobial resistance patterns in the Netherlands  
Maartje Visser, National Institute for Public Health and the Environment (RIVM), Netherlands

**P633** - Low gonorrhoea antimicrobial resistance and culture positivity rates in general practice: A pilot study  
Maartje Visser, National Institute for Public Health and the Environment (RIVM), Netherlands

**P634** - Surveillance for disseminated gonococcal infections, active bacterial core surveillance (ABCs) – United States, 2015 – 2018  
Emily Weston, US Centers for Disease Control and Prevention, USA

**P635** - The Enhanced Gonococcal Antimicrobial Surveillance Program (EGASP) in the Philippines, 2018  
Emily Weston, US Centers for Disease Control and Prevention, USA

**P636** - High diversity of *Neisseria gonorrhoeae* in Germany revealed by molecular typing using NG-MAST (2014-17)  
Klaus Jansen, Robert Koch Institute, Germany

**P637** - *Neisseria gonorrhoeae* genomic diversity in high risk groups in Switzerland  
Helena Seth-Smith, University Hospital Basel, Switzerland

**P638** - Surveillance of gonococcal infection treatment failures 2015-2018 in Québec, Canada  
Sylvie Venne, Quebec Health Ministry, Public Health direction, Canada

**P639** - Molecular markers to predict cefixime decreased susceptibility of *Neisseria gonorrhoeae*: A global review  
Xiaomeng Deng, David Geffen School of Medicine, USA

**P640** - Targeting Murl protein to combat drug resistance in *Neisseria gonorrhoeae* using homology modeling and drug docking studies  
Ravi Kant, University of Delhi, New Delhi, India

**P641** - Gonococcal antimicrobial susceptibility from the Thailand Enhanced Gonococcal Antimicrobial Surveillance Program, 2015 – 2018  
Pachara Sirivongrangson, Department of Disease Control, Thailand Ministry of Public Health, Thailand

**P642** - Whole genome sequencing of *N. gonorrhoeae* deconvolutes sexual behaviour, population structure and transmission in Singapore  
Mathew Beale, Wellcome Sanger Institute, UK

**P643** - Adverse pregnancy and neonatal outcomes associated with *Neisseria gonorrhoeae*: A systematic review and meta-analysis  
Dianne Egli-Gany, University of Bern, Switzerland

**P644** - Analyzing the genomes of *Neisseria gonorrhoeae* isolates using a novel integrated bioinformatic pipeline: Gen2Epi  
Nidhi Parmar, University of Saskatchewan, Canada

**P645** - Peruvian gonococcal strains reveal novel NG-MAST types and false-positive  $\beta$ -lactamase isolates with blaTEM gene mutations  
Adriana Le Van, Uniformed Services University of the Health Sciences, USA

**P646** - Agent-based modelling study of antimicrobial resistant *Neisseria gonorrhoeae* transmission  
Katy Turner, University of Bristol, UK

**P647** - Effective monotherapy due to high rate of azithromycin resistance in *Neisseria gonorrhoeae* infection in men in South Africa  
Remco Peters, University of Pretoria, South Africa

**P648** - Factors associated with *Neisseria gonorrhoeae* azithromycin resistance in the Quebec sentinel network, 2015-2017  
Karine Blouin, Institut National de Santé Publique du Québec, Canada

**P649** - Variations in time to clinical presentation for patients with uncomplicated genital gonorrhoea  
Jonathan Ross, University Hospital NHS Foundation Trust, UK

**P650** - Randomized clinical trial comparing gentamicin+azithromycin vs. ceftriaxone+ azithromycin for rectal and pharyngeal gonorrhoea  
Magnus Unemo, World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Faculty of Medicine of Health, Örebro University, Sweden

**P651** - Elucidating the effect of esculetin against glutamate racemase – a novel drug target of *Neisseria gonorrhoeae*  
Alka Pawar, University of Delhi, India

**P652** - Use of specimens submitted for *Neisseria gonorrhoeae* molecular testing to enhance surveillance in a Canadian arctic territory  
Ameeta Singh, University of Alberta, Canada

**P653** - Modeling the impact of partially efficacious gonorrhoea vaccines  
Shaheen Seedat, Weill Cornell Medicine-Qatar, Qatar

**P654** - Clonal spread of azithromycin resistant *Neisseria gonorrhoeae* in Canada, 2014-2017  
Irene Martin, National Microbiology Laboratory, Canada

**P655** - Molecular epidemiology associated with resistance in *Neisseria gonorrhoeae* isolates from south Brazil during 2008-2016  
Maria Bazzo, Federal University of Santa Catarina, Brazil

**P656** - GyrA and ParC mutations in fluoroquinolone-resistant *Neisseria gonorrhoeae* isolates from Kenya  
Mary Kivata, US Army Medical Research Directorate-Africa, Kenya

**P657** - High azithromycin resistance and decreasing ceftriaxone susceptibility in *Neisseria gonorrhoeae* in Shenzhen (2010-2017), China  
Feng Wang, Shenzhen Center for Chronic Disease Control, China

**P658** - Did minimum inhibitory concentrations in *N. gonorrhoeae* isolates change in Germany since 2014?  
Thalea Tamminga, Robert-Koch-Institute, Germany

**P659** - Improved typeability using culture-free genotyping of *Neisseria gonorrhoeae* compared to routine culture-derived surveillance  
Brian Van Der Veer, Maastricht University Medical Centre, Netherlands

**P660** - Extra-genital ciprofloxacin-resistant *Neisseria gonorrhoeae* infections among sexual-health clinic users in Lima, Peru  
Silver Vargas, Universidad Peruana Cayetano Heredia, Peru

**P661** - The evaluation of ResistancePlus GC (beta) assay for the detection of gonorrhoea ciprofloxacin resistance and susceptibility  
Litty Tan, SpeedX Pty Ltd., Australia

**P662** - Cell envelope damage of *N. gonorrhoeae* after 15-min beta-lactam exposure enables rapid antimicrobial susceptibility testing  
Emily Savelle, California Institute of Technology, USA

**P663** - Sharp increase of ciprofloxacin resistance of *Neisseria gonorrhoeae* in Yaoundé, Cameroon  
Tania Crucitti, Centre Pasteur du Cameroun, Cameroon

**P664** - In vitro evaluation of gepotidacin, an oral antimicrobial against multidrug-resistant *Mycoplasma genitalium*  
Jorgen Jensen, Statens Serum Institut, DK, Denmark

**P665** - Rapid sequence typing for antimicrobial resistance surveillance in *Neisseria gonorrhoeae* using whole genome sequencing  
S Tariq Sadiq, St George's University of London, UK

**P666** - Increased resistance to extended-spectrum cephalosporins in *Neisseria gonorrhoeae* isolates in Nanjing, China (2013-2018)  
Xiaohong Su, Institute of Dermatology, Chinese Academy of Medical Sciences, China

**P667** - Guiding *Neisseria gonorrhoeae* management by molecular detection of ciprofloxacin resistance by SpeeDx ResistancePlus GC assay  
Seb Cotton, Royal Infirmary Edinburgh, UK

**P668** - Transfer of high-level macrolide resistance in *Neisseria gonorrhoeae*  
Said Abdellati, Institute of Tropical Medicine, Belgium

**P669** - Clinically isolated thiamine auxotrophs of *Neisseria gonorrhoeae* indicate increased susceptibility to host innate defenses  
Nelson Dozier, Uniformed Services University of the Health Sciences, USA

**P670** - Internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain found in China  
Shaochun Chen, National Center for STD Control, China CDC Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College, China

**P671** - Distribution of antimicrobial resistance in *Neisseria gonorrhoeae* - 5 years of German Gonococcal Resistance Network (GORENET)  
Klaus Jansen, Robert Koch Institute, Germany

**P672** - Genetic pathway to high level azithromycin resistance in *Neisseria gonorrhoeae*  
Said Abdellati, Institute of Tropical Medicine, Belgium

**P673** - In-vitro activity of SMT-571 and comparators against clinical isolates and reference strains of *Neisseria gonorrhoeae*  
Paul Meo, Summit Therapeutics, UK

**P675** - Two recent cases of extensively drug-resistant (XDR) gonorrhoea in the UK linked to a European party destination  
Paddy Horner, University of Bristol, UK

**P676** - Azithromycin resistance among *Neisseria gonorrhoeae* cases in King County, Washington, USA, 2017-2018  
Christina Thibault, Public Health - Seattle & King County, USA

**P677** - Prescribed treatments for *Neisseria gonorrhoeae* infections and treatment failures in the Quebec sentinel network, 2015-2017  
Fannie Defay, Institut National de santé publique, Canada

**P678** - An effective gonococcal lipooligosaccharide (LOS) vaccine: We know enough to make one  
Mac Griffiss, Crapaud Bio, Inc., USA

**P679** - *Neisseria gonorrhoeae* (GC) culture positivity by indication for culture and anatomic site, Seattle, Washington, 2017-2018  
Christina Thibault, Public Health - Seattle & King County, USA

**P680** - Oropharyngeal gonorrhoea in the absence of urogenital gonorrhoea in a sexual network of males and females.  
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

**P681** - Importation of ciprofloxacin resistant *Neisseria gonorrhoeae* into the UK: A public health challenge  
Martina Furegato, St George's, University of London, UK

**P682** - Efficacy of Securidaca longipenduculata Fresen (Polygalaceae) against standard isolates of *Neisseria gonorrhoeae*  
Meshack Omolo, UNIVERSITY OF NAIROBI, Kenya

**P683** - Racial and ethnic disparities related to *Neisseria gonorrhoeae* among U.S. military active duty service members  
June Early, Infectious Disease Clinical Research Program, USA

**P684** - Gonorrhea sequence types in non-cultured specimens from a provincially representative sample in British Columbia Canada, 2018  
Amalia Plotogea, Public Health Agency of Canada, Canada

**P685** - Evaluation of Extragenital Swabs for Simultaneous *Neisseria Gonorrhoeae* Culture and Nucleic Acid Amplification Testing  
Olusegun Soge, University of Washington, USA

**P686** - The Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG) in Canada  
Irene Martin, National Microbiology Laboratory, Canada

**P687** - Sexual network and genotypic analysis of an outbreak of gonorrhea in Winnipeg, Canada  
Souradet Shaw, University of Manitoba, Canada

**P689** - Turning gonorrhea against HIV: Latent HIV 'shock-and-kill' using a gonococcal-derived metabolite  
Scott Gray-Owen, University of Toronto, Canada

**P690** - Establishment of the gonorrhoea mouse model for pre-clinical testing of antibiotics that follow the PK driver fauc/MIC  
Kristie Connolly, F. Edward Hebert School of Medicine, Uniformed Services of the Health Sciences, USA

**P691** - Widespread use of high-dose ceftriaxone therapy for uncomplicated gonorrhoea without reported Ceftriaxone treatment failure  
Yan Han, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, China

**P692** - Gentamicin susceptibility to *Neisseria gonorrhoeae* in Malawi after twenty-five years of sustained use  
Jane Chen, University of North Carolina at Chapel Hill, USA

**P693** - *Neisseria gonorrhoeae* In-vitro susceptibilities to Ceftriaxone, Cefixime and Azithromycin in GISP Isolates, 1987 - 2017  
Ellen Kersh, Centers for Disease Control and Prevention, USA

**P694** - Case-based enhanced gonorrhoea surveillance, Chicago, IL, 2018  
Irina Tabidze, Chicago Department of Public Health, USA

**P695** - Epidemiology of key STIs among female sex workers in the Middle East and North Africa: systematic review and meta-analyses  
Laith Abu-Raddad, Weill Cornell Medicine-Qatar, Qatar

**P696** - HIV among female sex workers and clients in the Middle East and North Africa: Subregional differences and epidemic potential  
Hiam Chemaitelly, Weill Cornell Medicine-Qatar, Qatar

**P697** - Feasibility of HPV self-collection for cervix screening in under-screened street entrenched women  
Sheona Mitchell-Foster, University of Northern British Columbia, Canada

**P698** - Comprehensive healthcare intervention for female sex workers in Ethiopian STI clinics: experience from Mekelle University  
Tesfay Gebrehiwot, Mekelle University, Ethiopia

**P699** - Role of management in enhancing efficiency of female sex workers HIV programs in Nigeria  
Idoteyin Ezirim, National Agency for the Control of AIDS, Nigeria

**P700** - Unintended pregnancy among female sex workers in Mekelle City, Northern Ethiopia: A cross-sectional study  
Tesfay Gebrehiwot, Mekelle University, Ethiopia

**P701** - Time trends in prevalence and incidence of HIV, gonorrhoea and chlamydia among female sex workers in Benin, 2008-2018  
Michel Alary, CHU de Quebec - Université Laval, Canada

**P702** - Characterizing HIV-associated vulnerabilities among women engaged in transactional sex to design programs in Ukraine  
Daryna Pavlova, NGO "Ukrainian Institute for Social Research after Oleksandr Yaremenko", Ukraine

**P703** - Pregnancy intention and prevalence according to HIV status among female sex workers in Mali  
Gentiane Perrault Sullivan, Laval University, Canada

**P705** - Bacterial sexually transmitted infections among women who inject drugs and exchange sex in King County, Washington  
Megan Curtis, University of Washington, USA

**P706** - Low gonorrhoea and chlamydia testing rate among female sex workers in Guangdong province: A cross-sectional analysis  
Peizhen Zhao, Dermatology Hospital of Southern Medical University, China

**P707** - Understanding the correlates of STI-HIV co-infections among female sex workers in Kitui  
Japheth Kioko, Partners for Health and Development in Africa, Kenya

**P708** - Women's encounters with venue-based HIV risk contexts in Abuja, Nigeria  
Laura Thompson, University of Manitoba, Canada

**P709** - Abnormal cervical screening test and sexually transmitted infections in West Africa's female sex workers  
Ibrahim Tégoué, CHU Gabriel Toure, Mali

**P710** - Epidemiology of abnormal cervical cytology in female sex workers in Mali, West Africa  
Fatoumata Korika Tounkara, Axe Santé des populations et pratiques optimales en santé, HSS, Canada

**P712** - "You need a cash buffer": Male sex work and condom use in the era of HIV pre-exposure prophylaxis  
Denton Callander, New York University, USA

**P713** - High prevalence of condomless anal intercourse among female sex workers in Iran  
Mohammad Karamouzian, BC Center on Substance Use, Canada

**P714** - HIV testing and undiagnosed fraction among adolescent girls and young women by engagement in sex work in Mombasa, Kenya  
Marissa Becker, University of Manitoba, Canada

**P715** - Violence and associated factors among female sex workers: analysis from a cross-sectional study in Guangdong, China  
Yajie Wang, Dermatology Hospital of Southern Medical University, China

**P716** - HIV prevalence in at-risk adolescent girls and young women in Kenya across locations associated with sex work  
Marissa Becker, University of Manitoba, Canada

**P717** - Using ethnography for planning and improving the quality of HIV prevention interventions for female sex workers in Nigeria  
Kalada Green, Centre for Global Public Health - Nigeria, Nigeria

**P718** - Risk and place: the association between hotspot typology and determinants of HIV risk among female sex workers in Ukraine  
Marissa Becker, University of Manitoba, Canada

**P719** - Prevalence and type-specific distribution of oncogenic Human papillomavirus among female sex workers in Cotonou, West Africa  
Fernand Guédou, Dispensaire IST, Benin

**P722** - An Unusual Constellation of Symptoms: Outpatient Diagnosis of Neurosyphilis with No History of Prior Syphilis Symptoms  
Elizabeth Liu, Mercy Muskegon, USA

**P724** - A conditional pay-for-performance program to Improve Syphilis Screening in Chinese STD Clinics: A Pilot Intervention  
M Kumi Smith, University of Minnesota Twin Cities, USA

**P725** - Frequency and characteristics of biologic false positive tests for syphilis, reported in Florida and New York City, 2013-2017  
James Matthias, Centers for Disease Control and Prevention, USA

**P726** - Syphilis - do we see the end of the steep rise in cases in Germany?  
Klaus Jansen, Robert Koch Institute, Germany

**P727** - County-level factors associated with reported congenital syphilis—United States, 2012–2015  
Kendra Cuffe, Centers for Disease Control and Prevention, USA

**P728** - Correlates of syphilis in women living with and without HIV in the US Women's Interagency HIV Study (WIHS)  
Kristal Aaron, University of Alabama at Birmingham, USA

**P729** - *Treponema pallidum*-platelet interactions and relevance to treponemal invasion  
Brigette Church, University of Victoria, Canada

**P730** - The demography of congenital syphilis elimination in the United States  
Najjuwah Walden, Washington University in St. Louis, USA

**P731** - Prevalence of self-reported syphilis among Brazilian young adults: Findings from a nationwide Survey  
Natalia Kops, Hospital Moinhos de Vento, Brazil

**P733** - Evaluating the use of rapid syphilis testing among patients in a sexually transmitted infections clinic in Lilongwe, Malawi  
Jane Chen, University of North Carolina at Chapel Hill, USA

**P734** - What do guys know about syphilis anyways?  
Dionne Gesink, U of Toronto, Canada

**P735** - Knowledge and attitudes around syphilis and syphilis pre-exposure prophylaxis among men who have sex with men in Vancouver  
Ronita Nath, British Columbia Centre for Disease Control, Canada

**P736** - Evaluation of the provincial infectious syphilis partner notification program in British Columbia, Canada  
Christine Lukac, BC Centre For Disease Control, Canada

**P737** - Evaluating syphilis partner notification outcomes in seven jurisdictions  
Anna Cope, Centers for Disease Control and Prevention, USA

**P738** - No bejel among *Treponema pallidum* isolates diagnosed as syphilis from Surinam, Antillean and Dutch clients in Amsterdam  
Helene Zondag, Public Health Service Amsterdam, Netherlands

**P739** - Novel rapid test for improved diagnosis of active syphilis at the point of care  
Minh Pham, Burnet Institute, Australia

**P740** - Improving Syphilis Diagnosis and Treatment in an Urban Population Through Routine Emergency Department Screening  
Kimberly Stanford, University of Chicago, USA

**P741** - Detection of *Treponema pallidum* DNA at various body locations  
Silvia Nieuwenburg, Public Health Service Amsterdam, Netherlands

**P742** - Using lottery incentives to attract sexually risky Chinese men who have sex with men to prevent syphilis  
Weiming Tang, UNC Project-China, China

**P743** - Clinical Profiles of 58 Hospitalized HIV-Negative Patients with Neurosyphilis in a General Hospital in China  
Minzhi Wu, The fifth people's hospital of Suzhou, China

**P745** - The pregnancy syphilis cascade of care: "95-95-95" goals for reducing of congenital syphilis in the state of Sao Paulo, Brazil  
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

**P746** - Maternal to child transmission prevention program for syphilis and HIV in Brazil: Missed opportunities  
Angelica Miranda, Universidade Federal do Espirito Santo, Brazil

**P747** - Characteristics of chlamydia/gonorrhea infections associated with a subsequent syphilis diagnosis in British Columbia, Canada  
Theodora Consolacion, BC Centre for Disease Control, Canada

**P748** - Syphilis diagnostic test of STANDARD™ Q Syphilis Ab using fingerprick whole blood and serum on high risk populations  
Rahma Lubis, Faculty of Medicine Universitas Indonesia/dr. Cipto Mangunkusumo National Hospital, Jakarta, Indonesia, Indonesia

**P750** - A comparison of *Treponema pallidum* molecular typing systems: MLST vs. ECDCT  
Sharon Sahi, University of Washington, USA

**P751** - Evaluation of a syphilis awareness campaign for gay, bisexual and other MSM (gbMSM): did we reach our targeted audience?  
Jason Wong, BC Centre for Disease Control, Canada

**P752** - Undersensitive non-treponemal tests: Implications for syphilis management  
John Scythes, Community Initiative for AIDS Research, Canada

**P753** - Monitoring the evaluation of congenital syphilis cases in the state of São Paulo, 2007 to 2017  
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

**P754** - Quantitation of cytokines in rabbits following tri-antigen vaccine cocktail immunization and *T. pallidum* challenge  
Charmie Godornes, University of Washington, USA

**P755** - *Treponema pallidum* stimulated macrophage-derived exosomal mir-146a-5p decreased monocyte transendothelial migration  
Qian-Qiu Wang, Institute of Dermatology, Chinese Academy of Medical Sciences, China

**P756** - Risk factors for primary and secondary syphilis among females in Chicago, 2010-2017  
Kimberly Stanford, University of Chicago, USA

**P757** - An evaluation of the provincial 'Syphistory' campaign in British Columbia, Canada  
Venessa Ryan, BC Centre For Disease Control, Canada

**P758** - Use of a rapid syphilis test for syphilis diagnosis among patients presenting to an STI clinic in North Carolina, USA  
Arlene Seña, University of North Carolina at Chapel Hill, USA

**P759** - Evaluation of the fully automated Bio-Rad BioPlex 2200 Syphilis Total & RPR antibody detection assay  
Vincent Boissonneault, Canada

**P760** - Sensitivity and specificity of the quantitative test for TPPA and RPR for diagnosis of congenital syphilis in neonates  
Xiangdong Gong, Institute of Dermatology, Chinese Academy of Medical Sciences, China

**P761** - Tip of the iceberg? An unusual syphilis outbreak among young Dutch heterosexuals indicating a larger epidemic  
Anne-Marie Niekamp, South Limburg Public Health Service, Netherlands

**P762** - Is kissing safe? Detection of *Treponema pallidum* in oral swabs from patients with syphilis  
Lauren Tantalio, University of Washington, USA

**P763** - Attenuation of syphilis infection following immunization of rabbits with a trivalent antigen cocktail  
Barbara Molini, University of Washington, USA

**P764** - Getting to the bottom of it: Sexual positioning and syphilis stage at diagnosis among men who have sex with men  
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

**P765** - Added value of *Treponema pallidum* PCR in diagnosing early syphilis  
Inge Van Loo, Maastricht University Medical Center, Netherlands

**P766** - Slings and arrows of syphilis surveillance: The department of defense experience with administrative case finding  
Eric Larsen, USUHS, USA

**P767** - Sex, drugs and the internet – the perfect storm for syphilis transmission among black gay and bisexual men (BMSM)  
Jacky Jennings, Johns Hopkins University School of Medicine, USA

**P768** - The evolution of an infectious syphilis epidemic in a Canadian urban setting  
Souradet Shaw, University of Manitoba, Canada

**P769** - A systematic review on alternative treatments for maternal syphilis  
Aishwarya Raich, UCLA David Geffen School of Medicine, USA

**P770** - Jarisch-Herxheimer reaction in central nervous system among neurosyphilis patients: discontinuation of therapy or not?  
Rui-Rui Peng, Sexually Transmitted Disease Institute, Shanghai Skin Disease Hospital, China

**P771** - Clinical trial of Cefixime for the Treatment of Early Syphilis - Preliminary results  
Chrysovalantis Stafylis, UCLA David Geffen School of Medicine, USA

**P772** - Gastric syphilis: A case of gastric syphilis developed into neurosyphilis.  
Lin Zhu, Shanghai Skin Disease Hospital, China

**P773** - Increased detection rates of primary syphilis by PCR in a Provincial Laboratory  
Prenilla Naidu, Provincial Laboratory for Public Health, Canada

**P774** - Prevalence of bacterial sexually transmitted infections and co-infection with HIV among MSM and TW in Tijuana, Mexico  
Claire Bristow, University of California San Diego, USA

**P775** - Hepatitis C is not a problem for female transgenders in Goiânia, Central Brazil - preliminary data  
Márcia Souza, Universidade Federal de Goias, Brazil

**P776** - HIV epidemiology among men who have sex with men and transgender women in Myanmar: Data from community-based surveillance  
Vanessa Veronese, CPOOP, Australia

**P777** - Difference between transvestites and transwomen for HIV prevalence and risk behaviors  
Sheila Teles, Universidade Federal de Goias, Brazil

**P778** - HIV infection in transgender women from a region far from the epicenter of the HIV epidemic in Brazil – preliminary results  
Sheila Teles, Universidade Federal de Goias, Brazil

**P779** - Pre-exposure prophylaxis use among trans and gender diverse people: Characteristics and behaviour from the EPIC-NSW trial  
Benjamin Bavinton, University of New South Wales, Sydney, Australia

**P781** - Patterns of HIV and STI among transgender women in eastern and southern U.S.: Interim baseline findings from the LTE cohort  
Tonia Poteat, University of North Carolina School of Medicine, USA

**P783** - Factors associated with syphilis testing in transgender women in central-west Brazil  
Sheila Teles, Universidade Federal de Goias, Brazil

**P784** - Prevalence of STIs and HIV in transgender women and men: A systematic review  
Olivia Van Gerwen, University of Alabama at Birmingham, USA

**P785** - Syphilis Among MSM/TW in the Americas: A systematic review and meta-analysis (1980-2017)  
Jesse Clark, UCLA Geffen School of Medicine, USA

**P787** - Trichomonas vaginalis positivity rates by HIV status among women in a clinical study  
Stephanie Taylor, Louisiana State University, USA

**P788** - Comparison of vaginal speculum and non-speculum specimens in the diagnosis of Trichomonas vaginalis  
Ibinabo Oboro, University of Port Harcourt teaching Hospital, Nigeria

**P789** - Bacterial vaginosis markers detected by BD MAX™ Vaginal Panel in relation to absence and presence of Trichomonas vaginalis  
Marie-Helene Tremblay, BD Life Sciences, Canada

**P790** - Determining the origins of repeat Trichomonas vaginalis infections using clinical versus genotype-informed criteria  
Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

**P791** - Assessment of urethritis etiology among HIV-infected men attending an STI clinic in Lilongwe, Malawi  
Mitch Matoga, UNC Project Malawi, Malawi

**P793** - Risk factors for incident non-gonococcal urethritis (NGU) in men who have sex with women (MSW) attending an STD clinic  
Emily Rowlinson, University of Washington, USA

**P794** - Signs and symptoms associated with single-pathogen nongonococcal urethritis in men  
Teresa Batteiger, Indiana University School of Medicine, USA

**P795** - Prevalence and Etiology of Post-azithromycin Persistent Nongonococcal Urethritis (NGU) Symptoms in Men  
Stephen Jordan, Indiana University School of Medicine, USA

**P796** - Reassessing the Gram stain smear (GSS) polymorphonuclear leukocyte (PMN) cutoff for diagnosing non-gonococcal urethritis (NGU)  
Gina Leipertz, University of Washington, USA

**P797** - Antibody response to *Mycoplasma genitalium* in longitudinally infected men with non-gonococcal urethritis  
Gwendolyn Wood, University of Washington, USA

**P799** - Accelerated HIV case finding and bridging enrolment gap for key populations in western Nigeria: A break-even in the 90-90-90  
Saheed Usman, APIN Public Health Initiatives, Nigeria

**P800** - Prevalence of curable sexually transmitted infections among refugees: Global systematic review and meta-analysis  
Ghina Mumtaz, American University of Beirut, Lebanon

**P802** - Size of female injecting drug users in 10 Nigerian states and implications for HIV/reproductive health  
Idoteyin Ezirim, National Agency for the Control of AIDS, Nigeria

**P803** - Assessing correct knowledge and positive attitude towards HIV/AIDS transmission homeless women in India  
MITHLESH Chourase, International Institute for Population Sciences, India

**P804** - Behavioral risk factors for sexually transmitted infections and health-seeking behavior of homeless women in Delhi, India  
MITHLESH Chourase, International Institute for Population Sciences, India

**P808** - Correlates of sexually transmitted infections symptoms among male prisoners in Iran, 2013: A nation-wide survey  
Mohammad Karamouzian, BC Centre on Substance Use, Canada

**P809** - Negotiating safer sexual relations with husband and associated STI/HIV vulnerabilities among married women in India  
Deepanjali Vishwakarma, International Institute for Population Sciences, India

**P810** - HIV/STI service coverage among key population in Nigeria - lessons from size estimation study in Abia and Taraba states  
Greg Ashefor, National Agency for the Control of AIDS, Nigeria

**P812** - Leveraging peak days/time at spots to improve key population HIV programs – size estimation study of 10 states in Nigeria  
Greg Ashefor, National Agency for the Control of AIDS, Nigeria

**P813** - Community-based health services delivery among key and priority populations - a case study in Uganda  
Geoffrey Mujisha, Most At-Risk Populations (MARPs) Network Limited, Uganda

**P814** - Comprehensive healthcare interventions at Mekelle University STI and ART clinics for key population, northern Ethiopia  
Tesfay Gebrehiwot, Mekelle University, Ethiopia

**P817** - Longitudinal associations between recent incarceration and STI/HIV risk: The role of prior trauma in exacerbating risk  
Maria Khan, New York University School of Medicine, USA

**P838** - Associations of the vaginal microbiota with HPV infection and cervical dysplasia in South African women living with HIV  
Janneke Van De Wijgert, University Medical Center Utrecht, Netherlands

**P854** - Interspecies chimeras: A tool to identify chlamydial virulence factors  
Mark Fernandez, University Of Washington, USA

**P855** - Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of *Chlamydia trachomatis* and *C. pneumoniae* serology  
Bernhard Kaltenboeck, Auburn University, USA

**P856** - Privacy and technology for young black men who have sex with men in the Southern US related to sexual care and research  
Christina Muzny, University of Alabama at Birmingham, USA

**P857** - Penile microbiome and urinary cytokines of Kenyan men who have sex with men and men who have sex with women  
Supriya Mehta, University of Illinois at Chicago, USA

**P858** - 2018/2019 Surveillance update on *Neisseria gonorrhoeae* isolates  
Meshack Omolo, University of Nairobi, Kenya

**P861** - Novel mutation conferring high-level azithromycin resistance in *Neisseria gonorrhoeae*  
Cau Pham, US Centers for Disease Control and Prevention, USA

**P862** - Female sex workers and their attitude towards oral pre-exposure prophylaxis  
Tinashe Mudzviti, University of Zimbabwe, Zimbabwe

**P863** - Transgender women in Lebanon: A qualitative study to understand HIV/STIs risk  
Ismael Maatouk, Clemenceau Medical Center, Lebanon



All Industry-Supported Symposia will be held at the Vancouver Convention Centre, East Building from Monday, July 15 to Wednesday, July 17.

Monday, July 15



**Time:**  
7:00 - 8:00  
**Location:**  
MR 1

**Maintaining Vaginal Health: Complexities in Diagnosis and Management**  
*Breakfast Symposium Supported by BD Diagnostic Systems*

- Diagnostics for Women with Discharge: Including Both Vaginal and Cervical Causes - **Barbara Van Der Pol**
- Clinical Management of Vaginal Syndromes - **Jeanne Marrazzo**

*Open to all registered delegates  
Breakfast will be served*



**Time:**  
12:30-13:30  
**Location:**  
MR 2+3

**Mycoplasma genitalium and the Evolution of Clinical Practice: What Matters for the Clinician and Laboratorian**  
*Lunch Symposium Supported by Roche*

- Understanding *Mycoplasma genitalium*: Epidemiology and Clinical Significance - **William M. Geisler**
- Clinical Performance of the Cobas TV/MG Assay for the Detection of *Mycoplasma genitalium* - **Barbara Van Der Pol**

*Open to all registered delegates  
Lunch will be served (first-come, first-served)*



**Time:**  
18:30-19:30  
**Location:**  
MR 8+15

**Achieving Precision Diagnostics for Sexually Transmitted Infections to Improve Public Health**  
*Evening Symposium Supported by Abbott Molecular*

- Insights to Improve Operational Efficiencies in Molecular Testing for STIs - **Dr. Kevin Nelson**
- Innovative Approaches in STI testing and Precision Diagnostics - **Dr. Ajith Jospeh**

*Appetizers and beverages will be served (first-come, first-served)*

Tuesday, July 16



**Time:**  
7:00 - 8:00  
**Location:**  
MR 2+3

**Point of Care Molecular Testing and Improved Patient Outcomes**  
*Breakfast Symposium Supported by Cepheid*

- Extragenital Testing for Chlamydial and Gonorrheal Disease: Study Review – **Claire C. Bristow**
- Improved Patient Care with STI Screening – **Pierre-Cédric B. Crouch**

*Open to all registered delegates  
Breakfast will be served (first-come, first-served)*

Wednesday, July 17



**Time:**  
7:00 - 8:00  
**Location:**  
MR 1

**Aptima Mycoplasma genitalium Evaluation Study**  
*Breakfast Symposium Supported by Hologic*

- *Mycoplasma genitalium*: History of the Discovery, Detection and Treatment of a Sexually Transmitted Pathogen – **Charlotte A. Gaydos**
- *Mycoplasma genitalium* Testing in the US: Results from a Prospective, Multi-Center Clinical study – **Damon Getman**

*Open to all registered delegates  
Breakfast will be served (first-come, first-served)*




**Time:**  
12:30-13:30  
**Location:**  
MR 2+3

**Aptima Vaginosis and Vaginitis Evaluation Study**  
*Lunch Symposium Supported by Hologic*

- Vaginitis and Vaginosis: Challenges in Diagnosis and Treatment – **Jane R. Schwebke**
- Clinical Performance of the Aptima BV and Aptima CV/TV Assays for Vaginitis and Vaginosis – **Craig Clark**

*Open to all registered delegates  
Lunch will be served (first-come, first-served)*



[www.Cepheidinternational.com](http://www.Cepheidinternational.com)

Please join us for a Cepheid Breakfast Symposium  
**Point of Care Molecular Testing and Improved Patient Outcomes**

Tuesday, 16 July 2019 from 07:00 to 8:00  
Meeting Room 2+3

**STI & HIV 2019 World Congress**  
14-17 July 2019  
Vancouver, Canada

➔ Come visit us at the **Cepheid at Booth #203**

IVD. *In Vitro* Diagnostic Medical Device

This presentation was approved by the Scientific Program Committee as an independent activity held in conjunction with the STI & HIV 2019 World Congress, Joint Meeting of the 23rd ISSTD & 20th IUSTI. This presentation is not sponsored or endorsed by STI & HIV 2019.

**Saturday, July 13**

- 08:00 – 12:30** | **ISSTDR Board Meeting (By Invitation Only)**  
Location: MR 1
- 12:30 – 13:00** | **ISSTDR Board Member-IUSTI Executive Committee Lunch (By Invitation Only)**  
Location: Meeting Level South Foyer
- 13:00 – 18:00** | **IUSTI Executive Committee Meeting (By Invitation Only)**  
Location: MR 1

**Sunday, July 14**

- 12:00 – 13:00** | **UCLA & WHO Lunch (By Invitation Only)**  
Location: MR 20
- 16:00 – 17:00** | **STD Journal Assoc. Editors Meeting (By Invitation Only)**  
Location: MR 20

**Monday, July 15**

- 07:00 - 08:00** | **ASTDA Young Investigator Mentor/Mentee Breakfast Session: Meet the Editor!**  
Location: MR 11+12  
  
Supported by:  MICHAEL SMITH FOUNDATION FOR HEALTH RESEARCH  
BC's health research funding agency
- 12:30 – 13:30** | **STI & HIV World Congress 2021 - ISC/LSC Meeting (By Invitation Only)**  
Location: MR 13
- 12:30 - 14:00** | **NIH Meeting (By Invitation Only)**  
Location: MR 9
- 12:45 – 13:45** | **IUSTI General Assembly (Members Only)**  
Location: MR 1
- 18:15 – 19:15** | **IUSTI-Canada AGM (Members Only)**  
Location: MR 1

**Tuesday, July 16**

- 07:00 – 08:00** | **Sexually Transmitted Infections Editorial Meeting (By Invitation Only)**  
Location: MR 13
- 07:00 – 08:00** | **ASTDA Young Investigator Mentor/Mentee Breakfast Session: Meet the NIH!**  
Location: MR 11+12

- 09:30 – 16:00** | **Meetings – Government of Canada (By Invitation Only)**  
Location: MR 19

Supported by:  Global Affairs Canada / Trade Commissioner Service | Affaires mondiales Canada / Service des délégués commerciaux

- 12:15 – 13:45** | **ASTDA Awards Luncheon**  
Location: Ballroom C (West Building)

Supported by: 

- 17:30 – 19:00** | **Trade Commissioner Service Networking Reception (By Invitation Only)**  
Location: MR 19 + 20

Supported by:  Global Affairs Canada / Trade Commissioner Service | Affaires mondiales Canada / Service des délégués commerciaux

- 17:45 - 18:45** | **2020 Bangkok Scientific Committee Meeting**  
Location: IUSTI Office - MR 4

**Wednesday, July 13**

- 07:00 - 08:00** | **ASTDA Young Investigator Mentor/Mentee Breakfast Session: Sexual Harassment in Sexual Health Professions: Breaking Silence and Making Solutions**  
Location: MR 11+12

- 10:15 - 10:45 & 15:15 - 15:45** | **Canadian Institutes of Health Research HIV/AIDS and STBBI Strategic Plan Consultation Session**  
Location: MR 19

Supported by:  Canadian Institutes of Health Research / Instituts de recherche en santé du Canada

- 12:30 – 13:30** | **Mycoplasma genitalium Global Surveillance Meeting (By Invitation Only)**  
Location: MR 9

- 18:00 – 20:00** | **2nd IUSTI Executive Meeting (By Invitation Only)**  
Location: MR 1

- 18:00 – 20:30** | **4th Annual Public Health Applications of C. trachomatis Serology (PHACTS) Meeting**  
Location: MR 13

## Saturday, July 13

**19:30 – 22:00** | **Presidents' Dinner** *(By Invitation Only)*  
*Location: The Teahouse, Stanley Park*

## Sunday, July 14

**19:30 – 21:00** | **Welcome Reception**  
*Location: Exhibit Hall A*

## Monday, July 15

**17:45 – 19:00** | **Poster Viewing**  
*Location: Exhibit Hall A*

**19:30 – 22:00** | **Speakers' Dinner** *(By Invitation Only)*  
*Location: The Vancouver Club*

## Tuesday, July 16

**17:45 – 19:00** | **Poster Viewing**  
*Location: Exhibit Hall A*

**19:30 – 22:00** | **Congress Dinner** *(Ticketed Event)*  
*Location: Ballroom C + D (West Building)*

### **ABSTRACTS**

Abstracts selected for the STI & HIV 2019 World Congress are presented in Oral and Poster Sessions. All abstracts approved for presentation will be published online in the journal of Sexually Transmitted Infections on July 14, 2019.

### **ATTIRE**

Business casual is appropriate. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

### **BADGES**

Your personalized badge is your admission card to the Congress. For organizational and security reasons, badges must be worn at the congress venue at all times.

### **CELL PHONES**

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

### **CERTIFICATE OF ATTENDANCE**

Congress attendees can request a 'Certificate of Attendance' by completing the Congress Evaluation Form available on the Congress website on the last day of the Congress. After completing the evaluation form you will be able to download your Certificate of Attendance.

### **CME ACCREDITATION AND CME CERTIFICATE**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of VCU Health Continuing Medical Education and International Conference Services, Ltd. VCU Health Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

VCU Health Continuing Medical Education designates this live activity for a maximum of **23 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Congress attendees can request a 'CME Certificate' by completing the Congress Evaluation Form available on the Congress website on the last day of the Congress. After completing the evaluation form you will be able to download your CME Certificate.

### **EMERGENCY SERVICES AND FIRST AID EMERGENCY NUMBER**

In the event of a health, safety, or criminal emergency, dial 7500 from any of the house phones or +1 604 647 7500 from your mobile phone. The First Aid Office is located in the East Lobby next to the washrooms. Kindly note that the First Aid office is not staffed. For access please call the above-mentioned emergency numbers.

### **EVALUATION SURVEY**

A Congress Evaluation Survey will be e-mailed to all delegates after the Congress. Please help us to improve the Congress by completing your Survey.

### **EXHIBITION**

The exhibits are an integral part of the experience at the STI & HIV 2019 World Congress and will feature the latest in technology and research. The exhibits are located in East Exhibit Hall A, Street/Convention Level at the Vancouver Convention Centre, East Building.

## EXHIBITION SHOW HOURS

Sunday, July 14 ..... 19:30 – 21:00 (Welcome Reception)  
 Monday, July 15 ..... 10:15 – 19:00  
 Tuesday, July 16 ..... 10:15 – 19:00  
 Wednesday, July 17 .... 10:15 – 15:45

## JOIN THE CONVERSATION – STI & HIV 2019 WORLD CONGRESS OFFICIAL SOCIAL MEDIA ACCOUNTS

Share your experience and images from the STI & HIV 2019 World Congress with colleagues and friends via Facebook and Twitter. Follow our official social media feeds throughout the Congress: @ISSTDRIUSTI2019. We encourage you to tag your posts with #ISSTDRIUSTI2019 and #IUSTIWorld2019.

www.facebook.com/ISSTDRIUSTI2019  
 www.twitter.com/ISSTDRIUSTI2019

## LOST AND FOUND

Lost and Found items should be returned/claimed at the Registration Desk.

## LUNCHES

There are many food options available in and around the convention centre. The Coal Harbour Café is located on the street level next to the registration area in the East Building. There is a food court located at the Waterfront Centre across the street from the Vancouver Convention Centre, with a variety of options to suit all tastes.

## NETWORKING BREAKS

Breaks will take place in the following locations and at the following times. Refreshments will be provided.

Monday, July 15  
 10:15 – 10:45  
 15:30 - 16:15  
 Exhibit Hall A, Street/Convention Level

Tuesday, July 16  
 10:15 – 10:45  
 15:30 - 16:15  
 Exhibit Hall A, Street/Convention Level

Wednesday, July 17  
 10:15 – 10:45  
 15:15 - 15:45  
 Exhibit Hall A, Street/Convention Level

## MOBILE APP

Supported by:



Download the free STI & HIV 2019 World Congress mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan, exhibitor bio, and general Conference and venue information on our easy to use app! The app is compatible with all iOS devices (iPhone,

iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts. You must enable notifications on your device to receive these alerts.

Search “**STI HIV**” in the App Store (for Apple) or Google Play Store (for Android).

## PARKING

Parking is available in the Vancouver Convention Centre West and East Building.

Vancouver Convention Centre East  
 999 Canada Place

## WestPark

- Enter at the foot of Howe Street, obtain ticket from dispenser and proceed to P1 or P2.
- Use Convention Centre/Hotel elevators (not World Trade Centre elevators).
- For Convention Level: press “G” for Registration, Ballrooms and Exhibits.
- For Meeting Rooms: press “M”.

## POSTER VIEWING

East Exhibit Hall A, Street/Convention Level

All posters have been split into two groups: Monday and Tuesday. A different set of posters will be displayed on these days so be sure to visit the Exhibit & Poster Hall. Posters will be on display for the entire day, but presenters will be standing by their poster during the poster viewing sessions.

## OFFICIAL POSTER VIEWING SESSIONS

Monday, July 15 ..... 17:45 – 19:00  
 Tuesday, July 16 ..... 17:45 – 19:00

## POSTER VIEWING IN THE EXHIBIT HALL DURING COFFEE BREAKS

10:15 – 10:45  
 15:30 – 16:15

## PUBLIC TRANSPORTATION

Vancouver is a walkable city and all Congress hotels are within a maximum of 20-minute walking distance.

## REGISTRATION COUNTER HOURS

Located in the lobby of the Vancouver Convention Centre East Building, Street/Convention Level.

Saturday, July 13..... 15:00 – 19:00  
 Sunday, July 14..... 07:30 – 20:00  
 Monday, July 15..... 06:30 – 16:00  
 Tuesday, July 16..... 06:30 – 16:00  
 Wednesday, July 17..... 06:30 – 15:00

## SMOKING

It is against the law to smoke in any indoor public place or worksite, including pubs, bars, restaurants, and shopping centres. Designated smoking rooms are non-existent, and public transit, transit shelters, taxis and work vehicles are also smoke-free.

In addition, there is a 3-metre non-smoking “buffer zone” around public and work place doorways, opening windows and air intakes including apartments and condominiums.

## SPEAKER READY ROOM

MR 10 in the East Building (on Meeting Room Level) is the designated Speaker Ready Room. Only digital material will be allowed for oral presentation (PowerPoint files).

- All oral presenters are requested to check-in at the Speaker Ready Room a minimum of 24 hours prior to your scheduled presentation, to review and upload your PowerPoint presentation.
- Once you have uploaded your PowerPoint, you may still make changes to it up to 4 hours before your presentation.
- If for any reason you are unable to meet this schedule, please inform the STI & HIV 2019 World Congress Secretariat at STIHIV2019-Speakers@icsevents.com before the Congress.
- PowerPoint presentations cannot be uploaded in the session rooms.
- Computers will be available for you in the Speaker Ready Room for your final check.
- Once the presentation has been checked, the technical staff will be responsible for its delivery to the session rooms in preparation for your presentation.

Hours of Operation:

Saturday, July 13 ..... 15:00 – 19:00  
 Sunday, July 14 ..... 07:00 – 18:30  
 Monday, July 15 ..... 06:30 – 16:30  
 Tuesday, July 16 ..... 06:30 – 16:30  
 Wednesday, July 17 ..... 06:30 – 16:00

## STAFF AND VOLUNTEERS

Supported by:



Volunteers are working throughout the Convention Centre and are happy to assist with any questions delegates may have regarding the Congress or the Convention Centre. Delegates can easily locate volunteers by their volunteer shirts.


## WIRELESS INTERNET

The Congress is happy to provide delegates with complimentary Wi-Fi.

Network: STI & HIV 2019 World Congress  
 Password: STIHIV2019

## DISCLAIMER

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.



**Vancouver Convention Centre, East Building Street / Convention Level**



- Lobby
- Ballroom
- Exhibit Hall A



**Vancouver Convention Centre, East Building Meeting Level / Level 1**

- MR 1
- MR 8+15
- MR 10
- MR 13
- MR 19
- MR 2+3
- MR 9
- MR 11+12
- MR 14
- MR 20

# EXHIBIT FLOOR PLAN



## Exhibitor Listing

Organization (sorted by Organization Name)	Booth #
Abbott Molecular	404
BD Diagnostic Systems	105
bioLytical Laboratories Inc.	104
Center for Disease Detection	408
Cepheid	203
Chembio Diagnostic Systems, Inc.	505
Clinical Prevention Services - BC Centre for Disease Control	409
Coplan	401
EUROIMMUN AG, a PerkinElmer Company	403
GIANTmicrobes	412
Hologic	300
ImmunoPrecise Antibodies	504
IUSTI-Europe	100
Mayer Labs	507
Novosanis	406
Pauktuutit Inuit Women of Canada	508
Roche	206
SD Biosensor	204
Seegene Inc.	400
Shield Diagnostics	410
SpeedX	200
Spot On Sciences	201
STEMCELL Technologies	202
Stichting World STI & HIV Congress 2021	407
World Health Organization	411
Youth against AIDS	509

Organization (Numerical)	Booth #
IUSTI-Europe	100
bioLytical Laboratories Inc.	104
BD Diagnostic Systems	105
SpeedX	200
Spot On Sciences	201
STEMCELL Technologies	202
Cepheid	203
SD Biosensor	204
Roche	206
Hologic	300
Seegene Inc.	400
Coplan	401
EUROIMMUN AG, a PerkinElmer Company	403
Abbott Molecular	404
Novosanis	406
Stichting World STI & HIV Congress 2021	407
Center for Disease Detection	408
Clinical Prevention Services - BC Centre for Disease Control	409
Shield Diagnostics	410
World Health Organization	411
GIANTmicrobes	412
ImmunoPrecise Antibodies	504
Chembio Diagnostic Systems, Inc.	505
Mayer Labs	507
Pauktuutit Inuit Women of Canada	508
Youth against AIDS	509




## Insight to work smarter, not harder

simplicity / flexibility / efficiency

When you know where you're going, you get there faster. Transform your lab with the simplicity, flexibility and efficiency of the **Molecular Work Area** from Roche... proven performance with a clear path for sustainable sexual health testing now and for the future.

Come and learn more about **Molecular Work Area** and the broad menu it delivers at **Booth 206**



COBAS is a trademark of Roche.  
©2019 Roche  
Roche Molecular Diagnostics, Pleasanton, CA 94588 USA

[molecularworkarea.com](http://molecularworkarea.com) MC--01379



### Abbott Molecular | Booth #404

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries. (abbott.com)



### BD Diagnostic Systems | Booth #105

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. (bd.com)



### bioLytical Laboratories Inc. | Booth #104

bioLytical Laboratories based in Richmond, BC, is a privately-owned Canadian company focused on the research, development, and commercialization of rapid, point-of-care in-vitro medical diagnostics using its proprietary INSTI® technology platform. The INSTI product line provides highly accurate test results in 60 seconds or less with over 99% accuracy. (insti.com)



### Center for Disease Detection | Booth #408

Center for Disease Detection (CDD) is one of the nation's leading laboratories, providing testing to customers in all 50 states as well as internationally. Founded in 1990, CDD services federal, state and local government agencies, STD clinics, and organizations dedicated to sexual health. (cddmedical.com)



### Cepheid | Booth #203

Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer. (cepheid.com)



### Chembio Diagnostic Systems, Inc. | Booth #505

Chembio Diagnostic Systems, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company's patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. The novel DPP® technology offers broad market applications beyond infectious disease. (chembio.com)



BC Centre for Disease Control  
Provincial Health Services Authority

### Clinical Prevention Services – BC Centre For Disease Control | Booth #409

Clinical Prevention Services at the BC Centre for Disease Control (BCCDC) provides low-barrier, culturally safe services for diverse communities around the prevention, testing, diagnosis and treatment of STIs and HIV. STI and HIV services offered at the BCCDC include integrated care, provincial STI clinics, community sexual health services, and prevention interventions. (bccdc.ca)



Innovating Together™

### Copan | Booth #401

With a rightful reputation for innovation, COPAN is the world leading manufacturer of collection and transport systems. In like manner, COPAN's collaborative approach to pre-analytics has resulted in the development of FLOQSwabs®, ESwab®, UTM® and modular laboratory automation, WASP® and WASPLab®. (copangroup.com)



EUROIMMUN  
a PerkinElmer company

### EUROIMMUN AG a PerkinElmer Company | Booth #403

EUROIMMUN is an international provider of medical laboratory products with a growing molecular genetic diagnostics portfolio. The company's EUROArray platform provides multiplex detection of sexually transmitted pathogens, HPV or dermatophytes. Real-time PCR tests for Zika virus and HSV-1/2 and microarrays for genetic risk determination in many different diseases complete the portfolio. (euroimmun.com)



### GIANTmicrobes | Booth #412

GIANTmicrobes are educational products based on health and biology. Our adorable Herpes, Syphilis, HIV, Chlamydia, Gonorrhea, HPV and other STDs are used globally by public health agencies, medical organizations, healthcare professionals and educators as an engaging and memorable way to get people talking about infectious diseases and important health topics. (giantmicrobes.com)



HOLOGIC®  
The Science of Sure

### Hologic | Booth #300

A global champion of women's health, Hologic is an innovative medical technology company that enables healthier lives everywhere, every day through The Science of Sure: Clinical superiority that delivers life-changing diagnostic, detection, surgical and medical aesthetic products rooted in science and driven by technology. (hologic.com)



### ImmunoPrecise Antibodies | Booth #504

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody solutions; delivering the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. Our comprehensive collection of discovery platforms include transgenic animals, B-cell selection, phage display, and hybridoma development. Our extensive experience with multiple transgenic platforms provides clients access to reliable and effective therapeutic human antibody selection, available through all ImmunoPrecise's discovery platforms. ([immunoprecise.com](http://immunoprecise.com))



### IUSTI-Europe | Booth # 100

The 33rd IUSTI-Europe Congress on Sexually Transmitted Infections will be held September 05 – 07, 2019 in Tallinn, Estonia. The meeting will take place in the historic venue of the Estonian National Opera in the heart of the medieval city. IUSTI-Europe 2019 Congress has been granted 11 European CME credits (ECMEC@s). ([iusti2019.eu](http://iusti2019.eu))



### Mayer Labs | Booth #507

Featuring Kimono Condoms, Aqua Lube, and Today Contraceptive Sponge, institutional and retail accounts rely on Mayer Labs to produce the finest reproductive healthcare. ISO 13485 and MDSAP certified, and US FDA and Health Canada registered, Mayer Labs' global sourcing, draws upon the finest manufacturing partnerships in Japan, India, Thailand, Korea, New York, and California to deliver the best in quality and user satisfaction. ([mayerlabs.com](http://mayerlabs.com))



### Novosanis | Booth #406

Novosanis is a subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices. Our flagship device platform, Colli-Pee, is suited for volumetric and standardized collection of first-void urine improving the quality of diagnostics tests for infectious diseases and oncology. ([novosanis.com](http://novosanis.com))



### Pauktuutit Inuit Women Of Canada | Booth #508

Pauktuutit is the national representative organization of Inuit women in Canada. We foster greater awareness of the needs of Inuit women, advocate for equality and social improvements, and encourage Inuit women's participation in the community, regional and national life of Canada. (<https://www.pauktuutit.ca/>)



### Roche | Booth #206

As the world leader in in-vitro diagnostics, Roche offers a broad portfolio of instruments and assays for the screening, diagnosis and prevention of infectious diseases. With an ongoing focus on patient needs and the depth and breadth of our comprehensive portfolio, Roche is your partner for improving patient outcome by offering a wide range of solutions to Microbiologists, Clinical Researchers and Infection Preventionists. Visit our booth for the latest molecular, PCR-based assays and proven immunochemistry innovations. ([diagnostics.roche.com](http://diagnostics.roche.com))



SD BIOSENSOR

### SD Biosensor | Booth #204

SD Biosensor is an IVD manufacturer based in Korea. It offers a large range of portfolio such as rapid diagnostic, glucometer, ELISA test, immunochromatography and fluorescence analyzer etc. Currently SD Biosensor is developing new POC MDx platform which makes SD Biosensor a total diagnostic provider from screening to confirmatory test. ([sdbiosensor.com](http://sdbiosensor.com))



### Seegene Inc. | Booth #400

Seegene is the world's leading developer of multiplex molecular technologies and diagnostic products. Seegene's innovative proprietary technologies enable the simultaneous detection, differentiation and quantification of multiple targets with high sensitivity, specificity and reproducibility and perform on unique streamlined automation solution. Seegene's products, in particularly for sexually transmitted infections, provide accurate and comprehensive information on infected STI, BV and HPV pathogens. ([seegene.com](http://seegene.com))



### Shield Diagnostics | Booth #410

Shield Diagnostics' mission is to provide clinicians with the ability to apply precision medicine to the most pressing bacterial infections. Our first rapid molecular test, Target-NG, evaluates Gonorrhea infections for antibiotic susceptibility to ciprofloxacin, as a rapid reflex to Gonorrhea & Chlamydia testing in our CLIA laboratory in San Jose, CA. ([shielddx.com](http://shielddx.com))



### Speedx | Booth #200

Speedx specializes in innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. Speedx has a portfolio of CE-IVD multiplex qPCR kits for detection of infectious disease pathogens and antimicrobial resistance markers. Resistance-guided therapy improves patient outcomes by empowering practitioners to make informed clinical decisions. ([plexpcr.com](http://plexpcr.com))





## Spot On Sciences | Booth # 201

Spot On Sciences develops and markets innovative devices that revolutionize collection and storage of biological fluids for medical research. HemaSpot™ devices enable collection of blood samples offering solutions for multiple markets including clinical research, biobanking, military field medicine and population studies. The company was founded to ultimately improve access to medical testing for home-bound, rural and economically disadvantaged patients by allowing easy sample collection and shipment. (spotonsciences.com)



## STEMCELL Technologies | Booth #202

STEMCELL Technologies provides cell isolation products for studying HIV and other infectious diseases. Our cell separation technologies, EasySep™, RosetteSep™ and SepMate™ facilitate rapid human blood processing. SepMate™ registered as an IVD device, isolates PBMC in just 15 minutes. RoboSep™ fully automates EasySep™ cell isolation, minimizing sample handling and eliminating cross-contamination. (stemcell.com)



## Stichting World STI & HIV Congress 2021 | Booth #407

Herewith we would like to welcome you to the 24th STI & HIV World Congress 2021, to be held from 18 until 21 July 2021 in Amsterdam, The Netherlands. The organisers have chosen "Sexual diversity and the city" as the conference theme, and they aim to address diversity, health and sexuality in the urban context. Amsterdam is a very popular destination and very easy to travel to. #sexualdiversityandthecity (stihiv2021.org)



## World Health Organization | Booth #411

WHO has a vision for the attainment of the highest possible standard of sexual and reproductive health for all people. It strives for a world where all people's rights to enjoy sexual and reproductive health and gender equality are promoted and protected, and all people, including adolescents and other underserved and marginalized populations, have access to comprehensive sexual and reproductive health information and services. (who.int/reproductivehealth)



## Youth against AIDS | Booth #509

In a world impacted by major technological and social disruptions "Youth against AIDS" goes new ways to face the HIV & STI epidemic among young generations. "Youth against AIDS" is convinced that great innovations are necessary to meet the needs of the young target group, and to become a close partner in young peoples lives. "Youth against AIDS" builds networks to create innovation in prevention and to create a major change in young peoples individual health management. (youth-against-aids.org)



"Over 60% of the current world population live in urbanised settings, places where a large portion of the STI epidemic is also focussed. At the same time, urban environments offer networks, infrastructures, multidisciplinary and creativity from which solutions can emerge. Cities can act as giant outdoor labs, experimental sites, research incubators and ideal environments for the implementation of interventions."

Henry de Vries,  
Congress President

[www.stihiv2021.org](http://www.stihiv2021.org)



We would like to welcome you to:


24th  
STI & HIV 2021  
World Congress  
July 18 - 21

RAI Congress Centre  
Amsterdam, The Netherlands






**IF YOU THINK IT'S  
CHLAMYDIA.**



**AND IT ACTS LIKE  
CHLAMYDIA.**

**IT MIGHT BE  
MYCOPLASMA  
GENITALIUM.**



Many healthcare providers are unfamiliar with *Mycoplasma genitalium*—that's why awareness is so important.

Visit **HologicEd.com** for diagnosis and treatment strategies.

**Aptima®** *Mycoplasma genitalium*  
Assay

**References:** **1.** Manhart LE, Kay N. *Mycoplasma genitalium*: Is it a sexually transmitted pathogen? *Curr Infect Dis Rep.* 2010;12(4):306-13. doi:10.1007/s11908-010-0114-3. **2.** Centers for Disease Control and Prevention. Sexually Transmitted Diseases and Treatment Guidelines, 2015. <http://www.cdc.gov/std/tg2015/>. Accessed November 13, 2018. **3.** Gatski M, et al. *Mycoplasma genitalium* infection among HIV-positive women: prevalence, risk factors and association with vaginal shedding. *Int J STD AIDS* 2011;22(3):155–9.